

PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL
FACULDADE DE BIOCÊNCIAS
PROGRAMA DE PÓS-GRADUAÇÃO EM BIOLOGIA CELULAR E MOLECULAR

STEFÂNIA KONRAD RICHETTI

**AVALIAÇÃO DOS EFEITOS DE COMPOSTOS POLIFENÓLICOS EM
PARÂMETROS BIOQUÍMICOS E NO TRATAMENTO DE DÉFICITS
COGNITIVOS ASSOCIADOS À ADMINISTRAÇÃO DE ESCOPOLAMINA EM
PEIXE ZEBRA (*Danio rerio*)**

Orientadora: Prof. Dra. Carla Denise Bonan

PORTO ALEGRE – RS

Setembro, 2010

PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL
FACULDADE DE BIOCÊNCIAS
PROGRAMA DE PÓS-GRADUAÇÃO EM BIOLOGIA CELULAR E MOLECULAR

STEFÂNIA KONRAD RICHETTI

**AVALIAÇÃO DOS EFEITOS DE COMPOSTOS POLIFENÓLICOS EM
PARÂMETROS BIOQUÍMICOS E NO TRATAMENTO DE DÉFICITS
COGNITIVOS ASSOCIADOS À ADMINISTRAÇÃO DE ESCOPOLAMINA EM
PEIXE ZEBRA (*Danio rerio*)**

Orientadora: Prof. Dra. Carla Denise Bonan

Dissertação apresentada como requisito para a obtenção do grau de Mestre pelo Programa de Pós-Graduação em Biologia Celular e Molecular da Faculdade de Biociências da Pontifícia Universidade Católica do Rio Grande do Sul.

PORTO ALEGRE – RS

Setembro, 2010

Dedico este trabalho a quem amo incondicionalmente: minha mãe e meu pai.

AGRADECIMENTOS

Por mais inteligentes, maduros e auto-suficientes que pensamos ser, nada somos sem as pessoas ao nosso redor. Aproveito este momento para agradecer as pessoas especiais que me acompanharam durante esta caminhada:

À minha mãe, Maria Beatriz Konrad, agradeço por tudo: pela força, pelo suporte emocional, por estar sempre presente, pelos cuidados, pelas preocupações, pela amizade, enfim, por simplesmente existir em minha vida.

Ao meu pai, Errol Domingos Richetti, agradeço por ser o meu herói: por todas as horas em que foi um apoio, em que me auxiliou em qualquer que fosse o problema, até mesmo (a tentativa de) desenvolvimento de aparatos absurdamente tecnológicos.

À esses dois acima, agradeço pela vida, por me proporcionarem a oportunidade de estudar, por não economizarem esforços para a minha formação pessoal, psicológica e profissional. Ainda, gostaria de agradecer por serem pessoas tão corretas, éticas, justas e admiráveis. Sem vocês dois, não sei o que seria de mim. Me mostraram o que é o amor, a superação e a família.

A toda minha família e amigos, Dinda Sara, Dindo Rodrigues, Isabela e Tia Jane, agradeço pela companhia, pelo carinho, compreensão, pelo apoio e pelo incentivo que sempre me deram, acreditando mais a cada passo que dei.

Às minhas melhores amigas Daniela Grimberg, Isabela Scheufler e Cristina Moreira, agradeço por serem amigas de verdade, todas as horas. Não consigo acreditar em um mundo sem amigos, portanto, obrigada por tornarem meu mundo tão real.

Aproveito para agradecer as pessoas que me ajudaram muito, também, na minha vida profissional:

À minha orientadora, Prof^ª. Dr^ª. Carla Denise Bonan, agradeço pelo apoio, pela paciência, por acreditar na minha competência e nas minhas idéias. Sou grata por ter sido orientada por uma pessoa tão competente, exemplo do que espero ser no futuro.

À minha amiga e orientadora na iniciação científica, Prof^ª. Dr^ª. Rosane Souza da Silva agradeço por ter me apresentado a bioquímica, por ter me ensinado tudo o que eu precisei saber no início, e principalmente pela paciência e persistência ao me ajudar a enxergar o caminho certo.

Ao excelentíssimo Prof. Dr. Renato Dutra Dias, agradeço por sempre me mostrar que a bioquímica é uma área apaixonante.

As minhas amigas e colegas de laboratório Katiucia Capiotti e Martina Blank, agradeço pelo auxílio e pelas horas incansáveis dedicadas à execução desta tese, pelo auxílio na redação dos manuscritos e pela companhia nas horas de diversão no laboratório.

Ao todos os colegas de laboratório, agradeço por fazerem com que estes anos de jornada fossem divertidos e saudáveis.

Da minha aldeia vejo quanto da terra se pode ver no Universo...

Por isso a minha aldeia é tão grande como outra qualquer

Porque eu sou do tamanho do que vejo

E não do tamanho da minha altura...

(Alberto Caeiro)

RESUMO

O peixe zebra é um dos modelos vertebrados mais importantes para estudos de genética, biologia do desenvolvimento, neurofisiologia e biomedicina, sendo utilizado como um modelo de doenças humanas e para triagem de novas drogas, tais como fármacos para o tratamento da doença de Alzheimer. A doença de Alzheimer é uma doença neurodegenerativa que se caracteriza pela deposição de placas amilóides, desenvolvimento de emaranhados de neurofibrilas, inflamação e perda neuronal em diversas partes do cérebro que contribuem para os déficits cognitivos característicos da doença. O sistema colinérgico, o principal sistema envolvido nesta doença, apresenta a acetilcolina (ACh) como neurotransmissor e está fortemente relacionado à processos de aprendizado e formação da memória. Além do sistema colinérgico, outros sistemas, como o sistema purinérgico, estão envolvidos na patologia da doença de Alzheimer. Os nucleosídeos e nucleotídeos derivados de purinas exercem um papel de moléculas sinalizadoras extracelulares em vários tecidos, através dos receptores purinérgicos. O ATP tem seus níveis extracelulares controlados por enzimas da família das ectonucleotidases, entre elas as ectonucleosídeo trifosfato difosfohidrolases (E-NTPDases) e a ecto-5'-nucleotidase, que realizam a degradação de nucleotídeos púricos até adenosina, um nucleosídeo neuromodulador da homeostase celular. Os polifenóis, os quais são compostos derivados de plantas, podem atuar como moduladores da sinalização purinérgica e colinérgica, além de apresentarem efeitos antioxidantes, com ausência de efeitos colaterais severos, apresentando um grande potencial como tratamento para a doença de Alzheimer. Portanto, o objetivo deste estudo foi avaliar o potencial neuroprotetor dos polifenóis quercetina e rutina na prevenção dos déficits cognitivos causados pela escopolamina, um antagonista colinérgico muito utilizado para testes de novos fármacos facilitadores da capacidade cognitiva, bem como seus efeitos sobre as enzimas responsáveis pela modulação dos níveis dos neurotransmissores ATP e acetilcolina. Os resultados obtidos demonstram que a administração intraperitoneal de quercetina ou rutina (50 mg/kg) em peixe zebra previniu o déficit cognitivo causado pela exposição à escopolamina (200 μ M), como demonstrado pelo aumento da latência para cruzar para o lado escuro do aparato da tarefa de esquiva inibitória. A exposição a estes compostos não promoveu alterações na locomoção dos animais. Além disso, foi observado que o tratamento com rutina seguido de exposição à água inibiu a hidrólise de acetilcolina enquanto que o tratamento com rutina seguido pela exposição à escopolamina diminuiu a hidrólise de ATP. Com relação aos efeitos da quercetina, esta inibiu a hidrólise de AMP quando sua administração foi seguida pela exposição à água ou escopolamina. Portanto, estes resultados demonstram que os polifenóis podem apresentar potencial protetor com relação ao prejuízo cognitivo induzido pela escopolamina. Além disso, nossos resultados demonstram que rutina e quercetina *per se* são capazes de modular os níveis de acetilcolina, ATP e adenosina em encéfalo de peixe zebra. Estes resultados são promissores em relação à possibilidade de terapia preventiva a ser realizada ao longo da vida, visando a não ocorrência de declínio cognitivo associado ao envelhecimento.

Palavras chaves: rutina, quercetina, peixe zebra, nucleosídeo trifosfato difosfohidrolase, ecto-5'-nucleotidase, acetilcolinesterase, memória.

ABSTRACT

The zebrafish is one of the most important vertebrate models for studying genetics, developmental biology, neurophysiology, and biomedicine, and it is used as a model of human diseases and for the development of new therapeutic drugs, including drugs for Alzheimer's disease treatment. Alzheimer's disease is a neurodegenerative disease characterized by amyloid plaques deposition, development of neurofibrillary tangles, inflammation and neuronal loss in different parts of the brain that contribute to the cognitive impairment characteristic of the disease. The cholinergic system, the main system involved in this disease, presents acetylcholine (ACh) as a neurotransmitter and is strongly related to processes of learning and memory formation. Besides the cholinergic system, other neurotransmitter systems, such as the purinergic system are involved in Alzheimer's pathology. The purine-derived nucleosides and nucleotides display a role as extracellular signaling molecules in various tissues via purinergic receptors. ATP has its extracellular levels controlled by a group of enzymes called ectonucleotidases, which includes ecto-nucleoside triphosphate diphosphohydrolases (E-NTPDases) and ecto-5'-nucleotidase, which carry out the degradation of purine nucleotides to adenosine, a nucleoside neuromodulator of cellular homeostasis. Polyphenols, compounds derived from plants, can act as modulators of cholinergic and purinergic signaling, present known antioxidant effects and no severe side effects, showing great potential as a treatment for Alzheimer's disease. Therefore, the aim of this study was to evaluate the potential neuroprotective role of polyphenols quercetin and rutin in the prevention of cognitive impairment caused by scopolamine, a cholinergic antagonist widely used for testing new drugs that facilitate cognitive abilities, as well as to analyze their effects on the enzymes responsible for modulation of neurotransmitters levels, such as ATP and acetylcholine. Our results have shown that administration of quercetin or rutin intraperitoneal (50 mg/kg) in zebrafish prevents cognitive deficits caused by exposure to scopolamine (200 μ M), as demonstrated by increased latency to cross to the dark side of the inhibitory avoidance apparatus. None of the compounds in which the animals were exposed are able to alter the locomotor activity of the animals. Moreover, it has been observed that treatment with rutin followed by water exposure inhibited acetylcholine hydrolysis whereas the treatment with rutin followed by scopolamine exposure reduced ATP hydrolysis. Regarding the effects of quercetin, it has inhibited the AMP hydrolysis when its administration was followed by water or scopolamine exposure. Therefore, these results have demonstrated that polyphenols may display protective potential on to the cognitive impairment induced by scopolamine. Moreover, our findings have shown that rutin and quercetin *per se* are able to modulate the levels of acetylcholine, ATP, and adenosine in zebrafish brain. These results are promising regarding the possibility of preventive therapy to be carried throughout lifespan to avoid the occurrence of cognitive decline associated with aging.

Keywords: rutin, quercetin, zebrafish, nucleoside triphosphate diphosphohydrolase, ecto-5'-nucleotidase, acetylcholinesterase, memory.

SUMÁRIO

CAPÍTULO 1 - INTRODUÇÃO E OBJETIVOS	10
1. INTRODUÇÃO.....	11
1.1. Peixe zebra	11
1.2. Sistema Purinérgico.....	14
1.3. Ectonucleotidasas	19
1.4. Sistema Colinérgico	19
1.5. Doença de Alzheimer	24
1.5.2. Escopolamina	28
1.6. Polifenóis.....	29
2. OBJETIVOS.....	33
2.1. Objetivo Geral.....	33
2.2. Objetivos Específicos.....	33
CAPITULO 2 - ARTIGO CIENTÍFICO	34
CAPITULO 3 - ARTIGO CIENTÍFICO	64
CAPÍTULO 4 - CONSIDERAÇÕES FINAIS	97
REFERÊNCIAS BIBLIOGRÁFICAS	104
ANEXO - ARTIGO CIENTÍFICO.....	126

CAPÍTULO 1 - INTRODUÇÃO E OBJETIVOS

1. INTRODUÇÃO

1.1. PEIXE ZEBRA

O peixe zebra, *Danio rerio* ou *zebrafish* (Hamilton 1822), pertence à família dos peixes de água-doce Cyprinidae, que corresponde à família de vertebrados mais rica em número de espécies (Nelson, 1994), sendo as espécies do gênero *Danio* distribuídas ao longo do sul e sudeste asiático. O nome *Danio* é derivado da palavra Bengali “*dhani*”, que significa “do campo de arroz” (Talwar e Jhingran, 1991). Este gênero é caracterizado pelo seu pequeno tamanho (até 12 cm de comprimento) e um distinto padrão de coloração baseado na alternância de linhas horizontais claras e escuras. O *Danio rerio* raramente excede o tamanho padrão de 4 cm da ponta do focinho até a origem da nadadeira caudal. O padrão de coloração compreende três tipos de células pigmentares, ou cromatóforos: os melanóforos azul-escuros, os xantóforos dourados e os iridóforos iridescentes (Parichy, 2006). Assim como na maioria dos teleósteos, os melanóforos podem ser concentrados ou dispersados em resposta aos estímulos, sendo úteis na camuflagem, em resposta às alterações na luminosidade (Guo, 2004), além de serem úteis para a demonstração de agressividade, medo e outras situações comportamentais (Kondo *et al.*, 2009; Larson *et al.*, 2006; Price *et al.*, 2008). Os machos e as fêmeas apresentam coloração semelhante, embora os machos apresentem nadadeiras anais maiores e com coloração mais amarelada em relação às das fêmeas (Schilling, 2002). O *Danio rerio* é uma espécie onívora, se alimentando principalmente de zooplâncton e insetos, além de fitoplâncton, algas

filamentosas, ovos de invertebrados, aracnídeos e detritos (Engeszer *et al.*, 2007; Spence *et al.*, 2007 e 2008).

O peixe zebra é um dos modelos vertebrados mais importantes para estudos de genética, biologia do desenvolvimento (Brittijn *et al.*, 2009), neurofisiologia e biomedicina (Amsterdam e Hopkins, 2006; Rubinstein, 2003). Esta espécie apresenta um grande número de atributos que a torna atrativa para o desenvolvimento de pesquisas. É um peixe pequeno permitindo que grandes quantidades deste animal sejam mantidas facilmente com a necessidade de pouco espaço e sem altos custos de manutenção em laboratório. Em relação à sua reprodução, esta ocorre ao longo de todo o ano, e cada fêmea pode se reproduzir a cada 2-3 dias e uma única postura pode conter várias centenas de ovos. O fato desta espécie apresentar fecundação e reprodução externas é uma característica ainda mais interessante do ponto de vista da utilização deste modelo para estudos de biologia do desenvolvimento. O peixe zebra apresenta ovos relativamente grandes em relação a outros peixes (0,7 mm no momento da fertilização) e estes são transparentes, permitindo o acompanhamento e a observação em tempo real da divisão celular e formação de um novo organismo. Além da sua importância em estudos ontogenéticos, o peixe zebra vem ganhando importância nas pesquisas biomédicas (Dooley e Zon, 2000; Shin e Fishman, 2002), particularmente como um modelo de doenças humanas (Guyon *et al.*, 2006; Ingham, 2009), doenças neurodegenerativas (Best e Alderton, 2008; Kishi *et al.*, 2009; Sager *et al.*, 2010), para testes com novas substâncias terapêuticas (Crawford *et al.*, 2008; Mandrekar e Thalur, 2009; Rihel *et al.*, 2010; Zon e Peterson, 2005), compreensão da evolução do genoma vertebrado, estudos teratológicos e neurociências (Ivetac *et al.*, 2000; Morris, 2009). Como possui a sua

genética bem caracterizada, o estudo do genoma do peixe zebra pode servir como um complemento funcional para o projeto genoma humano, o qual produz enormes quantidades de sequências, mas carece de informações funcionais para a maioria dos genes identificados (Dooley e Zon, 2000). Além disso, os genes deste teleósteo são evolutivamente conservados e apresentam um alto grau de similaridade com os genes humanos e de camundongo (Barbazuk *et al.*, 2000; Lieschke e Currie, 2000). Em relação às pesquisas de doenças humanas, o peixe zebra tem vantagem em relação a outros modelos animais, como drosófilas, pois devido ao fato de ser um vertebrado, estudos realizados neste modelo são mais comparáveis aos humanos do que modelos invertebrados (Barbazuk *et al.*, 2000; Postlethwait *et al.*, 2000). Além disto, o peixe zebra ainda apresenta certa vantagem em relação a animais modelos mamíferos como camundongos, pela maior facilidade de manipulações embriológicas neste animal (Zhang e Leung, 2010). Atualmente, mais de 400 laboratórios utilizam o peixe zebra como modelo animal (www.zfin.org). Há um crescente interesse em utilizá-lo como ferramenta para estudos sobre o ciclo celular (Eimon e Ashkenasi, 2010), estudos bioquímicos (Taylor *et al.*, 2004), farmacológicos (Chakraborty *et al.*, 2009; Eimon e Rubinstein, 2009; Goldsmith, 2004; Rubinstein, 2006; Vogt *et al.*, 2010; Yang *et al.*, 2009), e comportamentais, visando a compreensão da base genética do comportamento (Gerlai, 2003; Guo, 2004; Miklosi e Andrew, 2006; Mueller e Neuhauss, 2010; Rihel *et al.*, 2010) e para estudos toxicológicos (Hill *et al.*, 2005). Para tais pesquisas, a utilização deste modelo que absorve os componentes diretamente da água pelas suas brânquias e os acumula em diferentes tecidos, principalmente no sistema nervoso central (SNC) (Grosell

e Wood, 2002) vem ganhando importância significativa (Froehlicher *et al.*, 2009; Yang *et al.*, 2009).

Muitos estudos já foram realizados visando a caracterização de sistemas de neurotransmissão no peixe zebra, resultando na detecção dos sistemas glutamatérgico (Edwards e Michel, 2002; Rico *et al.*, 2010), colinérgico (Behra *et al.*, 2002; Clemente *et al.*, 2004), dopaminérgico (Boehmler *et al.*, 2004; Kastenhuber *et al.*, 2010; Schweitzer e Driever, 2009), serotoninérgico (Bencan *et al.*, 2009; Gabriel *et al.*, 2009; Rink e Guo, 2004), gabaérgico (Kim *et al.*, 2004) e purinérgico (Boehmler *et al.*, 2009; Kucenas *et al.*, 2003; Rico *et al.*, 2003; Young, 2010), além da caracterização de algumas enzimas e receptores envolvidos nestes sistemas.

1.2. SISTEMA PURINÉRGICO

A sinalização intercelular mediada por purinas está presente desde cedo na evolução e, portanto, é uma rota amplamente distribuída para comunicação célula-célula (Burnstock, 2008). As purinas parecem ser os mensageiros químicos mais primitivos e dispersos em animais e plantas (Burnstock e Verkhratsky, 2009). O conceito de transmissão purinérgica foi proposto por Geoffrey Burnstock em 1972 após a observação da ação do ATP como transmissor em nervos inibitórios não adrenérgicos, não colinérgicos em *Taenia coli* de roedores (Burnstock, 1972).

Os nucleosídeos e nucleotídeos derivados de purinas exercem um papel de moléculas sinalizadoras extracelulares em vários tecidos, através dos receptores purinérgicos (Abbraccio *et al.*, 2009; Burnstock e Knight, 2004). Diversas evidências têm

demonstrado o importante papel desempenhado por essas moléculas, entre elas o ATP e a adenosina, no SNC (Burnstock, 2009a e 2009b; Dunwiddie e Masino, 2001; Franco, 2009; Ralevic e Burnstock, 1998). O ATP é reconhecido como um neurotransmissor, pois é sintetizado e armazenado em terminais sinápticos e liberado após estímulo destes terminais. O ATP pode ser co-liberado juntamente com vários neurotransmissores, como a acetilcolina, glutamato, dopamina, noradrenalina, serotonina e ácido γ -amino butírico (GABA) (Burnstock, 1999; Di Iorio *et al.*, 1998; Zimmerman, 2008). Pode atuar tanto como um transmissor ou como um co-transmissor, na maioria dos nervos no SNC e periférico (Burnstock, 2007).

A transmissão de sinal via ATP desempenha papéis complexos, tais como a neurotransmissão excitatória ou inibitória, além de atuar como um fator trófico com efeitos a longo prazo sobre a proliferação celular, crescimento e desenvolvimento, em doenças e citotoxicidade (Abbracchio e Burnstock, 1998). O ATP pode ser liberado nos terminais pré- e pós-sinápticos. Esta liberação pode ocorrer tanto a partir de células saudáveis, como um mecanismo fisiológico ou em resposta à danos celulares, como hipóxia, injúrias e deformação celular (Burnstock, 2008). O ATP age através de receptores purinérgicos específicos do tipo P2, divididos em dois grupos de acordo com a base do mecanismo de ação, farmacologia e clonagem molecular: o primeiro grupo é constituído pelos receptores P2X (Skaper *et al.*, 2010; Surprenant e North, 2009), os quais são ionotrópicos (Ralevic e Burnstock, 1998) e o segundo grupo é constituído pelos receptores metabotrópicos P2Y, acoplados a uma proteína G. Estas duas classes de receptores apresentam uma ampla distribuição nos tecidos e sistemas, tais como sistema nervoso, vascular e cardíaco (Burnstock, 2004). Os sete receptores do tipo P2X são

ligados a canais iônicos e quando ativados resultam na abertura de um poro na membrana celular que permite a passagem de Na^+ , K^+ , Ca^{+2} . Estes receptores interagem com vários receptores ionotrópicos, incluindo receptores colinérgicos nicotínicos, receptores GABA_A , e receptores NMDA. Os mecanismos para estas interações parecem ser mediados pela fosforilação destes receptores através da ação de cinases ativadas por Ca^{+2} intracelular (Pankratov *et al.*, 2009). Os oito receptores do tipo P2Y podem ser divididos em dois subgrupos, de acordo com a similaridade filogenética e de acordo com a especificidade de proteínas G aos quais são ligados. O primeiro grupo contempla os receptores P2Y₁, P2Y₂, P2Y₄, P2Y₆ e P2Y₁₁, os quais utilizam proteínas G_q/G₁₁ para ativar a rota de liberação de Ca^{+2} através da ação da fosfolipase C. O segundo grupo, composto pelos receptores P2Y₁₂, P2Y₁₃ e P2Y₁₄, por sua vez, liga-se quase que exclusivamente a proteínas G_{i/o}, que quando ativadas inibem a adenilil ciclase e modulam canais iônicos. A clonagem e caracterização molecular dos receptores P2X do peixe zebra já foram realizadas (Appelbaum *et al.*, 2007; Diaz-Hernandez *et al.*, 2002; Low *et al.*, 2008; Young, 2010). A subfamília P2X possui nove membros, sendo destes seis ortólogos a genes dos receptores P2X de mamíferos, dois parálogos e um gene que ainda precisa ser devidamente classificado (Kucenas *et al.*, 2003 e 2009). Os subtipos dos receptores P2X do peixe zebra contêm resíduos altamente conservados, os quais são encontrados nas subunidades de mamíferos. Até o momento, na família de receptores P2Y foram identificadas oito proteínas funcionais (Ralevic e Burnstock, 1998), e somente os receptores P2Y1 foram identificados em trombócitos de peixe zebra (Gregory e Jagadeeswaran, 2002).

Uma vez liberado no espaço extracelular, o ATP pode ser metabolizado pela ação de ecto-enzimas que fazem a conversão deste nucleotídeo até adenosina (Robson *et al.*, 2006; Zimmermann, 2001). A concentração extracelular de adenosina é um fator determinante dos efeitos neuromoduladores desta molécula.

A adenosina é um metabólito constituinte de todas as células (Cunha, 2001) que desenvolve diversos papéis chave no organismo. Esta molécula está envolvida na síntese de ácidos nucléicos, metabolismo de aminoácidos e modulação do estado metabólico da célula. A adenosina não é considerada um neurotransmissor clássico, como o ATP, pelo fato de não ser armazenada em vesículas, não ser liberada por exocitose e não atuar predominantemente em sinapses (Fredholm, 2003). A adenosina pode ser sintetizada intracelularmente pela clivagem da S-adenosil-homocisteína pela enzima S-adenosil-homocisteína hidrolase ou pela degradação do nucleosídeo monofosfatado AMP pela enzima 5'-nucleotidase e extracelularmente por uma cascata enzimática de degradação de nucleotídeos, realizada pelas ectonucleotidases, a qual inclui uma ecto-5'-nucleotidase (Colgan *et al.*, 2006).

A ação da adenosina se dá através da ativação de receptores purinérgicos (Sebastião e Ribeiro, 2009), do tipo P1 acoplados à proteínas G (Trincavelli *et al.*, 2010). Estes receptores são divididos em 4 subtipos de acordo com suas características, como estrutura molecular, distribuição tecidual e afinidade pelo seu ligante. São eles: o receptor A₁, A_{2A}, A_{2B} e A₃. Os receptores A₁ e A₃ se ligam à família das proteínas G_{i/o}, responsáveis pela inibição da produção do segundo mensageiro AMP cíclico (AMPC) (Borea *et al.*, 2009; Dhalla *et al.*, 2009). Os receptores A_{2A} e A_{2B} estimulam a produção de AMPC via ativação de proteínas G_s (Brown e Short, 2008). A porção N-terminal do

receptor está voltada para o meio extracelular e a porção C-terminal está voltada para o lado citosólico da membrana plasmática (Ralevic e Burnstock, 1998). Recentemente, foi demonstrado a presença de duas formas de receptores A_{2A} (adora2a.1 e adora2a.2) e uma forma de receptor A_{2B} em embriões de peixe zebra (Boehmler *et al.*, 2009).

A adenosina desempenha dois papéis, atuando como uma molécula que mantém a homeostase no meio intracelular e como um neuromodulador do sistema nervoso. No SNC, age modulando a liberação de neurotransmissores, as respostas pós-sinápticas e a ação de outros sistemas (Cunha, 2001 e 2005), além de proteger o organismo em caso de isquemia e injúrias (Fredholm, 2003; Stone *et al.*, 2009). Devido a este papel neuromodulador, a adenosina está envolvida na regulação de importantes mecanismos no SNC, como inflamação (Di Virgilio *et al.*, 2009; Haskó *et al.*, 2008), estados de ansiedade (El Yacoubi *et al.*, 2000), sono (Porkka-Heiskanen, 1999), cognição e memória (Ribeiro *et al.*, 2003). Além disso, este nucleosídeo apresenta especial importância nos estudos de patofisiologias, como na doença de Parkinson e na esquizofrenia (Lara *et al.*, 2001), tendo os seus receptores como possíveis alvos para o desenvolvimento de fármacos (Fredholm, 2010). Recentemente, antagonistas de receptor adenosinérgico A_{2A} receberam uma elevada atenção por se tratarem de novas estratégias para prevenir ou retardar o desenvolvimento de doenças neurodegenerativas, como Parkinson (Cunha *et al.*, 2008; Jenner *et al.*, 2010; Schwartzchild *et al.*, 2006). Também foi observado o papel de antagonistas destes receptores em prevenir o déficit cognitivo associado à doença de Alzheimer (Arendash *et al.*, 2006; Cunha *et al.*, 2008; Dall'Igna *et al.*, 2007), como foi observado após a utilização do antagonista cafeína, que demonstrou uma atenuação do declínio da memória em idosos (Ritchie *et al.*, 2007; Takahashi *et al.*, 2008) e também

uma redução no risco do desenvolvimento da doença de Alzheimer (Maia e de Mendonça, 2002; Stone *et al.*, 2009).

1.3. ECTONUCLEOTIDASES

Os nucleotídeos extracelulares podem atuar como moléculas sinalizadoras que precisam ter o seu sinal inativado após a sua ação. A inativação deste sinal e a manutenção das concentrações dos nucleotídeos pode se dar pela hidrólise extracelular dos mesmos. Os nucleotídeos são hidrolisados por uma cascata que resulta na formação do respectivo nucleosídeo e fosfato livre. As enzimas que catalisam esta reação são as ectonucleotidasas. As ectonucleotidasas estão ancoradas na membrana celular, possuindo seu sítio ativo voltado para o meio extracelular ou estão presentes na forma solúvel no meio intersticial (Schetinger *et al.*, 2007). Diversas famílias de enzimas constituem o grupo das ectonucleotidasas constituído por quatro famílias de enzimas: Ecto-nucleosídeo trifosfato difosfohidrolases (E-NTPDases), Ecto-nucleotídeo pirofosfatase/fosfodiesterase (E-NPPs), fosfatases alcalinas e Ecto 5'-nucleotidasas (E- 5'NT) (Robson *et al.*, 2006) (Figura1) . Neste estudo, daremos ênfase às E-NTPDases e Ecto-5' nucleotidasas.

As E-NTPDases podem hidrolisar nucleosídeos-5'trifosfatados e nucleosídeos-5'difosfatados e apresentam membros em vertebrados, invertebrados, plantas, leveduras e protozoários (revisado em Zimmermann, 2001). Os membros desta família diferem em relação à preferência pelo substrato, neste caso nucleosídeos 5'-tri e nucleosídeos 5'-difosfatados, que vão ser hidrolisados. Os membros da família das NTPDases são codificados por oito genes diferentes, chamados de genes *entpd*. Dos oito membros

descritos até o momento, quatro estão localizados na membrana celular com o sítio ativo voltado para o meio extracelular (NTPDases 1, 2, 3 e 8). As NTPDases 5 e 6 se localizam intracelularmente, porém são secretadas após expressão heteróloga. As NTPDases 4 e 7 apresentam localização intracelular com o sítio ativo voltado para o lúmen de organelas citoplasmáticas (Robson *et al.*, 2006; Zimmermann, 2000).

A Ecto-5'-NT é uma enzima que desfosforila nucleosídeos monofosfatados não cíclicos (Bianchi e Sychala, 2003), através da hidrólise da ligação fosfodiéster de 5'-ribonucleotídeos, levando à formação do correspondente ribonucleosídeo e fosfato. A principal função em animais é a hidrólise de AMP até adenosina (Zimmermann, 2000). As Ecto-5'-NT apresentam uma ampla distribuição tecidual e fazem parte da cascata para finalizar a ação de nucleotídeos como ATP e moléculas sinalizadoras que agem em receptores P2X e P2Y, sendo a principal enzima responsável pela formação extracelular de adenosina (Zimmermann, 2000).




Figura 1: Topografia de membrana das ectonucleotidasas (Cognato e Bonan, 2010)

No peixe zebra, estudos demonstraram a presença de uma NTPDase e uma Ecto-5'-NT em membranas cerebrais. Estas duas enzimas foram caracterizadas como cátion-dependentes, apresentando atividade máxima à temperatura de 37 °C, pH ótimo entre 7,2 e 8,0, K_M na faixa do micromolar e uma ampla especificidade por outros nucleotídeos (Rico *et al.*, 2003; Senger *et al.*, 2004). Estudos do nosso laboratório identificaram a presença de três isoformas diferentes de NTPDase 2 (NTPDase2mv, NTPDase2mg, NTPDase2mq) em encéfalo de peixe zebra (Rico *et al.*, 2006) e duas isoformas de NTPDase5 (NTPDase5ms e NTPDase5me) (Rosemberg *et al.*, 2010). A co-localização da NTPDases 1 e 2 já foi descrita em células de retina de peixe zebra (Ricatti *et al.*, 2009)

e a NTPDase 3 foi caracterizada em neurônios sensoriais desta espécie (Appelbaum *et al.*, 2007).

1.4. SISTEMA COLINÉRGICO

O sistema colinérgico já foi muito estudado, visto que a acetilcolina foi o primeiro neurotransmissor identificado durante a primeira metade do século vinte, a partir de estudos de Henry Dale, Otto Loewi, Feldberg e outros pesquisadores (Anglade e Larabigodiot, 2010; Wessler *et al.*, 1999). O sistema colinérgico pode modular funções cognitivas de maneira eficiente no cérebro (Hasselmo e Giocomo, 2006; Karczmar, 2010), agindo em receptores metabotrópicos e ionotrópicos. A acetilcolina (ACh) é sintetizada nas extremidades dos axônios colinérgicos. A colina, um dos precursores da ACh é captada do meio extracelular pela ação de transportadores específicos. Outra importante fonte de acetilcolina é a quebra de fosfatidilcolina. A ACh é sintetizada pela ação da enzima colina-acetiltransferase (ChAT), responsável por transferir um grupamento acetil da acetilcoenzima A para a colina (Oda, 1999). O passo limitante na formação de acetilcolina é o transporte de acetil coenzima A, oriunda da membrana interna da mitocôndria após a via metabólica de transformação da glicose em piruvato. Após a síntese, a ACh é transportada dentro de vesículas para os terminais dos axônios colinérgicos, onde é armazenada (Amenta e Tayebati, 2008; Ferguson e Blakely, 2004). Quando liberada no meio extracelular a acetilcolina age em receptores específicos ionotrópicos nicotínicos e metabotrópicos muscarínicos. Os receptores nicotínicos

(nAChRs) quando ativados, permitem a passagem de íons, sendo responsáveis pelo aumento do influxo de íons como Na^+ , K^+ e Ca^{+2} (Dani e Bertrand, 2007). Os receptores nicotínicos estão envolvidos em mecanismos de recompensa no sistema nervoso central, isto explica em grande parte o mecanismo do uso de tabaco e nicotina (Adinoff, *et al.*, 2010; Changeux, 2010; Picciotto *et al.*, 1998; Sherva *et al.*, 2010).

Os receptores muscarínicos (mAChRs) se associam à proteínas G e consistem em cinco tipos diferentes de receptores (M1-M5). Assim como os nAChRs, um único neurônio colinérgico pode expressar mais de um tipo de subtipo de mAChR. Muitas evidências relacionam os receptores colinérgicos muscarínicos com processos de aprendizado e memória, entre elas a observação de déficits cognitivos em ratos *knockout* para o gene do receptor M1 (Anagnostaras *et al.*, 2003). Os receptores M5 são pouco expressos no cérebro e, até o momento, seu papel fisiológico não foi claramente estabelecido, porém foi atribuída a este receptor a dilatação induzida por ACh das veias cerebrais que podem ser importantes para o desenvolvimento da doença de Alzheimer. Os receptores muscarínicos M1, M3 e M5 se ligam às proteínas Gq e a sua ativação mobiliza Ca^{+2} intracelular. Através de proteínas Gq/11, estes mAChRs ativam a fosfolipase C e por consequência a proteína quinase C, a qual inicia a liberação de Ca^{+2} intracelular, o que resulta em um aumento da excitabilidade neuronal. Os receptores M2 e M4 ativam os canais iônicos de K^+ da membrana plasmática através de proteínas Gi, resultando em uma hiperpolarização, culminando em efeitos inibitórios na atividade neuronal. A ativação destes receptores também gera a inibição da liberação de neurotransmissores e a inibição da adenilato ciclase (Brown e Sihra, 2008).

No espaço extracelular, a acetilcolinesterase (AChE) é a enzima responsável pela degradação de acetilcolina, eliminando os efeitos desencadeados por esta molécula. A AChE é sintetizada no retículo endoplasmático, processada e transportada para o meio extracelular pela presença de um peptídeo sinal na região N-terminal. A AChE, já descrita em peixe zebra, é codificada por um único gene neste animal, porém várias formas moleculares são observadas (monômeros, dímeros, trímeros e tetrâmeros), resultado da ocorrência de splicing alternativo nos éxons da região C-terminal (Massoulié *et al.*, 2008).

1.5. DOENÇA DE ALZHEIMER

A doença de Alzheimer é uma doença neurodegenerativa progressiva com ocorrência principalmente em pessoas idosas (Francis *et al.*, 1999), sendo o envelhecimento um fator que contribui para o desenvolvimento da patologia. Esta doença acomete 18 milhões de pessoas no mundo, podendo chegar a 34 milhões em 2025, segundo a *Alzheimer's Society* (Mount e Downton, 2006). Tem causa multifatorial, com uma combinação complexa de componentes genéticos e não genéticos (De Strooper, 2010; Haberland, 2010; Mondragón-Rodríguez, *et al.*, 2010; Ramassamy, 2006; Singh *et al.*, 2008). Entre os componentes genéticos, a forma herdada da doença representa apenas uma pequena fração (< 5%) dos casos, enquanto a forma não-genética ou esporádica corresponde à maioria dos casos (Singh *et al.*, 2008). Em relação à forma herdada da doença, foram identificadas mutações em três genes, que parecem contribuir para o desenvolvimento da doença. Embora estas mutações ocorram em diferentes genes, elas

compartilham a mesma rota bioquímica: a produção alterada de peptídeo β -amilóide ($A\beta$) que leva à morte neuronal e demência (Singh *et al.*, 2008). Em nível celular, fatores como inflamação, toxicidade glutamatérgica, ativação de rotas apoptóticas, elevação do óxido nítrico e estresse oxidativo parecem estar envolvidos (Crews e Masliah, 2010; Ramassamy, 2006; Reddy, 2007).

A doença de Alzheimer resulta da neurodegeneração caracterizada pela deposição de placas amilóides (Chen *et al.*, 2008; Ramassamy, 2006), desenvolvimento de emaranhados de neurofibrilas, (Blennow *et al.*, 2006; Selkoe, 2001) inflamação e perda neuronal em diversas partes do cérebro, principalmente no prosencéfalo e hipocampo (Janas *et al.*, 2005; Sambamurti *et al.*, 2002). A deposição de placas amilóides, formada principalmente por fragmentos β -amilóides resulta de deficiências no metabolismo desta proteína, enquanto a formação dos emaranhados de neurofibrilas está relacionado com a hiperfosforilação da proteína TAU (Bertrand *et al.*, 2010; Cotman, 1997; Gustaw-Rothenberg *et al.*, 2010; Kovacech *et al.*, 2010; Siemers *et al.*, 2010; Zetterberg *et al.*, 2010).

Embora muitos sistemas de neurotransmissão, como glutamatérgico, serotoninérgico e catecolaminérgico estejam envolvidos nesta patologia, a degeneração e déficits funcionais no sistema colinérgico parecem estar fortemente relacionados com os sintomas da doença de Alzheimer (Giacobini, 2003; Kim *et al.*, 2007). Alguns autores, como Han *et al.* (2007), chegam a definir o sistema colinérgico como o principal sistema desencadeador dos sintomas desta doença.

A redução na expressão ou atividade da AChE resulta em um aumentado tônus colinérgico no cérebro, com concomitante regulação na expressão dos receptores

colinérgicos muscarínicos e nicotínicos (Fisher, 2008; Guan, 2008; Kihara e Shimohama, 2004; Poulin *et al.*, 2010). No caso de pacientes com a doença de Alzheimer, é observada uma redução da atividade colinérgica (Mufson *et al.*, 2008), através da perda de neurônios colinérgicos e suas projeções corticais e da redução nos níveis disponíveis deste neurotransmissor na fenda sináptica, o que significa que a molécula acetilcolina não consegue se ligar aos seus receptores e desencadear suas ações fisiológicas. Esta redução nos níveis da acetilcolina é resultado da redução da atividade da enzima responsável pela produção deste neurotransmissor e um aumento na atividade da AChE, ocasionando uma maior degradação de acetilcolina (Kim *et al.*, 2008). Isto desencadeia os principais sintomas da doença, que são a perda de memória e progressivo prejuízo cognitivo (Bartus *et al.*, 1982; Mattson, 2004; Mondragón-Rodríguez *et al.*, 2010; Roberson e Mucke, 2006). O aumento do tônus colinérgico através da inibição da atividade da AChE corresponde à principal terapia atualmente utilizada para o tratamento desta doença (Alcaro *et al.*, 2010; Darreh-Shori e Soininen, 2010; Desmarais e Gauthier, 2010; Grill e Cummings, 2010; Nieoullon, 2010; Pepeu e Giovannini, 2009).

O sistema purinérgico também está relacionado com esta doença. Foi observada uma expressão elevada dos receptores purinérgicos P2X₇ em cérebro de pacientes e modelos animais desta doença (McLarnon *et al.*, 2006). A estimulação destes receptores em macrófagos e microglia de humanos resultou em um aumento das lesões degenerativas observadas na doença de Alzheimer (Rampe *et al.*, 2004). Os receptores P2Y₁ são encontrados em estruturas características desta patologia como emaranhados de neurofibrilas e placas neuríticas (McLarnon *et al.*, 2006). Além disso, anormalidades na transmissão de sinal desencadeada por ATP e mediada por Ca⁺² foram observadas em

pacientes com a doença de Alzheimer (McLarnon *et al.*, 2006). Estudos demonstraram uma redução da expressão dos receptores de adenosina A₁ no hipocampo de pacientes com esta doença e um acúmulo destes receptores em estruturas neurodegenerativas, nas quais são responsáveis pela fosforilação da proteína TAU (Angulo *et al.*, 2003).

Atualmente, poucos medicamentos para o tratamento da doença de Alzheimer estão disponíveis (Cítron, 2010; Grill e Cummings, 2010). A hipótese colinérgica desta doença foi a base utilizada para o desenvolvimento de tratamentos pré-sinápticos, sinápticos e pós-sinápticos, formulados de maneira a manter e facilitar a atividade do sistema colinérgico (Han *et al.*, 2007; Kim *et al.*, 2008). Atualmente, os medicamentos disponíveis atuam inibindo a AChE, para aumentar os níveis deste nucleotídeo na fenda sináptica (Kang *et al.*, 2005). Os medicamentos disponíveis para pacientes são a rivastigmina, tacrina, galantamina, fisostigmina e donezepil (Kim *et al.*, 2008; Shigeta e Homma, 2001). Estes medicamentos apresentam efeitos colaterais gastrointestinais e hepatotóxicos muito severos (Coelho e Birks, 2001; Heydorn, 1997). Portanto, o desenvolvimento de novos medicamentos que não apresentem estes efeitos colaterais é necessário e se torna urgente (Colombres *et al.*, 2004; Lee *et al.*, 2003). Os polifenóis, moléculas encontradas na natureza, podem atuar como inibidores da acetilcolinesterase, além de apresentarem efeitos antioxidantes, com ausência de efeitos colaterais severos. Portanto, apresentam um grande potencial como tratamento para esta doença (Ji e Zhang, 2006). Vários estudos já demonstraram a ação neuroprotetora de diversos polifenóis (Chen *et al.*, 2008; Kang *et al.*, 2005; Lee *et al.*, 2003; Warda *et al.*, 2002; Youdim *et al.*, 2002).

1.5.1. Escopolamina

A escopolamina é um alcalóide que ocorre na natureza, e foi primeiramente isolada de plantas como *Atropa belladonna* L., *Datura stramonium* L. e *Hyosyamus niger* L. (Zhang *et al.*, 2008) É utilizada no tratamento de disfunções do SNC, como náusea, doença de Parkinson e dependência por opióides (Xiang *et al.*, 2006). Seu mecanismo de ação envolve principalmente o bloqueio dos receptores muscarínicos colinérgicos, agindo como um antagonista competitivo (Brouillette *et al.*, 2007; Hulme *et al.*, 2003), porém apresentando efeitos também em outros sistemas de neurotransmissão. Ela reduz os efeitos da acetilcolina ao se ligar aos receptores muscarínicos sem gerar a despolarização (Ebert e Kirsh, 1998). Ela penetra facilmente a barreira hemato-encefálica e apresenta uma ação prejudicial em relação à cognição, formação e armazenamento da memória em ratos, primatas e humanos saudáveis (Spinelli *et al.*, 2006). Portanto, a escopolamina vem sendo amplamente utilizada desde 1974 como um modelo animal de indução de déficits cognitivos e perda de memória, simulando um modelo de demência a até mesmo mimetizando os principais sintomas da doença de Alzheimer (Deiana *et al.*, 2009; Drachman e Leavitt, 1974; Kim *et al.*, 2008).

Esta molécula é muito utilizada para a avaliação da potencialidade de novas drogas anticolinérgicas e dos efeitos de drogas já existentes, para o tratamento da doença de Alzheimer. Sua utilização como modelo é maior em relação a outros modelos, pois ela apresenta a característica de induzir déficits cognitivos e impedir a formação da memória (Cunha G.M.A *et al.*, 2008; Deiana *et al.*, 2009) com a possibilidade de reversão após a utilização de fármacos anticolinérgicos, como donezepil. Muitos estudos avaliaram

parâmetros comportamentais relacionados ao aprendizado e memória em ratos e primatas, como esQUIVA INIBITÓRIA, labirinto em T, labirinto em Y e tarefa de esQUIVA PASSIVA e todos demonstraram uma redução no desempenho cognitivo (Kunesova *et al.*, 2008).

1.6. POLIFENÓIS


Atualmente, cerca de 10.000 metabólitos secundários de plantas são conhecidos e supõe-se que este número ultrapasse 100.000 (Halliwell e Gutteridge, 1999). Os três principais grupos de metabólitos secundários são os terpenos, os polifenóis e os alcalóides. Com algumas propriedades específicas, estes metabólitos secundários são essenciais para a fisiologia da planta (Rossi *et al.*, 2008), contribuindo para a sua pigmentação, crescimento, reprodução e resistência à patógenos e predadores (Harvsteen, 2002). Os polifenóis são encontrados em diversas fontes alimentares, pois estão presentes em aparentemente todas as plantas, fazendo parte da nossa dieta diária (Rossi *et al.*, 2008). Excluindo-se variações quanto às concentrações destes compostos em diferentes exemplares de plantas e variabilidade de consumo por humanos, é difícil o estabelecimento de uma dose diária de consumo de polifenol. Sabe-se que a ingestão humana diária de flavonóides corresponde a 13 mg/dia (Singh *et al.*, 2008). Plantas da mesma espécie, cultivadas em diferentes localidades normalmente possuem os mesmos componentes, mas as concentrações de cada composto, como os antioxidantes, podem diferir. Sabe-se que uma vasta gama de compostos orgânicos naturais de origem vegetal é fisiologicamente ativa, isto é, apresenta ação tranqüilizante, analgésica, antiinflamatória,

citotóxica, anticoncepcional, antimicrobiana, antiviral e fungicida (Ross e Kasum, 2002).
Dentre estas substâncias, esta a classe dos polifenóis (Cadenas e Packet, 2002).


Os polifenóis podem ser divididos em duas grandes categorias de acordo com a sua estrutura molecular: flavonóides e não-flavonóides. Os flavonóides representam dois terços da totalidade dos polifenóis, e podem ser divididos em diferentes subclasses de acordo com o grau de oxidação do anel heterocíclico (Weinreb *et al.*, 2004). São elas: flavonóis, flavanas, flavanóis, flavonas e isoflavonas. Os polifenóis não-flavonóides compreendem o grupo dos ácidos fenólicos, as lignanas e o grupo do resveratrol e participam com um terço da totalidade dos polifenóis encontrados na natureza (Singh *et al.*, 2008).

A determinação de polifenóis em extratos de plantas tem sido realizada principalmente por métodos de separação (Zheleva-Dimitrova *et al.*, 2007) como a cromatografia líquida de alta eficiência, a eletroforese capilar de zona e a cromatografia capilar electrocinética micelar. Dentre os compostos fenólicos mais comumente estudados por estes métodos estão a rutina e a quercetina (Figura 2).

Do ponto de vista fisiológico, toxicológico e farmacológico, o interesse por compostos fenólicos justifica-se pelo fato destes apresentarem uma série de vantagens em relação a outras drogas, principalmente em termos da ausência de efeitos colaterais. Neste sentido, o interesse pela descoberta de novos antioxidantes de fontes naturais tem aumentado, principalmente para prevenir a deterioração fisiológica de organelas e, conseqüentemente, minimizar o efeito oxidativo provocado pelos radicais livres.



Quercetina



Rutina

Figura 2: Estrutura química da quercetina e rutina.

Dentre os órgãos mais estudados nos últimos tempos, o cérebro destaca-se, devido à sua grande susceptibilidade em sofrer danos oxidativos e sua alta atividade metabólica, que induz a um alto consumo de oxigênio. Além disso, os radicais livres têm sido reconhecidos como moléculas que possuem um papel modulador na plasticidade sináptica, todavia, com um efeito deletério no processo de envelhecimento, aumentando o

número de mitocôndrias não-funcionais e diminuindo a plasticidade sináptica. Sabe-se, porém, que uma concentração moderada de radicais livres pode facilitar a memória através da ativação de cinases, enzimas que promovem a fosforilação protéica, o que favorece a memória de longo prazo. Desta forma, pode-se postular que a exposição de organismos a compostos como os polifenóis pode promover um aumento nas defesas antioxidantes, como também modular processos de memória nos organismos tratados com este tipo de compostos (Cadenas e Packet, 2002). Estudos têm demonstrado que a quercetina e outras substâncias polifenólicas podem inibir a ecto-5'-nucleotidase/ CD73 (Kavutcu e Melzig, 1999). Além disso, recentes estudos têm demonstrado que a quercetina tem um efeito antiproliferativo na linhagem de gliomas U138MG, provavelmente devido ao seu efeito inibitório sobre a atividade da 5'-nucleotidase (Braganhol *et al.*, 2007). Muitas evidências sugerem o papel neuroprotetor dos flavonóides (Youdim *et al.*, 2002), mas os mecanismos de ação destes compostos são complexos e envolvem muitos fatores (Zhang *et al.*, 2008). Sabe-se que eles apresentam ação no sistema nervoso central, visto que possuem a capacidade de atravessar a barreira hemato-encefálica (Youdim *et al.*, 2004). Vários estudos recentes mostram a relação da ingestão de polifenóis com o tratamento dos sintomas da doença de Alzheimer, já que vários polifenóis se mostram importantes agentes anticolinérgicos. Entre eles está o trabalho de Zhang *et al.*, (2008), que demonstrou que a fração solúvel em água do própolis apresenta propriedades anticolinérgicas, antiinflamatórias e positivas em relação a prevenir a redução do déficit cognitivo e perda de memória associada a doenças neurodegenerativas.

2. OBJETIVOS

2.1. OBJETIVO GERAL

Avaliar o potencial neuroprotetor preventivo dos polifenóis quercetina e rutina seguido de indução de déficits cognitivos através da utilização de escopolamina. Esta avaliação se dará através da análise das enzimas envolvidas no controle da sinalização purinérgica e colinérgica em cérebro de peixe zebra em nível enzimático, além da avaliação de parâmetros comportamentais, como memória e locomoção.

2.2. OBJETIVOS ESPECÍFICOS

- Estabelecer o modelo de indução de déficit cognitivo associado ao tratamento com escopolamina em peixe zebra;

- Verificar o efeito *in vivo* do tratamento com escopolamina, do tratamento com os compostos polifenólicos (quercetina e rutina) e do tratamento com escopolamina associado ao tratamento com os compostos polifenólicos (quercetina e rutina) sobre as atividades de degradação de ATP, ADP e AMP e ACh em cérebro de peixe zebra.

- Avaliar parâmetros comportamentais de peixe zebra, como memória e atividade locomotora após tratamento com escopolamina e com os compostos polifenólicos (quercetina e rutina) isolados e em associação a tratamento com escopolamina.

CAPITULO 2 - ARTIGO CIENTÍFICO

RICHETTI, S.K., BLANK, M., CAPIOTTI K. M., PIATO A.L., BOGO, M.R., VIANNA., M.R., BONAN, C.D. Quercetin and rutin prevent scopolamine-induced memory impairment in zebrafish (*Danio rerio* Hamilton 1822).

Artigo submetido em 20 de agosto de 2010 ao periódico Behavioural Brain Research.

De: ees.bbr.0.b2bf8.121d108f@eesmail.elsevier.com em nome de Behavioural Brain Research

Enviada: sex 20/8/2010 20:07

Para: Carla Denise Bonan

Assunto: Submission Confirmation

Dear cbonan,

Your submission entitled "Quercetin and rutin prevent scopolamine-induced memory impairment in zebrafish (Danio rerio Hamilton 1822)" has been received by Behavioural Brain Research

You may check on the progress of your paper by logging on to the Elsevier Editorial System as an author. The URL is <http://ees.elsevier.com/bbr/>.

Your username is: cbonan

If you need to retrieve password details, please go to: http://ees.elsevier.com/BBR/automail_query.asp

Your manuscript will be given a reference number once an Editor has been assigned.

Thank you for submitting your work to this journal.

Kind regards,

Elsevier Editorial System
Behavioural Brain Research

For further assistance, please visit our customer support site at <http://epsupport.elsevier.com>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EES via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

**Quercetin and rutin prevent scopolamine-induced memory impairment in zebrafish
(*Danio rerio* Hamilton 1822)**

Richetti, S.K.^{a,b}, Blank, M.^{b,c}, Capiotti K. M.^{a,b}, Piato A.L.^{a,b}, Bogo, M.R.^{b,d}, Vianna.,
M.R.^{b,c} Bonan, C.D.^{a,b*}.

^a Laboratório de Neuroquímica e Psicofarmacologia, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

^b Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM) 90035-003, Porto Alegre, RS, Brazil.

^c Laboratório de Biologia e Desenvolvimento do Sistema Nervoso, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

^d Laboratório de Biologia Genômica e Molecular, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul. Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

Number of pages (including figures): 26

Number of figures: 03

Corresponding author:

Bonan, C.D. Laboratório de Neuroquímica e Psicofarmacologia, Departamento de Biologia Celular e Molecular, Faculdade de Biociências, Pontifícia Universidade Católica

do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

Tel.: +55 51 3353 4158; fax: +55 51 3320 3568. cbonan@pucrs.br

Abstract

Demographic aging gives rise to a growing population with age-associated behavioral and cognitive deficits that may be associated at least partially to the increasing prevalence of neurodegenerative disorders, such as Alzheimer's disease. The aim of our study was to investigate the potential protective role of quercetin and rutin against scopolamine-induced inhibitory avoidance memory deficits in zebrafish. Scopolamine (200 μ M dissolved in the tank water for one hour) given pre-training hindered memory formation while both quercetin and rutin pretreatments (50 mg/kg, single injection, i.p.) prevented the scopolamine induced amnesia. None of the compounds affected zebrafish general locomotor activity. Together, these results contribute to the increase of the knowledge about plant compounds applicability as medicines to prevent and treat neurodegenerative diseases, like Alzheimer's disease.

Keywords: Quercetin; rutin; acetylcholinesterase; zebrafish; Alzheimer's disease; polyphenols; scopolamine.

1. Introduction

Aging in humans is accompanied by structural and neurophysiological changes in the brain and variable degrees of cognitive decline. A central issue arises when these behavioral and cognitive deficits are accompanied with severe dementia, impacting individuals and their caring personal life quality. Demographic aging, in combination with population increasing life expectancies [30], favors the manifestation of neurodegenerative diseases since the best known risk factor for age-related diseases, including Alzheimer's disease (AD), is aging itself [2].

The Alzheimer's disease is a multifactorial disorder with a complex combination of genetic and non-genetic components[43, 52], whereas the non-genetic or sporadic form represents the majority of the cases [52] and involves inflammation, glutamatergic toxicity, mitochondrial and proteasomal dysfunction, the activation of apoptosis pathways and oxidative stress [34, 37, 44]. Despite these components, AD patients experience disturbances in various neurotransmitter systems. Although deficits in glutamatergic, serotonergic, and catecholaminergic systems are common in this pathology, functional deficits in the cholinergic system are strongly related to AD symptoms [7,18, 21, 27]. These changes include a reduction in acetylcholine (ACh) production, leading to a decreased availability of ACh at the neuronal synapse [5, 12, 28]. This reduction is believed to contribute to memory decline characteristic of AD. Furthermore, AD patients also present an augmented clearance of acetylcholine in the synaptic cleft, as a result of an increase in the enzymatic activity of the protein responsible for the hydrolysis of this neurotransmitter, acetylcholinesterase (AChE) [46].

These findings resulted in the establishment of the AD cholinergic hypothesis, in 1982 by Raymond T. Bartus [3].

This hypothesis was the basis for the development of drugs prescribed until today for AD treatment, called acetylcholinesterase inhibitors (ChEi), which prolong the action of acetylcholine in the synapse by preventing its breakdown. This strategy results in improvements of cognition, mood and behavior [36]. Even though there are modest benefits following the treatment with ChEi to the progression of AD, its use is limited because of the occurrence of severe side effects [9]. The identification of effective treatments will require a better understanding of the physiological mechanisms involved and the development of multi-targeted drugs as a result of innovative approaches [37].

There is a growing interest in the potential of phytochemicals to improve memory, learning and general cognitive ability [43, 48]. There is a large amount of excellent reviews highlighting the effects of phytochemicals as modulators of brain function [53-56, 59]. The main dietary sources of these phytochemicals are fruits, vegetables and plant-derived beverages such as tea and red wine [for a complete review see 52] This wide class of phytochemicals includes the polyphenols, the most abundant dietary antioxidants [29]. Some studies already reported a possible relationship between polyphenol ingestion and the prevention of AD [25, 52]. The polyphenols are a large group of compounds that can be divided into several subgroups, including the flavonoids. Two of the flavonoids most widely and abundantly present in herbs and plants consumed by men are quercetin and rutin [47, 52].

Quercetin has been reported to exert numerous pharmacological activities, such as free radical scavenging [24, 55, 56] and anticarcinogenic effects [8]. In addition,

quercetin has the potential to bind to the ATP-binding sites of a large number of proteins [10]. Studies have suggested that quercetin and other polyphenolic substances can inhibit ecto-5- NT/CD73 activity [26]. These actions can affect the cell function by altering the phosphorylation state of target molecules and/or by modulating gene expression [64]. In addition, rutin, studied since 1946, is a quercetin glycoside which has been reported to increase the scavenge of free radicals [24, 38, 39, 51], vascular resistance [50], decrease hepatic and blood cholesterol levels, and also shows antiplatelet activity [38, 51].

Therefore, considering that: (i) AD is a multifactorial disease which prevalence is expected to increase throughout the years (ii) available treatments present modest cognitive benefits but severe side effects, a fact that claims for the development of other strategies to treat this neurodegenerative disease (iii) recent studies suggest the multitargeted action of polyphenols and, finally (iv) polyphenols are natural compounds that do not present collateral effects, we sought to investigate the effects of acute quercetin and rutin treatment in a model of pharmacological cognitive impairment achieved with scopolamine, an antimuscarinic drug, in zebrafish.

2. Materials and methods

2.1 Animals

Wild-type adult (>8 months old) zebrafish of both sexes were obtained from specialized supplier (Redfish Agroloja, RS, Brazil). Animals were kept in 50L housing tanks with tap water previously treated with Tetra's AquaSafe® (to neutralize chlorine, chloramines, and heavy metals present in the water that could be harmful to fish) and continuously

aerated (7.20mgO₂/l) at 25 ± 2°C, under a 14-10 h light/dark photoperiod at a density of up to five animals per liter. Animals were acclimated for at least 2 weeks before the experiments. They were fed three times a day with TetraMin Tropical Flake fish®. The procedures were previously approved by the Animal Ethics Committee of Pontifical Catholic University of the Rio Grande do Sul (PUCRS) under the number 109/09-CEUA.

2.2 Chemicals

Quercetin (C₁₅H₁₀O₇, CAS number 117-39-5), Rutin hydrate (C₂₇H₃₀O₁₆ · H₂O, CAS number 207671-50-9), (-)-Scopolamine hydrobromide trihydrate (C₁₇H₂₁NO₄ · HBr · 3H₂O, CAS number 6533-68-2), Benzocaine (C₉H₁₁NO₂, CAS number 94-09-7), Tween 20 (C₅₈H₁₁₄O₂₆ CAS number 9005-64-5) were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). All other reagents used were of analytical grade.

2.3. Animal procedures

Quercetin and Rutin were suspended in Tween 20 (1%) in saline. The doses of the polyphenols were chosen based on [42], which have shown that the i.p. treatment with quercetin and rutin at 50mg/kg reduced the spatial memory impairment and neuronal death induced by repeated cerebral ischemia in rats. The drugs were administered intraperitoneally (i.p.) in a volume of 20 mL/kg body weight (mean injection volume was 10 µL). I.p. injections were conducted using a 3/10-ml U-100 BD Ultra-Fine™ Short

Insulin Syringe 8mm (5/16") x 31G Short Needle (Becton Dickinson and Company, New Jersey, USA) according to the protocol established by Phelps, Runft and Neely [40].

Briefly, anesthesia of the animals prior to the injection was obtained by its immersion in a Benzocaine solution (1 mM in MeOH 1%) until the animal shows lack of motor coordination and reduced respiration rate. The anesthetized animal was gently put in a water-soaked gauze-wrapped hemostat with the abdomen facing up and the head of the fish positioned at the hinge of the hemostat (the pectoral fins were used as a landmark on the abdomen). The needle was inserted parallel to the spine into the midline of the abdomen posterior to the pectoral fins. The injection procedure was conducted to guarantee that the animal do not spend more than 10 seconds out of the water. After the injection the animals were placed in a separate tank with highly aerated unchlorinated tap water ($25 \pm 2^\circ\text{C}$) to facilitate the animals recovery from the anesthesia. Quercetin and rutin were injected two hours before the beginning of experiment. One hour before the beginning of the training session, the animals were transferred another tank to receive the second treatment, consisted of the scopolamine treatment (200 μM dissolved in the water for one hour as described by [29]). The animals that did not receive scopolamine were also transferred to another tank filled with water to ensure the homogeneity of stress presented to the fish. After the training the animals were transferred to another empty tank equal to the previous one. Tween 20 was used as control. Both drugs and vehicle were prepared freshly in the experimental day. All the animals have recovered after 2-3 minutes following the injection. Animals that did not recover during this period were discarded.

2.4. Behavioral analysis:

2.4.1 Inhibitory avoidance:

Zebrafish were individually trained and tested for long-term memory in the inhibitory avoidance paradigm as described in detail by [6]. Briefly, an 18 cm L x 9 cm W x 7 cm H glass tank divided in two equally sized compartments, designated hereon as dark and white, by a sliding guillotine-type partition (9 cm x 7 cm) was used. The tank water level was 3 cm and the partition raised 1 cm above the tank floor to allow zebrafish to swim freely from one side of the tank to the other. Two electrodes extending through the wall height and placed on each end side of the dark walls attached to an 8 V stimulator administered a final 3 ± 0.2 V AC shock when manually activated. On training session, animals were placed in the white side of the tank while the partition between compartments was closed. After 1 min of familiarization with the new environment the partition was raised, allowing fish to cross to the dark side of the tank. When animals entered the dark side with their entire body the sliding partition was closed and a pulsed electric shock administered for 5 seconds. Fish were then removed from the apparatus and placed in the dedicated temporary tank. Animals were tested 24 hr after training. The test session repeated the training protocol except that no shock was administered and animals immediately removed from the dark compartment. The latency to completely enter the dark compartment was measured on both sessions and the test latencies used as an index of retention. The saline and Tween 20 control groups did not differ on any measure; therefore, the saline treated-groups were excluded from the graphic representation of the results. Tween 20 will be referred to as the control group.

2.4.2 Exploratory assessment

Behavioral testing of drug effects took place during the light phase between 10:00 a.m. and 12:00 a.m. The behavioral screening test was performed thirty minutes after the injection (saline, Tween 20, quercetin or rutin) or after the beginning of the second drug treatment (water or scopolamine), on the inhibitory avoidance training day. The animals were individually transferred to a 2,7 L tank (24 cm L X 8 cm W X 20 cm H) with laterals and bottom white covered, except of the front to avoid any visual disturbances, and were first habituated to the tank for 30 s, as previously described [17]. There was no drug exposure during behavioral experiments. The locomotor activity of the animals was video recorded using Logitech Quickcam PRO 9000 for 5 min after the habituation period and further analyzed using the ANY-Maze recording software (Stoelting Co., Wood Dale, IL, USA). The tank was divided into two equal sections with one horizontal line, and the following behavioral patterns were measured: distance traveled, mean speed, number of line crossings (horizontal line), absolute turn angle, and time spent in upper and lower half.

2.5 Statistical Analysis

Inhibitory avoidance memory data are presented as median + interquartile range since a ceiling of 50s was used to each session. Training and test sessions for each group were compared by Wilcoxon matched pairs test. Training latencies were compared using by Mann-Whitney test. Data of the exploratory assessment were expressed as mean \pm S.E.M. of 4 representative animals for each group and were analyzed by one-way

ANOVA test followed by Tukey test as post-test. $*p < 0.05$ denotes a significant difference from the control group.

3. Results

3.1 Scopolamine induces memory deficits in an inhibitory avoidance paradigm

Adult (>8 months old) male zebrafish long-term memory was tested in the inhibitory avoidance apparatus developed by [6]. To first establish the effectiveness of the scopolamine in the one-trial inhibitory avoidance task, we have treated the animals with scopolamine (200 μ M dissolved in tank water) for one hour previous to training session (Figure 1). While water-exposed animals showed a robust retention of memory on the test session performed 24h after training when training and test latencies were compared ($p = 0.0355$), pre-training scopolamine hindered memory formation ($p = 0.7792$, comparison between training and test session of scopolamine treated animals). Importantly, no differences were found between training latencies for both groups (Mann-Whitney test). Scopolamine's ability to induce memory deficits when given pre-training at the inhibitory avoidance has been shown in rodents and our data in zebrafish supports its effect to evaluate memory enhancing drugs.

3.2 Scopolamine deficits are prevented by quercetin and rutin treatment

The ability of quercetin and rutin to prevent scopolamine-induced inhibitory avoidance memory deficits was evaluated by combining an initial quercetin and rutin i.p. treatment with the pre-training scopolamine exposure (Figure 2). Tween 20 was used as the vehicle for quercetin and rutin and it did not differ from water being therefore considered the

standard control treatment of the experiment. Animals receiving Tween 20 (control group), quercetin or rutin only effectively learned, showing significant differences from their respective training and test sessions ($p < 0.05$ for each group analyzed separately). Scopolamine pre-training again hindered memory formation, as observed in the lack of long-term memory retention when training and test sessions were compared in animals that received Tween 20 i.p. followed by scopolamine ($p = 0.2291$). Acute single pre-treatment with quercetin or rutin one hour before the beginning of scopolamine treatment prevented the memory impairment caused by scopolamine, as shown by a statistically different latency between training and test sessions for both rutin and quercetin-treated animals ($p < 0.05$ for either group).

3.3 Scopolamine and polyphenols effects on exploratory assessment

Distinct parameters of zebrafish swimming activity were examined in the tank diving behavioral test. As indicated by the distance traveled, mean speed and line crossings, no differences were found in the locomotor activity of animals receiving any of the treatments when compared to the control group (Fig. 3 A, B, and C, respectively). None of the treatments have affected the swimming coordination neither the general swimming pattern of the animals, as shown by the absence of statistically different alterations in the absolute turn angle (Fig. 3 D). No differences in the time spent in the upper half or the lower half were found in treated animals in comparison with the control group (Fig. 3 E and F respectively) showing no anxiogenic properties of any treatment.

4. Discussion

In the present study, we have evaluated the potential preventive role of the flavonoids quercetin and rutin to prevent the scopolamine-induced memory deficits in zebrafish. Interestingly, we have found that one single intraperitoneal injection of 50 mg/kg of quercetin or rutin at one hour before the scopolamine treatment prevented scopolamine induced memory deficits. Scopolamine, the tropane alkaloid originally isolated from classical nightshade, such as *Atropa belladonna* L. [64] is a competitive antagonist of the muscarinic acetylcholine receptor (mAChR) [60]. Besides its use as a treatment for central nervous system dysfunctions such as motion sickness, shaking palsy and opioid addiction [63], it became widely used as a standard/reference drug for inducing cognitive deficits in a wide range of animal models, especially after the postulation of the cholinergic hypothesis of geriatric memory dysfunction [3].

Despite the scopolamine classical use as an amnesic agent, there is a lot of discrepancy in relation to scopolamine effects in the locomotion. Some studies, in fact, challenge the viability of scopolamine use as a cognitive impairer, questioning if the alterations in behavior are related to peripheral locomotor effects, instead of memory disruption [for a review see 31]. To address this problem we have performed a general analysis on zebrafish locomotor behavior. As shown in the Fig. 3, there were no changes in none of the parameters analyzed. We have also shown that pre-exposure to scopolamine for one hour immediately before inhibitory avoidance training did not impact training performance, since control and scopolamine-treated animals training session latencies did not differ. In light of this evidence we believe that the scopolamine

induced memory deficits observed were solely due to the drug effect on the cholinergic system.

The cholinergic system is involved in many physiological processes, including synaptic plasticity and learning and memory [14, 41, 57, 62]. Cholinergic agonists can facilitate memory, whereas cholinergic antagonists can impair memory [34]. Studies of the effects on brain plasticity of cholinergic agents, particularly those engaging muscarinic receptors, have provided robust and clarifying information about learning and memory processes [23]. In addition, the cholinergic hypothesis of geriatric memory dysfunction and evidence of the involvement of this system in the etiology of AD have brought global attention to cholinergic interventions as a treatment for this disease.

In that sense, molecules that could modulate the cholinergic hypoactivity related cognitive effects have potential clinical use [13]. Cholinesterase inhibitors, such as Tacrine, Galantamine, Physostigmine and Donepezil were designed to ameliorate cholinergic deficits by slowing the rate of acetylcholine degradation after its synaptic release, but the use of these medicines is not always well accepted by the patients due to their severe side effects [9, 45], high cost and scarcity of robust benefits [7, 33].

Quercetin and rutin, natural compounds widely found in the diet, have been studied for a long time and shown to have wide physiological effects [52]. The effects of flavonoid-rich diet on cognitive function have been linked to the ability of flavonoids to interact with the cellular and molecular framework involved in learning and memory, including synaptic potentiation and plasticity [22]. Flavonoids also have known antioxidant abilities, effectively protecting neurons against neurotoxins, suppressing neuroinflammation, and enhancing neuronal function [reviewed in 61], stimulating

neuronal regeneration and revascularization [22, 52]. Flavonoids have also been reported to act as ChEi [1].

Here we have shown that these polyphenols could protect against scopolamine-induced cognitive deficits, using an inhibitory avoidance task. Aversive conditioning tasks, such as the inhibitory avoidance, have been shown useful to analyze cholinergic effects on memory, as muscarinic and nicotinic neurotransmission have been demonstrated to affect every aspect of aversive conditioning. Compelling evidence shows that cholinergic manipulations can affect memory acquisition, consolidation, and retrieval in inhibitory avoidance behavioral task, since cholinergic neurons are presented in areas engaged in learning and memory processes from this task in rodents [58].

Zebrafish (*Danio rerio*, Hamilton 1822), is a powerful animal model in many areas of biological research. Its use ranges from toxicology, developmental biology, biomedicine, neurophysiology, drug discovery [49] model for human diseases [4, 32] and behavioral analysis [6, 16, 17, 35]. In addition to the known advantages of its use, such as the small size and maintenance cost, the transparency of embryos and larvae, and the speed at which these develop *ex utero* [19, 20], zebrafish has been suited for large throughput screening for drug discovery, including those from natural sources [11, 15]. Zebrafish combines the ability to perform large scale screenings yet requiring a smaller infrastructure when compared to rodents, bringing new perspectives for the drug discovery process to yet untreatable diseases, such as Alzheimer's disease.

According to our results, quercetin and rutin administration prevented scopolamine induced memory deficits in zebrafish, suggesting that these flavonoids might be a preventive strategy against the development of AD. These findings, although

restrict to behavioral analysis, raise a new perspective to the prevention and treatment of AD. More experiments are already being conducted to investigate candidate biochemical targets of polyphenols in the scopolamine-induced memory deficits.

Acknowledgments

This work was supported by DECIT/SCTIEMS through Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and by the FINEP research grant “Rede Instituto Brasileiro de Neurociência (IBN-Net)” # 01.06.0842-00.

Conflict of Interests

The authors declare no conflict of interests.

References

- [1] Ahmed T, Gilani A-H. Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. *Pharmacol Biochem Behav* 2009; 91: 554–59.
- [2] Alzheimer's Association. 2010 Alzheimer's Disease Facts and Figures. *Alzheimers Dement* 2010; 6(2):158-94.
- [3] Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. *Science* 1982; 217(4558): 408-14.
- [4] Best JD, Alderton WK. Zebrafish: An in vivo model for the study of neurological diseases. *Neuropsychiatr Dis Treat* 2008; 4(3): 567-76.
- [5] Birks J. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev* 2006; 1:CD005593.
- [6] Blank M, Guerim LD, Cordeiro RF, Vianna MR. A one-trial inhibitory avoidance task to zebrafish: Rapid acquisition of an NMDA-dependent long-term memory. *Neurobiol Learn Mem* 2009; 92(4): 529-34.
- [7] Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. *Lancet*. 2006; 368: 387-403.
- [8] Braganhol E, Tamajusuku AS, Bernardi A, Wink MR, Battastini AM. Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. *Biochim Biophys Acta*. 2007; 1770(9):1352-59.
- [9] Casey DA, Antimisiaris D, O' Brien J. Drugs for Alzheimer's Disease: Are they effective? *P. T.* 2010; 35(4): 208-11.

- [10] Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP and steroid binding sites on mouse P-glycoprotein. *Proc. Natl. Acad. Sci. U. S. A.* 1998; 95: 9831-36.
- [11] Crawford AD, Esguerra CV, de Witte PAM. Fishing for Drugs from Nature: Zebrafish as a Technology Platform for Natural Product Discovery. *Planta Med* 2008; 74: 624-32.
- [12] Deutsch JA. The cholinergic synapse and the site of memory. *Science* 1971; 174: 788-94.
- [13] Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. *Int. Psychogeriatr.* 2002; 14: 93-126.
- [14] Flood JF, Landry DW, Jarvik ME. Cholinergic receptor interactions and their effects on long-term memory processing. *Brain Res* 1981; 215: 177-85.
- [15] Gerlai R. High-throughput behavioral screens: the first step towards finding genes involved in vertebrate brain function using zebrafish. *Molecules* 2010; 15(4): 2609-22.
- [16] Gerlai, R. Zebrafish: An uncharted behavior genetic model. *Behav Genet.* 2003; 33: 461-68.
- [17] Gerlai R, Lahav M, Guo S, Rosenthal A. Drinks like a fish: zebra fish (*Danio rerio*) as a behavior genetic model to study alcohol effects. *Pharmacol Biochem Behav* 2000; 67: 773-82.

- [18] Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. *Neurochem Res* 2003; 28: 515-22.
- [19] Goldsmith P. Zebrafish as a pharmacological tool: the how, why and when. *Curr Opin Pharmacol* 2004; 4(5): 504-12.
- [20] Guo S. Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish? *Genes Brain Behav* 2004; 3: 63-74.
- [21] Han CK, Park YH, Jin DQ, Hwang YK, Oh KB, Han JS. SK-PC-B70M from *Pulsatilla koreana* improves scopolamine-induced impairments of memory consolidation and spatial working memory. *Brain Res* 2007; 1184: 254-59.
- [22] Harvsteen BH. The biochemistry and medical significance of the flavonoids *Pharmacol Ther* 2002; 96: 67-202.
- [23] Hasselmo ME. The Role of Acetylcholine in Learning and Memory, *Curr Opin Neurobiol* 2006; 16(6): 710-15.
- [24] Horvathova K, Novotny L, Vachalkova A. The free radical scavenging activity of four flavonoids determined by the comet assay. *Neoplasma* 2003; 50: 291-95.
- [25] Ji HF, Zhang HY. Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer's disease. *J Mol Struct.* 2006; 767: 3-9.
- [26] Kavutcu M, Melzig MF. In vitro effects of selected flavonoids on the 5-nucleotidase activity. *Pharmazie* 1999; 54: 457-59.
- [27] Kim DH, Yoon BH, Kim YW, Lee S, Shin BY, Jung JW, Kim HJ, Lee YS, Choi JS, Kim SY, Lee KT, Ryu JH. The seed extract of *Cassia obtusifolia* ameliorates learning and memory impairments induced by scopolamine or transient cerebral hypoperfusion in mice. *J Pharmacol Sci.* 2007; 105: 82-93.

- [28] Kim MJ, Choi SJ, Lim ST, Kim HK, Kim YJ, Yoon HG, Shin DH. Zeatin Supplement Improves Scopolamine-Induced Memory Impairment in Mice. *Biosci Biotechnol Biochem* 2008; 72(2): 577-81.
- [29] Kim YH, Lee Y, Kim D, Jung MW, Lee CJ.. Scopolamine-induced learning impairment reversed by physostigmine in zebrafish. *Neurosci Res.* 2010; 67(2):156-61.
- [30] Kinsella K, Wan H. "An Ageing World". US Census Bureau, International Population Reports, (2009) P95/09-1, Washington DC: US Government Printing Office.
- [31] Klinkenberg I, Blokland, A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. *Neurosci Biobehav Rev* 2010; 34(8):1307-50.
- [32] Lieschke GJ, Currie PD. Animal models of human disease: zebrafish swim into view. *Nat Rev Genet* 2000; 8(5): 353-67.
- [33] Maggini M, Vanacore N, Raschetti R. Cholinesterase Inhibitors: Drugs Looking for a Disease? *PLoS Med.* 2006; 3(4) e140.
- [34] Mattson MP. Pathways towards and away from Alzheimer's disease. *Nature.* 2004; 430: 631-39.
- [35] Miklosi A, Andrew RJ. The zebrafish as a model for behavioral studies. *Zebrafish* 2006; 3: 227-234.
- [36] Mount C, Downton C. Alzheimer disease: progress or profit? *Nat Med* 2006; 12: 780-84.
- [37] Mucke L. Neuroscience: Alzheimer's disease. *Nature* 2009; 461: 895-97.

- [38] Park SY, Bok SH, Jeon SM, Park YB, Lee SJ, Jeong TS, Choi MS. Effect of Rutin and tannic acid supplements on cholesterol metabolism in rats. *Nutr Res* 2002; 22: 283-95.
- [39] Park YC, Rimbach G, Saliou C, Valacchi G, Packer L. Activity of monomeric, dimeric, and trimeric flavonoids on NO production, TNF- α secretion, and NF- κ B-dependent gene expression in RAW 264.7 macrophages. *FEBS Lett* 2000; 464: 93-97.
- [40] Phelps HA, Runft DL, Neely MN. Adult zebrafish model of streptococcal infection. *Curr Protocol Microbiol* 2009; 9D.1.1-9D.1.27.
- [41] Power AE, Vazdarjanova A, McGaugh JL. Muscarinic cholinergic influences in memory consolidation. *Neurobiol. Learn. Mem.* 2003; 80:178-193.
- [42] Pu F, Mishima K, Irie K, Motohashi K, Tanaka Y, Orito K, Egawa T, Kitamura Y, Egashira N, Iwasaki K, Fujiwara M. Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. *J Pharmacol Sci.* 2007; 104(4): 329-34.
- [43] Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. *Eur J Pharmacol.* 2006; 545: 51-64.
- [44] Reddy, P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. *Antioxid Redox Signal.* 2007; 9(10): 1647-58.
- [45] Roberson ED, Mucke, L. 100 Years and Counting: Prospects for Defeating Alzheimer's Disease. *Science* 2006; 314: 781-84.

- [46] Roger ML, Miia K, Nigel HG. Acetylcholinesterase and its inhibition in Alzheimer's disease. *Clin Neuropharmacol* 2004; 27: 141-49.
- [47] Ross JA, Kasum, CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annu Rev Nutr.* 2002; 22: 19-34.
- [48] Rossi L, Mazzitelli S, Arciello M, Capo CR, Rotilio G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. *Neurochem Res.* 2008; 33: 2390-2400.
- [49] Rubinstein AL. Zebrafish: from disease modelling to drug discovery. *Cur Opin Drug Discov Devel* 2003; 6: 218-23.
- [50] Shanno RL. Rutin: a new drug for the treatment of increased capillary fragility. *Am. J. Med. Sci.* 1946; 211: 539-43.
- [51] Sheu JR, Hsiao G, Chou PH, Shen MY, Chou DS. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonols quercetin, in human platelets. *J Agric Food Chem* 2004; 52: 4414-18.
- [52] Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. *J Agric Food Chem* 2008; 56: 4855-73.
- [53] Spencer JP. Flavonoids: modulators of brain function? *Br J Nutr.* 2008; 99 E Suppl 1:ES 60-77.
- [54] Spencer JP. The impact of flavonoids on memory: physiological and molecular considerations. *Chem Soc Rev* 2009; 38(4): 1152-61.

- [55] Spencer JP, Abd El Mohsen MM, Minihane AM, Mathers JC. Biomarkers of the intake of dietary polyphenols: strengths, limitations and application in nutrition research. *Br J Nutr.* 2008; 99(1): 12-22.
- [56] Spencer JP, Vauzour D, Rendeiro C. Flavonoids and cognition: the molecular mechanisms underlying their behavioural effects. *Arch Biochem Biophys.* 2009; 492(1-2): 1-9.
- [57] Stratton LO, Petrinovich L. Post-trial injections of an anti-cholinesterase drug and maze learning in two strains of rats. *Psychopharmacol* 1963; 5: 47-54.
- [58] Tinsley MR, Quinn JJ, Fanselow MS. The Role of Muscarinic and Nicotinic Cholinergic Neurotransmission in Aversive Conditioning: Comparing Pavlovian Fear Conditioning and Inhibitory Avoidance. *Learn Mem.* 2004; 11: 35-42.
- [59] Vafeiadou K, Vauzour D, Spencer JP. Neuroinflammation and its modulation by flavonoids. *Endocr Metab Immune Disord Drug Targets* 2007; 7(3): 211-24.
- [60] Wang H, Lu Y, Chen HZ. Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice, *Neurosci. Lett.* 2003; 344: 173-76.
- [61] Ward CP, Redd K, Williams BM, Caler JR, Luo Y, McCoy JG. Ginkgo biloba extract: cognitive enhancer or antistress buffer. *Pharmacol Biochem Behav.* 2002; 72: 913-22.
- [62] Weinberger NM. Food for Thought: Honeybee Foraging, Memory, and Acetylcholine. *Sci. STKE* 2006; (336) pe23.

- [63] Xiang XH, Wang HL, Wu WR, Guo Y, Cao DY, Wang HS, Zhao Y. Ethological analysis of scopolamine treatment or pretreatment in morphine dependent rats. *Physiol. Behav.* 2006; 88: 183-189.
- [64] Zhang WW, Song MK, Cui YY, Wang H, Zhu L, Niu YY, Yang LM, Lu Y, Chen HZ. Differential neuropsychopharmacological influences of naturally occurring tropane alkaloids anisodamine versus scopolamine. *Neurosci Lett.* 2008; 443: 241-245.

Figure legends:**Figure 1: Scopolamine induces long-term memory deficits in inhibitory avoidance**

Effect of scopolamine on latency to cross to dark compartment in training and long-term memory test sessions in the inhibitory avoidance task. Animals were pre-treated with scopolamine 1 hour prior to training session. Control animals were manipulated similarly but exposed to water only. Data are presented as median + interquartile range (N = 7 per group). * indicates $p < 0.05$ between training and test sessions compared by Wilcoxon matched pairs test. No differences were found between training latencies for both groups (Mann-Whitney test).

Figure 2: Scopolamine induced cognitive deficits are prevented by quercetin and rutin

Effects of scopolamine on latencies to enter the dark compartment for animals trained on the inhibitory avoidance task. T, tween treated animals, Q, quercetin treated animals, R, Rutin treated animals. Animals received single intraperitoneal injection of Tween 20 (1%), quercetin or rutin (50 mg/kg) two hours before the training session. The i.p. treatment was combined by water or scopolamine 1h exposure prior to test. Control animals were manipulated as equal as the treated animals, except that they received water instead scopolamine. Data are presented as median + interquartile range (N > 7 per group). * indicates $p < 0.05$ between training and test sessions for each group compared by Wilcoxon matched pairs test. No differences were found between training latencies for

both groups (Mann-Whitney test). # Comparison between test sessions in relation to the Tween 20 test session latency.

Figure 3: Neither scopolamine nor quercetin or rutin affects zebrafish locomotor activity. Effect of exposure to saline, Tween 20, quercetin and rutin, followed by water or scopolamine exposure on the distance traveled (A), mean speed (B), number of line crossings (C), absolute turn angle (D), time spent in the upper zone (E) and in the lower zone (F) determined during 5 min of video recording in the tank diving behavioral test. SW, saline + water, SS, saline + scopolamine, TW, tween + water, TS, tween + scopolamine, QW, quercetin + water, QS, quercetin + scopolamine, RW, rutin + water, RS, rutin + scopolamine. Animals received single intraperitoneal injection of Saline, Tween 20 (1%), quercetin and rutin (50 mg/kg) two hours before the beginning of the video recording, and were transferred to the second treatment (water or scopolamine 200uM dissolved in the tank water) one hour before the video recording. Data were expressed as mean \pm S.E.M. of 4 representative animals for each group and were analyzed by one-way ANOVA test. * $p < 0.05$ denotes a significant difference from the control group.




Figure 1




Figure 2




Figure 3

CAPITULO 3 - ARTIGO CIENTÍFICO

**RICHETTI, S.K., CAPIOTTI K. M., BLANK, M., PIATO A.L., BOGO, M.R.,
VIANNA., M.R., BONAN, C.D.** Quercetin and rutin affects acetylcholine and adenine
nucleotide hydrolysis in zebrafish (*Danio rerio* Hamilton 1822)

Artigo em preparação que será submetido ao periódico

Naunyn-Schmiedeberg's Archives of Pharmacology

Quercetin and rutin affects acetylcholine and adenine nucleotide hydrolysis in zebrafish (*Danio rerio* Hamilton 1822)

Richetti, S.K.^{1,2}, Capiotti K. M.^{1,2}, Blank, M.^{2,3}, Bogo, M.R.^{2,4}, Vianna., M.R.^{2,3} Bonan, C.D.^{1,2*}.

¹ Programa de Pós-Graduação em Biologia Celular e Molecular, Laboratório de Neuroquímica e Psicofarmacologia, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

² Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM) 90035-003, Porto Alegre, RS, Brazil.

³ Programa de Pós-Graduação em Biologia Celular e Molecular, Laboratório de Biologia e Desenvolvimento do Sistema Nervoso, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

⁴ Programa de Pós-Graduação em Biologia Celular e Molecular, Laboratório de Biologia Genômica e Molecular, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul. Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

Corresponding author:

Bonan, C.D. Laboratório de Neuroquímica e Psicofarmacologia Departamento de Biologia Celular e Molecular, Faculdade de Biociências, Pontifícia Universidade Católica do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil. Tel.: +55 51 3353 4158; fax: +55 51 3320 3568. cbonan@pucrs.br

Abstract

The purpose of this manuscript was to analyze the effects of the polyphenols quercetin and rutin on the ATP, ADP, AMP, and acetylcholine hydrolysis in a model of pharmacological cholinergic disruption achieved with scopolamine, an antimuscarinic drug, in zebrafish. To address this question, animals were treated with quercetin or rutin (50mg/kg, i.p. injection) followed by exposure in water or scopolamine (200 μ M dissolved in the water) during one hour. Rutin treatment followed by exposure to water inhibited the acetylcholine hydrolysis (27% inhibition) whereas the treatment with rutin followed by exposure to scopolamine reduced ATP hydrolysis (48.2% inhibition). Regarding the effects of quercetin, it inhibited the AMP hydrolysis either when its administration was followed by exposure to water or scopolamine (54.4 and 50.7% inhibition respectively). Moreover, our results showed that rutin and quercetin *per se* are able to modulate the levels of acetylcholine, ATP, and adenosine in zebrafish brain. Considering the important role of adenine nucleotides and acetylcholine in learning and memory processes, the results demonstrated in this study give rise to new perspective in relation to preventive strategies to be conducted throughout the lifespan, seeking for the prevention of age-associated cognitive decline.

Keywords: Quercetin, Rutin, Acetylcholinesterase, Ectonucleotidases, Zebrafish, Alzheimer.

1. Introduction

The increase in the life expectancy, as a result of medicine and medical technologies advances, contributes to a phenomenon related to the augment in the elder population worldwide. As a consequence, many age-related diseases are expected to raise as serious public health problems. The best-known risk factor in ageing is dementia and dementia-related diseases, such as Alzheimer's disease (AD). AD is expected to commit millions of people with 65 years or more in the next decades (Wimo et al., 2003; Mount and Downton, 2006).

This multifactorial disease is a consequence of the combination of genetic and non genetic factors (Ramassamy, 2006; Singh et al., 2008). Between the genetic factors, mutations in genes related to the β -amyloid peptide synthesis pathway are involved (Ramassamy, 2006; Reddy, 2007), resulting in a disturbance of this route. The non genetic form of the disease counts for the majority of the cases. These non genetic factors include for example inflammation, glutamatergic toxicity, dysfunction of mitochondrial activity, activation of apoptotic pathways and alteration of the homeostasis of antioxidants/oxidation (Ramassamy, 2006; Reddy, 2007; Roberson and Mucke, 2006). In addition, alterations in many neurotransmission systems, such as the purinergic and cholinergic systems are common in this pathology (Cuello et al., 2010; Cunha, 2008; Stone et al., 2009; Thathiah and De Strooper, 2009).

ATP and adenosine are important endogenous signaling molecules of the purinergic system that exerts a wide range of actions. ATP, besides its energetic role, also acts as an excitatory or inhibitory neurotransmitter, as a trophic factor with effects on the cellular proliferation, as an excitotoxicity biomarker and as a component of pathologies

(Abbracchio and Burnstock, 1998). These actions are triggered by ATP binding to specific receptors called P2 receptors, subdivided in the P2X family, composed by ionotropic receptors, and the P2Y family, composed by metabotropic receptors (Burnstock, 2004, 2007, 2008; Burnstock and Knight, 2004). ATP is released in the synaptic cleft together with other neurotransmitters such as dopamine and acetylcholine (Burnstock 1999, 2004) and has its signal cleared by the action of a family of ecto-enzymes, the ectonucleotidases, which hydrolyze the neurotransmitter ATP to the neuromodulator adenosine. Adenosine is a neuromodulator that regulates neurotransmitter release in the synaptic cleft, protects organism against injury (Cunha, 2001, 2005; Fredholm, 2003) and is involved in the regulation of anxiety, sleep, memory, and cognition (El Yacoubi et al., 2000; Porkka-Heiskanen, 1999; Ribeiro et al., 2003). Adenosine acts through P1 metabotropic receptors divided in A_1 , A_{2A} , A_{2B} and A_3 . The A_1 and A_3 receptors are coupled to $G_{i/o}$ proteins, leading to an inhibition in cyclic AMP (cAMP) synthesis, in contrast to the A_{2A} e A_{2B} receptors, which are coupled to G_s proteins, resulting in stimulation of cAMP synthesis. Alterations in the purinergic system are common in neurodegenerative diseases, such as AD (For a review see Burnstock 2008; Jenner et al., 2009; Rosso et al., 2008).

In the cholinergic system, the signaling molecule acetylcholine acts in the synaptic cleft by its binding to nicotinic receptors (nAChr), which are ionotropic and the muscarinic receptors (mAChr), which are metabotropic coupled to different G proteins and are strongly related to learning and memory (Anagnostaras et al., 2003; Picciotto et al., 1998). Acetylcholine clearance and the control of its signal are performed by the enzyme acetylcholinesterase (AChE) in the synaptic cleft. Alzheimer's disease patients

present an augmented clearance of acetylcholine in the synaptic cleft, as a result of an increase in AChE activity (Roger et al., 2004). Besides that, other cholinergic alterations are common to AD patients. These alterations include a reduction in acetylcholine (ACh) production, leading to a decreased availability of ACh at the neuronal synapse (Birks, 2006; Kim et al., 2008). This reduction is believed to contribute to memory decline characteristic of AD.

Recently, there is an intense interest in the development of new strategies to treat neurodegenerative diseases. In that sense, there is a broad interest in analyzing the properties of phytochemicals, based on reportings of its ability to influence cognition and learning, enhancing existing neuronal function and stimulating neuronal regeneration (reviewed in Spencer 2008, 2009). The polyphenols, a group of phytochemicals are the most abundant dietary antioxidants (Kim et al., 2010). Some studies already reported a possible relationship between polyphenol ingestion and the prevention of AD (Weinreb et al., 2004). The polyphenols are large group that can be divided into several subgroups, including the flavonoids. Two of the flavonoids most widely and abundantly present in herbs and plant foods are quercetin and rutin (Singh et al., 2008).

Therefore, considering that AD is a multifactorial disease with alterations in purinergic and cholinergic neurotransmission systems and recent studies suggest the multitargeted actions of polyphenols, the aim of this study was to investigate the effects of acute quercetin and rutin treatment in the hydrolysis of ATP, ADP, AMP, and ACh in a model of pharmacological cholinergic disruption achieved with scopolamine, an antimuscarinic drug, in zebrafish.

2. Materials and methods

2.1 Animals

Adult (>8 months old) and healthy zebrafish of both sexes were obtained from specialized supplier (Redfish Agroloja, RS, Brazil) and were of genetically heterogeneous (randomly bred) stock. Animals were kept in standard conditions (tap water treated with Tetra's AquaSafe® to neutralize chlorine, chloramines, and heavy metals present in the water that could be harmful to fish) continuously aerated water (7.20mgO₂/l , 25 ± 2°C, under a 14-10 h light/dark cycle photoperiod) in 50L housing tank and a density of up to five animals per liter (Westerfield, 2007) for at least 2 weeks to acclimate before the experiments. The animals were maintained healthy and free of any signs of disease, according to the "Guide for the Care and Use of Laboratory Animals" published by the US National Institutes of Health (NIH publication No. 85–23, revised 1996) and fed three times a day with TetraMin Tropical Flake fish. The Ethics Committee of Pontifical Catholic University of the Rio Grande do Sul (PUCRS) approved the protocol under the number 109/09- CEUA.

2.2 Chemicals

Quercetin ($C_{15}H_{10}O_7$, CAS number 117-39-5), Rutin hydrate ($C_{27}H_{30}O_{16} \cdot H_2O$, CAS number 207671-50-9), (-)-Scopolamine hydrobromide trihydrate ($C_{17}H_{21}NO_4 \cdot HBr \cdot 3H_2O$, CAS number 6533-68-2), Benzocaine ($C_9H_{11}NO_2$, CAS number 94-09-7), Tween 20 ($C_{58}H_{114}O_{26}$ CAS number 9005-64-5), Trizma Base, EDTA, EGTA, sodium citrate, Coomassie Blue G, bovine serum albumin, acetylthiocholine, 5,5'-dithiobis-2-nitrobenzoic acid (DNTB) were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). KCl was purchased from Labsynth (Brazil). $MgCl_2$ was purchased from Isofar and Vetec (Brazil) respectively. All other reagents used were of analytical grade.

2.3. Animal procedures

Quercetin and Rutin were suspended in Tween 20 (1%). The doses of the polyphenols were chosen based on Pu et al., 2007, which has shown that the i.p. treatment with quercetin and rutin at 50mg/kg reduced the spatial memory impairment and neuronal death induced by repeated cerebral ischemia in rats. The drugs were administered intraperitoneally (i.p.) in a volume of 20 mL/kg (mean injection volume was 10 μ L) body weight. I.p. injection was conducted using a 3/10-ml U-100 BD Ultra-Fine™ Short Insulin Syringe 8mm (5/16") x 31G Short Needle (Becton Dickinson and Company, New Jersey, USA) according to the protocol established previously (Phelps et al., 2009). Briefly, animal's anesthesia prior to the injection was obtained by its immersion in a benzocaine solution (1 mM in MeOH 1%) until the animal shows lack of motor coordination and reduced respiration rate. The anesthetized animal was gently put in a gauze-wrapped hemostat with the abdomen facing up and the head of the fish positioned

at the hinge of the hemostat (the pectoral fins were used as a landmark on the abdomen). The needle was inserted parallel to the spine into the midline of the abdomen posterior to the pectoral fins. The injection procedure was conducted to guarantee that the animal don't spend more than 10 seconds out of the water. After the injection the animals were placed in a separate tank with highly aerated unchlorinated tap water ($25 \pm 2^{\circ}\text{C}$) to facilitate the animals recovery from the anesthesia. Quercetin and rutin were injected two hours before the euthanasia. One hour before the euthanasia, the animals were transferred another tank to receive the second treatment, consisted of the scopolamine treatment ($200 \mu\text{M}$ dissolved in the water for one hour as described by Kim et al., 2010). The animals that did not receive scopolamine were also transferred to another tank filled with water to ensure the homogeneity of stress presented to the fish. Tween 20 was used as control. Both drugs and vehicle were prepared freshly in the experimental day. All the animals have recovered after 2-3 minutes following the injection. Animals that did not recover during this period were discarded.

2.4 In vitro assays

Scopolamine ($50\text{-}500 \mu\text{M}$) was added to the reaction medium before the pre-incubation with the enzyme and maintained throughout the enzymatic assay. Control group was performed with no addition of scopolamine in the enzyme assay.

2.5 Determination of AChE activity

Zebrafish brains were homogenized on ice in 60 vol (v/w) of 0.05 M Tris-HCL, pH 8.0, using a Teflon-glass homogenizer. AChE activity was determined according the method of Ellmann et al., (1961) with minor modifications. Briefly, the activity on the homogenate was measured by determining the rate of hydrolysis of acetylthiocholine iodide (ACSh, 0.88 mM) in a final volume of 300 μ L, with 33 μ L of 100 mM phosphate buffer, pH 7.5, and 2 mM DTNB. In this solution, 5 μ g of protein of each sample were added and pre-incubated at 25°C for 10 min. The reaction was started with the addition of the substrate acetylthiocholine, and as soon as the substrate was added the hydrolysis and the formation of the dianion of DTNB were analyzed in 412 nM for 2.5 min (in intervals of 30 s) using a microplate reader. AChE activity was expressed as micromole of thiocholine (SCh) released per hour per milligram of protein. To ensure the consistence of our results, the tests were performed at least in triplicates.

2.6 Determination of ATP, ADP and AMP hydrolysis:

2.6.1 Membrane preparation

The preparation of brain membranes was performed as described previously by Barnes et al. (1993). Zebrafish were euthanized by decapitation, their brains were removed from the cranial skull by the dissection technique. For each sample (membrane preparation), a pool of fifteen zebrafish brains was used for *in vitro* experiments, and five for *in vivo* experiments. Zebrafish brains were briefly homogenized in 60 volumes (v/w) of chilled Tris-citrate buffer (50 mM Tris, 2 mM EDTA, 2 mM EGTA, pH 7.4, with citric acid) in a motor driven Teflon-glass homogenizer. The samples were centrifuged at 1000 x g for

10 min and the pellet was discarded. The supernatant was centrifuged for 25 min at 40000 x g. The resultant pellet was frozen in liquid nitrogen, thawed, resuspended in Tris–citrate buffer, and centrifuged for 20 min at 40000 x g. This fresh-thaw-wash procedure was used to promote the lysis of the brain membranes. The final pellet was resuspended and used in the enzyme assays. All samples were maintained at 2–4 °C.

2.6.2 *Enzyme assays*

The conditions of NTPDase and 5'-nucleotidase assays were performed as described previously (Rico et al., 2003, Senger et al., 2004). Zebrafish brain membranes (3–10 µg protein) were added to the reaction mixture containing 50 mM Tris–HCl (pH 8.0) and 5 mM CaCl₂ (for the NTPDase activity) or 50 mM Tris–HCl (pH 7.2) and 5 mM MgCl₂ (for the 5'-nucleotidase activity) in a final volume of 200 µL. The samples were preincubated for 10 min at 37 °C and the reaction was initiated by the addition of substrate (ATP, ADP or AMP) to a final concentration of 1 mM. The reaction was stopped by the addition of trichloroacetic acid in a final concentration of 5% and the samples were chilled on ice for 10 min. Samples were then removed and it was added 1 ml of a mixture containing 2.3% polyvinyl alcohol, 5.7% ammonium molybdate and 0.08% Malachite Green in order to determine the inorganic phosphate released (Pi) (Chan et al., 1986). Controls with the addition of the enzyme preparation after mixing with trichloroacetic acid were used to correct non-enzymatic hydrolysis of the substrates. Incubation times and protein concentrations were chosen in order to ensure the linearity

of the reactions. Specific activity was expressed as nanomol of Pi released per minute per milligram of protein. All enzyme assays were run at least in triplicate.

2.7 Protein determination

Protein was measured by the Coomassie Blue method considering bovine serum albumin as standard (Bradford, 1976).

2.8 Statistical Analysis

Data were expressed as means \pm S.E.M. and analyzed by one-way analysis of variance (ANOVA), following the post-hoc test of Tukey, considering $P < 0.05$ as significant.

Before ANOVA analysis, its assumptions (normality and variances homogeneity) were checked.

3. Results

In vitro effects of scopolamine treatment on AChE activity and on ATP, ADP and AMP hydrolysis.

To analyze possible effects of scopolamine on the hydrolysis of ACh, ATP, ADP, and AMP we have performed *in vitro* experiments, investigating a wide range of scopolamine concentrations (50-500 μ M). As shown by Figure 1, scopolamine *in vitro* was not able to change neither in ACh (A), ATP (B), ADP (C) nor AMP (D) hydrolysis.

In vivo effects of scopolamine and polyphenols treatment on the AChE activity.

As shown by Figure 2, the effects of scopolamine and polyphenols treatment were investigated on AChE activity in zebrafish brain. Rutin treatment reduced the AChE activity in 27% ($P>0.05$) when compared to the Tween 20 + water group. This effect was absent when rutin treatment was followed by scopolamine treatment. Quercetin did not alter the enzyme activity neither when administered alone nor in combination with scopolamine treatment.

In vivo effects of scopolamine and polyphenols treatment on the ATP, ADP and AMP hydrolysis

In Figure 3 we have analyzed the effects of the treatment with polyphenols and scopolamine on the ATP, ADP, and AMP hydrolysis in zebrafish brain. According to the Figure 3A, rutin was able to strongly inhibit the ATPase activity (48.2% inhibition, p

<0.05). In Figure 3B, we can see that Tween 20 + scopolamine and quercetin + scopolamine have shown an inhibition of the ADPase activity (38.5 and 45% inhibition respectively, $p < 0.05$) in comparison with the saline + scopolamine-treated group. Since Tween 20, used as the vehicle, altered the activity of the enzyme per se, we cannot exclude the possibility that the effect attributed to quercetin is in fact a consequence of Tween 20 actions. Finally, in Figure 3C, we observe the effect of the treatment with polyphenols and scopolamine on the AMP hydrolysis. As shown, quercetin inhibited the AMPase activity when administered in combination with water or scopolamine (54.4 and 50.7% inhibition respectively, $p < 0.05$) in comparison with saline + water and saline + scopolamine groups, respectively.

4. Discussion

In the present study, we have evaluated the effects of scopolamine, quercetin, and rutin on ACh, ATP, ADP, and AMP hydrolysis in zebrafish brain. To first understand if scopolamine could influence directly to the enzymes analyzed, we have performed *in vitro* experiments, and according to our results scopolamine does not affect any of the enzymes evaluated, suggesting that the scopolamine effects on memory are due to alterations in signaling cascades that involve other targets than the enzymes investigated here.

In addition, we have found that the polyphenols have different effects in the enzymes investigated. Many studies describe the relation between plant extracts ingestion and the treatment of Alzheimer's disease symptoms, since a great portion of these extracts presents beneficial characteristics, including anticholinergic properties (Adams et al., 2007; Houghton and Howes, 2005; Howes et al., 2003; Loizzo et al., 2008; Marchalant et al., 2008; Mukherjee et al., 2007; Perry et al., 1998; Zhang et al., 2006). Considering the reports of the plant extracts anticholinergic properties, as well as the great importance to an AD drug to have anticholinergic properties, we have investigated the effects of rutin and quercetin on the AChE activity. As shown, rutin reduced this enzymatic activity when administered alone, but this effect was not visible when rutin was administered followed by scopolamine treatment. Quercetin does not show any effects on AChE activity.

Purine derived nucleotides and nucleosides are widely recognized as signaling molecules (Burnstock e Knight, 2004; Dunwiddie e Masino, 2001; Ralevic e Burnstock,

1998) in peripheral and central nervous system, affecting several physiological and pathological processes, including cognition and memory (Ribeiro et al., 2003). Adenosine is considered a neuromodulator in the central nervous system (Williams, 1989) and acts by depressing cholinergic, noradrenergic and GABAergic transmission via adenosine A₁ receptors (Phillis and Kostopoulos, 1975; Hollins and Stone, 1980). Considering that the cholinergic system is involved in learning and memory processes (Bartus et al., 1982), a reduction in adenosine levels could lead to a decrease in A₁ activation, resulting in an attenuation of the depression of cholinergic transmission, and thereby promoting an enhancement in cognition. In addition, there is evidence on the ability of the nonselective adenosine receptor antagonist, caffeine, to protect against cognitive impairment in different animal models, an effect that mainly seems to involve adenosine A_{2A} receptors (for review, see Cunha, 2008b; Takahashi et al., 2008). Also, caffeine consumption inversely correlates with the incidence of AD (Maia and de Mendonca, 2002) and prevents memory impairment in animal models of AD (Arendash et al., 2006; Dall'Igna et al., 2007). Additionally, Canas et al., (2009) have shown that A_{2A} blockade prevents A β 1-42-induced synaptotoxicity and subsequent memory dysfunction by a mechanism involving the control of the p38 mitogen-activated protein kinase (MAPK) pathway. This evidence suggests that a reduction in the adenosinergic signaling would have beneficial effects on cognition. In this study we show that rutin treatment has reduced the ATP hydrolysis and that quercetin treatment has induced a decrease in AMP hydrolysis. Considering that the extracellular nucleotide hydrolysis is an important pathway for the production of adenosine, the results presented here can suggest that the reduction of ATP

and AMP hydrolysis rate could be a protective strategy to avoid effects of adenosine by reducing the activation of A₁ and A_{2A} receptors.

In summary, we have shown that the polyphenols quercetin and rutin are capable to modulate per se the levels of the signaling molecules, such as ACh, ATP, and adenosine in zebrafish brain. Considering the important role of adenine nucleotides and acetylcholine in learning and memory processes, the results demonstrated in this study give rise to a new perspective in relation to preventive strategies to be conducted throughout the lifespan, seeking for the prevention of cognitive decline age-associated.

Acknowledgments

This work was supported by DECIT/SCTIE-MS (Proc. No. 10/0036-5, 700545/2008) through Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and by the FINEP research grant “Rede Instituto Brasileiro de Neurociência (IBN-Net)” # 01.06.0842-00.

Conflict of Interests

The authors declare no conflict of interests.

References

- Abbracchio, M.P., Burnstock, G., 1998. Purinergic signalling: pathophysiological roles. *Jpn J Pharmacol.* 78(2):113-145.
- Adams, M., Gmünder, F. and Hamburger, M., 2007. Plants traditionally used in age related brain disorders-A survey of ethnobotanical literature. *J Ethnopharmacol.* 133: 363-381.
- Anagnostaras, S.G., Murphy, G.G., Hamilton, S.E., et al., 2003. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. *Nat Neurosci.* 6(1):51-58.
- Arendash, G.W., Schleif, W., Rezai-Zadeh, K., et al., 2006. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β -amyloid production, *Neuroscience* 142:941-952.
- Barnes, J.M., Murphy, P.A., Kirkham, D., 1993. Interaction of guanine nucleotides with [3H]kainate and 6-[3H]cyano-7-nitroquinoxaline-2,3-dione binding in goldfish brain. *J Neurochem.* 61:1685-1691.
- Birks J., 2006. Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev* (1):CD005593.

Bradford, M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 72: 248-254.

Burnstock, G., 1972. Purinergic Nerves. *Pharmacol Rev.* 24(3): 509-581.

Burnstock, G., 1999. Purinergic cotransmission. *Brain Res Bull.* 50(5-6): 355-357.

Burnstock, G., 2004. Cotransmission. *Curr Opin Pharmacol.* 4:47-52.

Burnstock, G., 2007. Physiology and pathophysiology of purinergic neurotransmission. *Physiol Rev.* 87(2):659-797.

Burnstock, G., 2008. Purinergic signalling and disorders of the central nervous system. *Nat Rev Drug Discov.* 7(7):575-590.

Burnstock, G.; Knight, G.E., 2004. Cellular distribution and functions of P2 receptor subtypes in different systems. *Rev Cytol Clin.* 240: 231-304.

Canas, P.M., Porciúncula, L.O., Cunha, G.M., et al., 2009. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. *J Neurosci.* 29(47):14741-51.

Chan, K., et al., 1986. A direct colorimetric assay for Ca²⁺ -stimulated ATPase activity.

Anal Biochem. 157(2): 375-380.

Cuello, A.C., Bruno, M.A., Allard S, et al., 2010. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci. 40(1-2):230-5.

Cunha, G.M.A., Canas, P.M., Melo, C.S., et al., 2008. Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol. 210:776-781.

Cunha, R.A., 2001. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int. 38(2):107-125.

Cunha, R.A., 2005. Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade. Purinergic Signal. 1: 111-134.

Cunha, R.A., 2008. Caffeine, adenosine receptors, memory and Alzheimer disease. Med Clin (Barc). 131(20):790-5.

Dall'Igna, O.P., Fett, P., Gomes, M.W., et al., 2007. Caffeine and adenosine A2a receptor antagonists prevent β -amyloid (25–35)-induced cognitive deficits in mice, *Exp. Neurol.* 203: 241-245.

Ellman, G.L., Courtney, K.D., Andrés, J.V., et al., 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. *Biochem Pharmacol.* 7: 88-95.

El Yacoubi, M, Ledent, C, Menard, J.F., et al., 2000. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. *Br J Pharmacol.* 129(7):1465-73.

Francis P.T., Nordberg A., and Arnold S.E., 2005. A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer's disease? *Trends Pharmacol Sci.* 26: 105-115.

Fredholm, B., 2003. Adenosine and Brain Function. *Int Rev Neurobiol.* 63: 191 – 241.

Hollins, C. and Stone, T.W., 1980. Characteristics of the release of adenosine from slices of rat cerebral cortex. *J Physiol.* 303:73-82.

Houghton, P.J., Howes, M.J., 2005. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. *Neurosignals* 14: 6-22.

Howes, M.J.R. and Houghton, P.J., 2003. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. *Pharmacol Biochem Beh.* 75: 513-527.

Jenner, P., Mori, A., Hauser, R., et al., 2009. Adenosine, adenosine A_{2A} antagonists, and Parkinson's disease. *Parkinsonism Relat Disord* 15,406-413.

Johnson-Kozlow, M., Kritz-Silverstein, D., Barrett-Connor, E., et al., 2002. Coffee consumption and cognitive function among older adults, *Am. J. Epidemiol.* 156: 842-850.

Kim, M.J., Choi, S.J., Lim, S, et al., 2008. Zeatin Supplement Improves Scopolamine-Induced Memory Impairment in Mice. *Biosci Biotechnol Biochem* 72(2): 577-581.

Kim, Y.H., Lee, Y., Kim, D., et al., 2010. Scopolamine-induced learning impairment reversed by physostigmine in zebrafish. *Neurosci Res.* 67(2):156-161

Loizzo, M.R., Tundis, R., Menichini, F., et al., 2008. Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: An update. *Curr Med Chem.* 15: 1209-1228.

Maia, L., and de Mendonça, A. 2002. Does caffeine intake protect from Alzheimer's disease?, *Eur. J. Neurol.* 9: 377-382.

Marchalant, Y., Brothers, H.M. and Wenk, G.L., 2008 Inflammation and aging: Can endocannabinoids help? *Biomed Pharmacother.* 62: 212-217.

Mount, C., and Downton, C. 2006. Alzheimer disease: progress or profit? *Nat. Med.* 12: 780-784.

Mukherjee, P.K., Kumar, V., Mal, M., et al., 2007. Acetylcholinesterase inhibitors from plants. *Phytomed.* 14: 289-300.

Orhan, G., Orhan, I., Subutay-Oztekin, N., et al., 2009. Contemporary anticholinesterase pharmaceuticals of natural origin and their synthetic analogues for the treatment of Alzheimer's disease. *Recent Pat CNS Drug Discov.* 4(1):43-51.

Perry, E.K., Pickering, A.T., Wang, W.W., et al., 1998. Medicinal plants and Alzheimer's disease: Integrating ethnobotanical and contemporary scientific evidence. *J Altern Comp Med.* 4: 419-428.

Phelps, H.A., Runft, D.L., and Neely, M.N., 2009. Adult zebrafish model of streptococcal infection. *Current Protocols in Microbiology* 9D.1.1-9D.1.27

Phillis, JW and Kostopoulos GK. 1975. Adenosine as a putative transmitter in the cerebral cortex. Studies with potentiators and antagonists. *Life Sci.* 17(7):1085-1094

Picciotto, M.R., Zoli, M., Rimondini, R., et al., 1998. Acetylcholine receptors containing the $\beta 2$ subunit are involved in the reinforcing properties of nicotine. *Nature*. 390:173-177.

Pitsikas, N., and Borsini, F., 1997. The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat. *Eur J Pharm*.328(1): 19-22.

Porkka-Heiskanen, T., 1999. Adenosine in sleep and wakefulness. *Ann Med*. 31(2):125-129.

Prediger, R.D., Batista, L.C., and Takahashi, R.N., 2005. Caffeine reverses age-related deficits in olfactory discrimination and social recognition memory in rats. Involvement of adenosine A1 and A2A receptors, *Neurobiol. Aging* 26: 957-964.

Pu, F., Mishima, K., Irie, K., et al., 2007. Neuroprotective effects of quercetin and rutin on spatial memory impairment in an 8-arm radial maze task and neuronal death induced by repeated cerebral ischemia in rats. *J Pharmacol Sci*. 104(4):329-334.

Ralevic, V. and Burnstock, G., 1998. Receptors for purines and Pyrimidines. *Pharmacol Rev*. 50(3):413-492.

Ramassamy, C., 2006. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. *Eur J Pharmacol.* 545: 51-64.

Reddy, P.H., 2007. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. *Antioxid Redox Signal.* 9(10):1647-1658.

Ribeiro, J.A., Sebastião, A.M., Mendonca, A., 2003. Participation of adenosine receptors in neuroprotection. *Drug News Perspect.* 16(2): 80-86.

Rico, E.P., Senger, M.R., Fauth, M.G., et al., 2003. ATP and ADP hydrolysis in brain membranes of zebrafish (*Danio rerio*). *Life Sci.* 73: 2071-2082.

Ritchie, K., Carrière, I., Portet, F et al., 2007. The neuro-protective effects of caffeine: a prospective population study (the Three City Study), *Neurology* 69: 536-545.

Roberson, E.D., and Mucke, L. 2006. 100 Years and Counting: Prospects for Defeating Alzheimer's Disease. *Science* 314:781-784.

Roger, M.L., Mii, K., and Nigam, H. G., 2004. Acetylcholinesterase and its inhibition in Alzheimer's disease. *Clin. Neuropharmacol.*, 27: 141-149.

Shah, R.S., Lee, H.G., Xiongwei, Z., et al., 2008. Current approaches in the treatment of Alzheimer's disease. *Biomed Pharmacother.* 62: 199-207.

Singh, M., Arseneault, M., Sanderson, T., et al., 2008. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. *J Agric Food Chem.* 56: 4855-4873.

Spencer, J.P., 2008. Flavonoids: modulators of brain function? *Br J Nutr.* 99 E Suppl 1:ES60-77.

Spencer, J.P., 2009. The impact of flavonoids on memory: physiological and molecular considerations. *Chem Soc Rev.* 38(4):1152-61.

Spencer, J.P., Abd El Mohsen, M.M., Minihane, A.M., et al., 2008. Biomarkers of the intake of dietary polyphenols: strengths, limitations and application in nutrition research. *Br J Nutr.* 99(1): 12-22.

Spencer, J.P., Vauzour, D. and Rendeiro C., 2009. Flavonoids and cognition: the molecular mechanisms underlying their behavioural effects. *Arch Biochem Biophys.* 492(1-2):1-9.

Stone, T.W., Ceruti, S. and Abbracchio, M.P., 2009. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. *Handb Exp Pharmacol.* 193:535-87.

Takahashi, R.N., Pamplona, F.A. and Prediger, R.D., 2008. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. *Front Biosci* 13:2614-2632.

Thathiah, A. and De Strooper, B., 2009. G protein-coupled receptors, cholinergic dysfunction, and Abeta toxicity in Alzheimer's disease. *Sci Signal.* 2(93):re8.

Vafeiadou, K., Vauzour, D., Spencer, J.P., 2007. Neuroinflammation and its modulation by flavonoids. *Endocr Metab Immune Disord Drug Targets.* 7(3):211-24.

Weinreb, O., Mandel, S., Amit, T., Youdim, M.B.H., 2004. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. *J Nutr Biochem.* 15:506-516.

Westerfield, M., 2007. *The zebrafish book.* 5th ed. Eugene: University of Oregon Press.

Williams, R.J., Spencer, J.P., Rice-Evans, C., 2004. Flavonoids: antioxidants or signalling molecules? *Free Radic Biol Med.* 36(7): 838-49.

Wimo, A., Winblad, B., Aguero-Torres, H., et al., 2003. The Magnitude of Dementia Occurrence in the World. *Alzheimer Disease & Associated Disorders*. 17(2): 63-67.

Youdim, K.A., Spencer, J.P., Schroeter, H., Rice-Evans C., 2002. Dietary flavonoids as potential neuroprotectants. *Biol Chem*. 383(3-4):503-519.

Zhang, H.Y., 2007. Can food-derived multipotent agents reduce the risk of Alzheimer's Disease. *Trends in Food Science & Technology* 18: 492-495.

Zhang, H.Y., Yang, D.P. and Ji, H.F. 2006. Naturally occurring multipotent anti-Alzheimer's agents. *Expert Opin Drug Discov*. 1: 269-277.

Figure Legends

Figure 1: *In vitro* effect of scopolamine on ACh (A), ATP (B), ADP (C) and AMP hydrolysis evaluated in different concentrations (50–1000 μ M). Bars represent mean \pm S.E. of at least four independent experiments. *Significantly different from control group (without scopolamine added). (ANOVA, followed by Dunnett's Multiple Comparison Test as post-hoc, $P \leq 0.05$).

Figure 2. *In vivo* effect of different treatments (SW, saline + water; SS, saline + scopolamine; TW, tween + water; TS, tween + scopolamine; QW, quercetin + water; QS, quercetin + scopolamine; RW, rutin + water; RS, rutin + scopolamine) in ACh hydrolysis in zebrafish brain. Animals received single intraperitoneal injection of saline, tween 20 (1%), quercetin and rutin (50 mg/kg) two hours before the euthanasia, and were transferred to the second treatment (water or scopolamine 200 μ M dissolved in the tank water) one hour before the euthanasia. Data were expressed as mean \pm S.E.M. of at least 4 independent experiments. Data were analyzed by one-way ANOVA test followed by Tukey's test as post hoc. * $p < 0.05$ denotes a significant difference from the tween + water group.

Figure 3. *In vivo* effect of different treatments (SW, saline + water; SS, saline + scopolamine; TW, tween + water; TS, tween + scopolamine; QW, quercetin + water; QS, quercetin + scopolamine; RW, rutin + water; RS, rutin + scopolamine) in ATP, ADP, and AMP hydrolysis in zebrafish brain. Animals received single intraperitoneal injection of

saline, tween 20 (1%), quercetin and rutin (50 mg/kg) two hours before the euthanasia, and were transferred to the second treatment (water or scopolamine 200 μ M dissolved in the tank water) one hour before the euthanasia. Data were expressed as mean \pm S.E.M. of at least 4 independent experiments. Data were analyzed by one-way ANOVA test followed by Tukey's test as post hoc. * denotes a significant difference ($p < 0.05$) from the saline + scopolamine group and # denotes a significant difference ($p < 0.05$) from the saline + water group.




Figure 1




Figure 2




Figure 3

CAPÍTULO 4 - CONSIDERAÇÕES FINAIS

O envelhecimento populacional observado nas estatísticas ao redor do mundo gera sérias preocupações governamentais em relação à possibilidade de concomitante aumento da incidência de déficits cognitivos e comportamentais que podem estar associados, pelo menos parcialmente com o aumento da prevalência de doenças neurodegenerativas, como a doença de Alzheimer (Kinsella e Wan, 2009). Hoje, os tratamentos eficazes estão disponíveis para muitas condições neurológicas. Entretanto, para milhões de novos pacientes que serão afetados pela Doença de Alzheimer em todo o mundo (Alzheimer's Association, 2010), a realidade parece desanimadora. Apesar de vários medicamentos já terem sido aprovados, os benefícios do seu uso são poucos. Mais de cem anos após a descoberta da doença de Alzheimer, ainda não foram estabelecidas abordagens farmacológicas com melhorias robustas. Os inibidores da colinesterase, como a tacrina, galantamina, donepezil e fisostigmina, são a principal abordagem utilizada atualmente, apesar de apresentarem modestos benefícios associados aos severos efeitos colaterais, o que contribui para reduzir a, muitas vezes já diminuta, qualidade de vida do paciente (Blennow *et al.*, 2006; Casey *et al.*, 2010; Maggini *et al.* 2006; Roberson e Mucke, 2006). Os polifenóis, metabólitos secundários de plantas amplamente distribuídos na natureza e na ingesta diária da população humana, apresentam diversas características que os tornam moléculas interessantes com potencial farmacológico. Entre elas, destaca-se a ausência de efeitos colaterais. Ainda, diversos estudos relacionam os efeitos dos flavonóides na função cognitiva, evidenciado pela capacidade destes compostos em interagir com os processos moleculares e celulares envolvidos na aprendizagem e memória, incluindo a potenciação sináptica e plasticidade (Harvsteen, 2002).

Considerando a necessidade do desenvolvimento de novas abordagens para o tratamento da doença de Alzheimer, o amplo repertório de alvos bioquímicos dos polifenóis e ainda, a ausência de efeitos colaterais severos relacionados ao seu uso, foi objetivo do nosso trabalho entender os mecanismos de ação dos polifenóis quercetina e rutina, bem como seus alvos bioquímicos, para avaliar a possibilidade de utilização destes compostos na profilaxia ou terapia desta doença. Quercetina e rutina, dois dos polifenóis mais prevalentes na natureza (Ross and Kasum, 2002; Singh *et al.*, 2008), foram abordados nesta dissertação.

No capítulo dois, nós avaliamos o potencial papel dos polifenóis quercetina e rutina na prevenção dos deficits cognitivos induzidos por escopolamina em peixe zebra. O emprego de escopolamina tornou-se uma estratégia amplamente utilizada para induzir deficits cognitivos em uma grande variedade de modelos animais, especialmente após a postulação da hipótese colinérgica da disfunção da memória associada ao envelhecimento (Bartus *et al.*, 1982). A escopolamina, o alcalóide originalmente isolado a partir de plantas como *Atropa belladonna L.* (Zhang *et al.*, 2008) é um antagonista competitivo do receptor colinérgico muscarínico (mAChR) (Wang *et al.*, 2003). Considerando que o sistema colinérgico está envolvido em muitos processos fisiológicos, incluindo processos cognitivos (Flood *et al.*, 1981; Power, *et al.*, 2003; Stratton e Petrinovich, 1963; Weinberger, 2006), agonistas colinérgicos podem facilitar a memória, enquanto os antagonistas colinérgicos pode prejudicar a memória (Mattson, 2004). Estudos dos efeitos sinápticos de agentes colinérgicos, principalmente aqueles relacionados à receptores muscarínicos contribuíram para o entendimento de processos relacionados ao aprendizado e memória (Hasselmo, 2006).

Neste estudo, surpreendentemente, apenas uma injeção intraperitoneal de quercetina ou rutina (50 mg/kg) administrada uma hora antes do tratamento com escopolamina foi suficiente para prevenir os déficits cognitivos induzidos por este fármaco. Esta rápida ação dos polifenóis pode acontecer, uma vez que a quercetina e rutina apresentam uma rápida elevação da sua concentração no plasma sanguíneo (Yang *et al.* 2005), que demonstraram que em ratos a quercetina e a rutina apresentam um pico de concentração plasmática 60 minutos após a sua administração. Tais resultados levam ao surgimento de diversas abordagens científicas, a partir de subseqüentes estudos visando confirmar a sugestão de que estes flavonóides podem ser uma estratégia preventiva contra o desenvolvimento da AD. Estes resultados, apesar de se restringirem a análise comportamental, trazem uma nova perspectiva para a prevenção e tratamento da doença de Alzheimer.

No capítulo três, representado por um artigo científico em processo de preparação, investigamos possíveis alvos bioquímicos dos polifenóis nos sistemas purinérgico e colinérgico. Tal estudo foi desenvolvido visando entender os mecanismos de ação que poderiam estar desencadeando a prevenção da perda de memória observada com o tratamento prévio com os polifenóis quercetina e rutina seguido de tratamento com escopolamina, demonstrado no capítulo 2 desta dissertação. Neste trabalho foi demonstrado que o tratamento com rutina reduziu a atividade enzimática da acetilcolinesterase, porém este efeito não foi mantido quando o tratamento com rutina foi seguido de tratamento com escopolamina. Em relação à quercetina, esta não apresentou efeito sobre a atividade enzimática da acetilcolinesterase. Vários estudos recentes mostram a relação da ingestão de polifenóis com o tratamento dos sintomas da doença de

Alzheimer, já que vários polifenóis se mostram importantes agentes anticolinérgicos. Zhang *et al.* (2008) demonstraram que a fração solúvel em água do própolis possui propriedades anticolinérgicas, apresentando resultados positivos em relação a prevenção e redução do déficit cognitivo e perda de memória associado a doenças neurodegenerativas. Ainda, neste trabalho foram avaliados os efeitos dos polifenóis sobre a hidrólise de nucleotídeos da adenina, no qual foi observado que tanto quercetina quanto rutina podem afetar a hidrólise de nucleotídeos da adenina. Os nucleosídeos e nucleotídeos derivados de purinas são amplamente reconhecidos como moléculas sinalizadoras em vários tecidos, entre eles o sistema nervoso central e periférico (Burnstock e Knight, 2004; Dunwiddie e Masino, 2001; Ralevic e Burnstock, 1998). No sistema nervoso central, estas moléculas estão envolvidas em diversos processos fisiológicos e patológicos, inclusive desempenhando papéis na cognição e memória (Ribeiro *et al.*, 2003). A adenosina é considerada um neuromodulador do sistema nervoso central (Burnstock, 2009; Sebastião e Ribeiro, 2009) e age deprimindo a neurotransmissão colinérgica, noradrenergica e GABAérgica via os receptores adenosinérgicos do tipo A₁ (Hollins e Stone, 1980; Phillis e Kostopoulos, 1975). Considerando que o sistema colinérgico é fortemente relacionado a processos de aprendizado e memória (Bartus *et al.*, 1982), uma redução nos níveis de adenosina poderia resultar em uma redução da ativação dos receptores A₁, o que levaria a uma atenuação da depressão da transmissão colinérgica, com conseqüente aumento na cognição (Pitsikas e Borsini, 1997). Ainda, evidências demonstram a habilidade da cafeína, um antagonista não-seletivo dos receptores adenosinérgicos, de proteger o organismo contra déficits cognitivos em diversos modelos animais (Arendash *et al.*,

2006; Dall'Igna *et al.*, 2007). Tal efeito é mediado principalmente pelos receptores A_{2A} (para revisão veja Cunha, 2008 e Takahashi *et al.*, 2008). Ainda, já foi relatada a relação inversa entre o consumo de cafeína e a incidência de AD (Maia e De Mendonça, 2002). Canas *et al.*, (2009) também demonstraram que o bloqueio de receptores A_{2A} previne a sinaptotoxicidade induzida por $A\beta_{1-42}$ e a consequente perturbação na memória através de um mecanismo envolvendo o controle da via de sinalização dependente da proteína p38 tirosina quinase ativada por mitógenos (p38MAPK). Portanto, estas evidências sugerem que uma redução na sinalização adenosinérgica poderia resultar em benefícios para a cognição.

Como demonstrado no nosso estudo, o tratamento com rutina reduziu a hidrólise de ATP, enquanto o tratamento com quercetina reduziu a hidrólise de AMP. Considerando que a hidrólise destes nucleotídeos é necessária para ocorrer a formação de adenosina, os resultados demonstrados aqui podem indicar que a redução na atividade ATPásica e AMPásica pode ser uma estratégia para proteger o organismo das ações adenosina, pela redução da ativação dos receptores A_1 e A_{2A} .

Considerando dados estatísticos que demonstram o provável aumento da prevalência de doenças neurodegenerativas nas próximas décadas, a ocorrência de benefícios insatisfatórios do tratamento atualmente disponível para a AD, associado a efeitos colaterais severos, surge a necessidade de desenvolvimento de novas abordagens terapêuticas para o tratamento da doença de Alzheimer. Os resultados apresentados nesta dissertação demonstram pela primeira vez o potencial protetor dos polifenóis quercetina e rutina com relação ao prejuízo cognitivo induzido pela escopolamina em zebrafish. Além disso, nossos resultados demonstram que rutina e quercetina *per se* são capazes de

modular os níveis de acetilcolina, ATP e adenosina, moléculas sinalizadoras fortemente relacionadas a processos de cognição e memória, em encéfalo de peixe zebra. Estes resultados são promissores em relação à possibilidade de terapia preventiva a ser realizada ao longo da vida, visando a não ocorrência de declínio cognitivo associado ao envelhecimento.

REFERÊNCIAS BIBLIOGRÁFICAS

ABBRACCHIO, M.P., e BURNSTOCK, G. Purinergic signalling: pathophysiological roles. *Jpn J Pharmacol.* v. 78 n. 2 p.113-145, 1998.

ABBRACCHIO, M.P., *et al.* Purinergic signalling in the nervous system: an overview. *Trends Neurosci.* v. 32 n. 1 p. 19-29, 2009.

ADINOFF, B., *et al.*, Altered Neural Cholinergic Receptor Systems in Cocaine-Addicted Subjects. *Neuropsychopharmacology* v. 35 p. 1485-1499, 2010.

ALCARO, S., *et al.* Simple choline esters as potential anti-Alzheimer agents. *Curr Pharm Des.* v. 16 n. 6 p. 692-7, 2010.

ALZHEIMER'S ASSOCIATION, 2010 Alzheimer's Disease Facts and Figures. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association.* v. 6 n. 2 p. 158-194, 2010.

AMENTA, F., e TAYEBATI, S.K. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. *Curr Med Chem.* v. 15 n. 5 p. 488-98, 2008.

AMSTERDAM, A., e HOPKINS, N. Mutagenesis strategies in zebrafish for identifying genes involved in development and disease. *Trends in Genet.* v. 22, p. 473-478, 2006.

ANAGNOSTARAS, S.G., *et al.*, Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. *Nat Neurosci.* v. 6 n. 1 p. 51-58, 2003.

ANGLADE, P., e LARABI-GODINOT, Y. Historical landmarks in the histochemistry of the cholinergic synapse: Perspectives for future researches. *Biomed Res.* v. 31 n. 1 p. 1-12, 2010.

ANGULO, E., *et al.* A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. *Brain Pathol.* v. 13 n.4 p. 440-451, 2003.

APPELBAUM, L., *et al.* Comparative expression of p2x receptors and ecto-nucleoside triphosphate diphosphohydrolase 3 in hypocretin and sensory neurons in zebrafish. *Brain Res.* v. 1174 p. 66-75, 2007.

ARENDASH, G.W., *et al.* Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β -amyloid production, *Neuroscience* v. 142 p. 941-952, 2006.

BARBAZUK, W.B., *et al.* The syntenic relationship of the zebrafish and human genomes. *Genome Res.* v.10, p.1351-1358, 2000.

BARTUS, R.T., *et al.* The cholinergic hypothesis of geriatric memory dysfunction. *Science*, v. 217 n. 4558 p. 408-414, 1982.

BEHRA, M., *et al.*, Acetylcholinesterase is required for neuronal and muscular development in the zebrafish embryo. *Nat Neurosci.* v. 5 n. 2 p. 111-118, 2002.

BENCAN, Z., SLEDGE, D., LEVIN, E.D. Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. *Pharmacol Biochem Behav.* v. 94 n. 1 p. 75-80, 2009.

BERTRAND, J., *et al.* The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons. v.168 n. 2 p. 323-34, 2010.

BEST, J.D., e ALDERTON, W.K. Zebrafish: An in vivo model for the study of neurological diseases. *Neuropsychiatr Dis Treat.* v.4 n.3 p. 567-576, 2008.

BIANCHI, V., e SPYCHALA, J. Mammalian 5'-nucleotidases. *J Biol Chem.* v. 278, n. 47, p. 46195-46198, 2003.

BLENNOW, K., DE LEON, M.J., ZETTERBERG, H. Alzheimer's disease. *The Lancet.* v. 368 p. 387-403, 2006

BOEHMLER, W., *et al.*, Evolution and expression of D2 and D3 dopamine receptor genes in zebrafish. *Dev Dyn.* v. 230 p. 481-493, 2004.

- BOEHMLER, W., *et al.* Identification of zebrafish A2 adenosine receptors and expression in developing embryos. *Gene Expr Patterns*. v. 9 n.3 p. 144-51, 2009.
- BOREA, P.A., *et al.* A3 adenosine receptor: pharmacology and role in disease. *Handb Exp Pharmacol* v. 193 p. 297-327, 2009.
- BRAGANHOL, E., *et al.* Ecto-5'-nucleotidase/CD73 inhibition by quercetin in the human U138MG gliomas cell line. *Biochim Biophys Acta*. v.1770 n.9 p.1352-1959, 2007.
- BRITTIJN, S.A., *et al.* Zebrafish development and regeneration: new tools for biomedical research. *Int J Dev Biol*. v. 53 n.5-6 p. 835-50, 2009.
- BROUILLETTE, J., *et al.* Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia. *J Neurochem*. v. 102 p. 1978-1989, 2007.
- BROWN, D.A., e SIHRA, T.S. Presynaptic signaling by heterotrimeric G-proteins. *Handb Exp Pharmacol*. v. 184 p. 207-260, 2008
- BROWN, R.M., e SHORT, J.L. Adenosine A(2A) receptors and their role in drug addiction. *J Pharm Pharmacol*. v. 60 n. 11 p. 1409-30, 2008.
- BURNSTOCK, G. Purinergic Nerves. *Pharmacol Rev*. v. 24, n. 3, p. 509-581, 1972.
- BURNSTOCK, G. Purinergic cotransmission. *Brain Res Bull*. v. 50, n. 5-6, p. 355-357, 1999
- BURNSTOCK, G. Cotransmission. *Curr Opin Pharmacol*. v. 4 p. 47-52, 2004.
- BURNSTOCK, G. Physiology and pathophysiology of purinergic neurotransmission. *Physiol Rev*. v.87 n.2 p.659-797, 2007.

BURNSTOCK, G. Purinergic signalling and disorders of the central nervous system. *Nat Rev Drug Discov.* v. 7, n. 7, p. 575-590, 2008.

BURNSTOCK, G. Purinergic signalling: past, present and future. *Braz J Med Biol Res.* v. 42 n.1 p. 3-8, 2009a.

BURNSTOCK, G. Purines and sensory nerves. *Handb Exp Pharmacol.* v. 194 p. 333-92, 2009b.

BURNSTOCK, G., e KNIGHT, G.E. Cellular distribution and functions of P2 receptor subtypes in different systems. *Rev Cytol Clin.* v. 240 p. 231-304, 2004.

BURNSTOCK, G., e VERKHRATSKY, A. Evolutionary origins of the purinergic signalling system. *Acta Physiol (Oxf).* v. 195 n.4 p.415-447, 2009.

CADENAS, E., e PACKET, L. Marcel Dekker, New York, 2002.

CANAS, P.M., *et al.* Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. *J Neurosci.* v. 29 n. 47 p. 14741-51, 2009.

CASEY, D.A., ANTIMISIARIS, D., O'BRIEN, J. Drugs for Alzheimer's Disease: Are they effective? *P. T.* v. 35 n. 4 p.208-211, 2010.

CHAKRABORTY, C., *et al.* Zebrafish: a complete animal model for in vivo drug discovery and development. *Curr Drug Metab.* v. 10 n. 2 p. 116-24, 2009.

CHANGEUX, J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. *Nature Reviews Neuroscience* v. 11 p. 389-40, 2010.

CHEN, J., *et al.* Water-soluble derivative of propolis mitigates scopolamine-induced learning and memory impairment in mice. *Pharmacol Biochem Behav.* v.90 p. 441-446, 2008.

CITRON, M. Alzheimer's disease: strategies for disease modification. *Nat Rev Drug Discov.* v. 9 n. 5 p. 387-98, 2010.

CLEMENTE, D., *et al.* Cholinergic elements in the zebrafish central nervous system: Histochemical and immunohistochemical analysis. *J Comp Neurol.* v. 474 p.75-107, 2004.

COELHO, F., e BIRKS, J. Physostigmine for Alzheimer's disease. *Cochrane Database Syst Rev.* v. 2:CD001499, 2001.

COGNATO, G.P., e BONAN, C.D. Ectonucleotidases and Epilepsy. *Open Neurosci J* v. 4 p. 44-52, 2010.

COLGAN, S. P. *et al.* Physiological roles for ecto-5'-nucleotidase (CD73). *Purinergic Signal.* v.2, n.2, p. 351-360, 2006.

COLOMBRES, M., SAGAL, J.P., INESTROSA, N.C. An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. *Curr Pharm Des.* v.10 p. 3121-3130, 2004.

COTMAN, C.W. The beta-amyloid peptide, peptide self-assembly, and the emergence of biological activities. A new principle in peptide function and the induction of neuropathology. *Ann NY Acad Sci.* v. 814 p. 1-16, 1997.

CRAWFORD, A.D., ESGUERRA, C.V., DE WITTE, P.A. Fishing for drugs from nature: zebrafish as a technology platform for natural product discovery. *Planta Med.* v.74 n. 6 p. 624-32, 2008.

CREWS, L., e MASLIAH, E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. *Hum Mol Genet.* 19(R1):R12-20, 2010.

CUNHA, G.M.A., *et al.* Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. *Exp Neurol.* v. 210 p. 776-781, 2008.

CUNHA, R.A. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. *Neurochem Int.* v. 38, n. 2, p.107-125, 2001.

CUNHA, R.A. Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade. *Purinergic Signal.* v. 1, p. 111-134, 2005.

CUNHA, R.A., FERRÉ, S., VAUGEOIS, J.M. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. *Curr Pharm Des.* v. 14 n. 15 p. 1512-24, 2008.

DALL'IGNA, O.P., *et al.* Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid 25-35) induced cognitive deficits in mice. *Exp Neurol.* v. 203 p. 241-245, 2007.

DANI, J.A., e BERTRAND, D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. *Annu Rev Pharmacol Toxicol.* v. 47 p. 699-729, 2007.

DARREH-SHORI, T., e SOININEN, H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. *Curr Alzheimer Res.* v. 7 n. 1 p. 67-73, 2010.

DE STROOPER, B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. *Physiol Rev.* v. 90 n. 2 p. 465-94, 2010

DEIANA, S., *et al.* Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. *Psychopharmacology.* v. 202 p.53-65, 2009.

DESMARAIS, J.E., e GAUTHIER, S. Alzheimer disease: clinical use of cholinergic drugs in Alzheimer disease. *Nat Rev Neurol.* v. 6 n. 8 p. 418-20, 2010

DHALLA, A.K., *et al.* A1 adenosine receptor: role in diabetes and obesity. *Handb Exp Pharmacol.* v.193 p. 271-95, 2009.

DI IORIO, P., *et al.* Purinoceptor-mediated modulation of purine and neurotransmitter release from nervous tissue. *Pharmacol Res.* v.37 p.169-178, 1998.

DI VIRGILIO, F., *et al.* Purinergic signalling in inflammation of the central nervous system. *Trends Neurosci.* v. 32 n. 2 p. 79-87, 2009.

DIAZ-HERNANDEZ, M., *et al.* Cloning and characterization of two novel zebrafish P2X receptor subunits. *Biochem Biophys Res Commun.* v. 295 n.4 p. 849-853, 2002.

DOOLEY, K. e ZON, L.I. Zebrafish: a model system for the study of human disease. *Curr Opin Genet Dev.* v.10 p.252-256, 2000.

DRACHMAN, D.A., e LEAVITT, J. Human memory and the cholinergic system. A relationship to aging? *Arch Neurol.* v. 30 p.113-121, 1974.

DUNWIDDIE, T., e MASINO, S. The Role and Regulation of Adenosine in the Central Nervous System. *Annu Rev Neurosci.* v. 24 p. 31-55, 2001.

EBERT, U., e KIRCH, W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. *Eur J Clin Invest.* v. 28 p. 944-949, 1998.

EDWARDS, J.G., e MICHEL, W.C. Odor-stimulated glutamatergic neurotransmission in the zebrafish olfactory bulb. *J Comp Neurol.* v. 454 n.3 p. 294-309, 2002.

EIMON, P.M., e ASHKENAZI, A. The zebrafish as a model organism for the study of apoptosis. *Apoptosis.* v. 15 n. 3 p. 331-49, 2010.

EIMON, P.M., e RUBINSTEIN, A.L. The use of in vivo zebrafish assays in drug toxicity screening. *Expert Opin Drug Metab Toxicol.* v. 5 n. 4 p. 393-401, 2009.

EL YACOUBI, M., *et al.* The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. *Br J Pharmacol.* v. 129 n.7 p.1465-73, 2000.

ENGESZER, R.E., *et al.* Zebrafish in the wild: a review of natural history and new notes from the field. *Zebrafish* v. 4 n. 1 p. 21-40, 2007.

FERGUSON, S.M., e BLAKELY, R.D. The choline transporter resurfaces: new roles for synaptic vesicles? *Mol Interv.* v. 4 n. 1 p. 22-37, 2004.

FISHER, A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. *Neurotherapeutics.* v. 5 n. 3 p. 433-42, 2008.

FLOOD, J.F., LANDRY, D.W., JARVIK, M.E. Cholinergic receptor interactions and their effects on long-term memory processing. *Brain Res.* v. 215: p. 177-185, 1981.

FRANCIS, P.T., *et al.* The cholinergic hypothesis of Alzheimer's disease: a review of progress. *J Neurol Neurosurg Psychiatry.* v. 66 n.2 p.137-147, 1999.

FRANCO, R. Neurotransmitter receptor heteromers in neurodegenerative diseases and neural plasticity. *J Neural Transm* v. 116 n. 8 p. 983-7, 2009.

FREDHOLM, B.B. Adenosine and Brain Function. *Int Rev Neurobiol.* v. 63, p.191-241, 2003.

FREDHOLM, B.B. Adenosine receptors as drug targets. *Exp Cell Res.* v. 316 n.8 p. 1284-8, 2010.

FROEHLICHER, M., *et al.* Zebrafish (*Danio rerio*) neuromast: Promising biological endpoint linking developmental and toxicological studies. *Aquat Toxicol.* V. 95 n. 4 p. 307-319, 2009.

GABRIEL, J.P., *et al.* Serotonergic modulation of locomotion in zebrafish: endogenous release and synaptic mechanisms. *J Neurosci.* v. 29 n. 33 p. 10387-95, 2009.

GERLAI, R. Zebrafish: An uncharted behavior genetic model. *Behav Genet.* v. 33, p. 461-468, 2003.

GIACOBINI, E. Cholinesterases: new roles in brain function and in Alzheimer's disease. *Neurochem Res.* v. 28 p. 515-522, 2003.

GOLDSMITH, P. Zebrafish as a pharmacological tool: the how, why and when. *Curr. Opin. Pharmacol.* v. 4 n.5 p. 504-12, 2004.

GREGORY, M., e JAGADEESWARAN, P. Genetic analysis of hemostasis and thrombosis using vascular occlusion. *Blood Cells Mol Dis.* v.29 p. 286-295, 2002.

GRILL, J.D., e CUMMINGS, J.L. Current therapeutic targets for the treatment of Alzheimer's disease. *Expert Rev Neurother.* v. 10 n.5 p. 711-28, 2010.

GROSELL, M., WOOD, C.M. Copper uptake across rainbow trout gills: mechanisms of apical entry. *J Exp Biol.* v. 205 p. 1179-1188, 2002.

GUAN, Z.Z. Cross-talk between oxidative stress and modifications of cholinergic and glutaminergic receptors in the pathogenesis of Alzheimer's disease. *Acta Pharmacol Sin.* v. 29 n. 7 p. 773-80, 2008.

GUO, S. Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish? *Genes Brain Behav.* v.3, p. 63-74, 2004.

GUSTAW-ROTHENBERG, K., *et al.* Biomarkers in Alzheimer's disease: past, present and future. *Biomark Med.* v. 4 n. 1 p. 15-26, 2010.

GUYON, J.R., *et al.* Modeling human muscle disease in zebrafish. *Biochim Biophys Acta.* v. 1772 p. 205-215, 2006.

HABERLAND, C. Frontotemporal dementia or frontotemporal lobar degeneration--overview of a group of proteinopathies. *Ideggyogy Sz.* v. 63 n. 3-4 p. 87-93, 2010.

HALLIWELL, B., e GUTTERIDGE, J.M.C. 3. Aufl., Oxford University Press, Oxford, 1999.

HAN, C.K., *et al.* SK-PC-B70M from *Pulsatilla koreana* improves scopolamine-induced impairments of memory consolidation and spatial working memory. *Brain Res.* v. 1184 p. 254-259, 2007.

HARVSTEEN, B.H. The biochemistry and medical significance of the flavonoids *Pharmacol Ther.* v. 96 p. 67-202, 2002.

HASKÓ, G., *et al.* Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat Rev Drug Discov.* 7(9):759-70, 2008.

HASSELMO, M.E. The Role of Acetylcholine in Learning and Memory, *Curr Opin Neurobiol.* v. 16 n. 6 p.710-715, 2006.

HASSELMO, M.E., e GIOCOMO, L.M. Cholinergic modulation of cortical function. *J Mol Neurosci.* v. 30 n. 1-2 p. 133-5, 2006.

HEYDORN, W.E. Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. *Expert Opin Investig Drugs.* v.6 p.1527-1535, 1997.

HILL, A.J., *et al.* Zebrafish as a model vertebrate for. investigating chemical toxicity. *Toxicol Sci.* v. 86 n.1 p. 6-19, 2005.

HOLLINS, C., e STONE, T.W. Characteristics of the release of adenosine from slices of rat cerebral cortex. *J Physiol.* v. 303 p. 73-82, 1980.

HULME, E.C., *et al.* Structure and activation of muscarínico acetylcholine receptors. *Biochem Soc Trans.* v. 31 n.1 p. 29-34, 2003.

INGHAM, P.W. The power of the zebrafish for disease analysis. *Hum Mol Genet.* v. 18 n. R1 p.R107-12, 2009.

IVETAC, I., BECANOVIC, J., KRISHNAPILLAI, V. Zebrafish: Genetic tools and genomics. *Asia Pac J Mol Biol Biotechnol* v. 8 p.1-11, 2000.

JANAS, A., *et al.* The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats. *Life Sci* v. 76 p.1073-1081, 2005.

JENNER, P., *et al.* Adenosine, adenosine A_{2A} antagonists, and Parkinson's disease. *Parkinsonism Relat Disord*, v. 15 n. 6 p. 406-13, 2010

JI, H.F., e ZHANG, H.Y. Theoretical evaluation of flavonoids as multipotent agents to combat Alzheimer's disease. *J Mol Struct.* v. 767 p. 3–9, 2006.

KANG, S.Y., *et al.* Water-soluble derivative of propolis mitigates scopolamine-induced learning and memory impairment in mice. *Life Sci* v.76 p.1691-705, 2005.

KARCZMAR, A.G. Do all human functions and behaviors, as well as the "self", have cholinergic correlates? *J Mol Neurosci.* v. 40 n. 1-2 p. 121-6, 2010.

KASTENHUBER, E., *et al.* Genetic dissection of dopaminergic and noradrenergic contributions to catecholaminergic tracts in early larval zebrafish. *J Comp Neurol.*v.518 n.4 p. 439-58, 2010.

KAVUTCU, M., e MELZIG, M.F. In vitro effects of selected flavonoids on the 5' nucleotidase activity. *Pharmazie.* v.54 p. 457-459, 1999.

KIHARA, T., e SHIMOHAMA, S. Alzheimer's disease and acetylcholine receptors. *Acta Neurobiol Exp (Wars).* v. 64 n. 1 p. 99-105, 2004.

KIM, D.H., *et al.* The seed extract of *Cassia obtusifolia* ameliorates learning and memory impairments induced by scopolamine or transient cerebral hypoperfusion in mice. *J Pharmacol Sci.* v. 105 p. 82-93, 2007.

KIM, M.J., *et al.* Zeatin Supplement Improves Scopolamine-Induced Memory Impairment in Mice. *Biosci Biotechnol Biochem* v.72 n.2 p.577-581, 2008.

KIM, Y.J., *et al.* Identification and functional evidence of GABAergic neurons in parts of the brain of adult zebrafish (*Danio rerio*). *Neurosci Lett.* v.355 p.29-32, 2004.

KINSELLA, K., e WAN, H. "An Ageing World". US Census Bureau, International Population Reports, P95/09-1, Washington DC: US Government Printing Office. 2009.

KISHI, S., *et al.* Zebrafish as a genetic model in biological and behavioral gerontology: where development meets aging in vertebrates--a mini-review. *Gerontology*. v. 55 n. 4 p. 430-41, 2009.

KONDO, S., IWASHITA, M., YAMAGUCHI, M. How animals get their skin patterns: fish pigment pattern as a live Turing wave. *Int J Dev Biol*. v. 53 n. 5-6 p. 851-6, 2009.

KOVACECH, B., SKRABANA, R., NOVAK, M. Transition of tau protein from disordered to misordered in Alzheimer's disease. *Neurodegener Dis*. v. 7 n. 1-3 p. 24-7, 2010.

KUCENAS, S., *et al.* Molecular characterization of the zebrafish P2X receptor subunit gene family. *Neuroscience*. v.121 p.935-945, 2003.

KUCENAS, S., *et al.* Ectodermal P2X receptor function plays a pivotal role in craniofacial development of the zebrafish. *Purinergic Signal*. v.5 n. 3 p. 395-407, 2009.

KUNESOVA, G., *et al.* The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. *Peptides*. v.29 p. 1982-1987, 2008.

LARA, D.R., *et al.* Allopurinol augmentation for poorly responsive schizophrenia. *Int Clin Psychopharmacol*. v.16 n.4 p.235-237, 2001.

LARSON, E.T., O'MALLEY, D.M., MELLONI JR, R.H. Aggression and vasotocin are associated with dominant-subordinate relationships in zebrafish. *Behav Brain Res*. v.167 p.94-102, 2006.

LEE, B., *et al.* Protective effects of methanol extract of *Acori graminei* rhizoma and *Uncariae Ramulus et Uncus* on ischemia-induced neuronal death and cognitive impairments in the rat. *Life Sci*. v.74 p. 435-450, 2003.

LIESCHKE, G.J., e CURRIE, P.D. Animal models of human disease: zebrafish swim into view. *Nat Rev Genet.* V.8 n.5 p.353-367, 2000.

LOW, S.E., KUWADA, J.Y., HUME, R.I. Amino acid variations resulting in functional and nonfunctional zebrafish P2X(1) and P2X (5.1) receptors. *Purinergic Signal.*v. 4 n. 4 p. 383-92, 2008.

MAGGINI, M., VANACORE, N., RASCHETTI, R. Cholinesterase Inhibitors: Drugs Looking for a Disease? *PLoS Med.* 3(4) e140, 2006

MAIA, L., e DE MENDONÇA, A. Does caffeine intake protect from Alzheimer's disease? *Eur J Neurol.* v.9 p. 377–382, 2002.

MANDREKAR, N., e THAKUR, N.L. Significance of the zebrafish model in the discovery of bioactive molecules from nature. *Biotechnol Lett.* v. 31 n.2 p.171-9, 2009.

MASSOULIÉ J, *et al.* Old and new questions about cholinesterases. *Chem Biol Interact.* v.175 n.1-3 p.30-44, 2008.

MATTSON, M.P. Pathways towards and away from Alzheimer's disease. *Nature.* v. 430 p.631-639, 2004.

MC LARNON, J.G., *et al.* Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. *J Neuropathol Exp Neurol.* v. 65 n.11 p.1090-1097, 2006.

MIKLÓSI, A. e ANDREW, R.J. The zebrafish as a model for behavioral studies. *Zebrafish.* v.3 p.227-234, 2006.

MONDRAGÓN-RODRÍGUEZ, S., *et al.* Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. *Expert Rev Neurother.* v. 10 n. 5 p. 683-91, 2010.

MORRIS, J.A. Zebrafish: a model system to examine the neurodevelopmental basis of schizophrenia. *Prog Brain Res.* v. 179 p. 97-106, 2009.

MOUNT, C., e DOWNTON, C. Alzheimer disease: progress or profit? *Nat. Med.* v.12 p.780-784, 2006.

MUELLER, K.P., e NEUHAUSS, S.C. Behavioral neurobiology: how larval fish orient towards the light. *Curr Biol.* v.20 n.4 p.R159-61, 2010.

MUFSON, E.J., *et al.* Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. *Expert Rev Neurother.* v. 8 n. 11 p. 1703-18, 2008.

NELSON, J.S. *Fishes of the world.* 3rd edn. Wiley, New York, 1994.

NIEOULLON, A. Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences. *Psychol Neuropsychiatr Vieil.* v. 8 n. 2 p. 123-31, 2010.

ODA, Y. Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. *Pathol Int.* v. 49 n. 11 p. 921-37, 1999.

PANKRATOV, Y., *et al.* P2X receptors and synaptic plasticity. *Neuroscience.* v.158 n.1 p.137-148, 2009.

PARICHY, D.M. Evolution of danio pigment pattern development. *Heredity.* v.97 p. 200-210, 2006.

PEPEU, G., e GIOVANNINI, M.G. Cholinesterase inhibitors and beyond. *Curr Alzheimer Res.* v. 6 n. 2 p. 86-96, 2009.

PICCIOTTO, M.R., *et al.* Acetylcholine receptors containing the $\beta 2$ subunit are involved in the reinforcing properties of nicotine. *Nature.* v. 390 p. 173-177, 1998.

PITSIKAS, N., e BORSINI, F. The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat. *Eur J Pharm.* v. 328 n. 1 p. 19-22, 1997.

PHILLIS, J.W., e KOSTOPOULOS, G.K. Adenosine as a putative transmitter in the cerebral cortex. Studies with potentiators and antagonists. *Life Sci.* v. 17 n. 7 p. 1085-1094, 1975.

PORKKA-HEISKANEN, T. Adenosine in sleep and wakefulness. *Ann Med.* v.31 n.2 p.125-129, 1999.

POSTLETHWAIT, J.H., *et al.* Zebrafish comparative genomics and the origins of vertebrate chromosomes. *Genome Res.* v.10 n.12 p.1890-1902, 2000.

POULIN, B., *et al.* The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. *Proc Natl Acad Sci U S A.* v. 107 n. 20 p. 9440-5, 2010.

POWER, A.E., VAZDARJANOVA, A., MCGAUGH, J.L. Muscarinic cholinergic influences in memory consolidation. *Neurobiol. Learn. Mem.* v. 80 p. 178.193, 2003.

PRICE, A.C., *et al.* Pigments, patterns, and fish behavior. *Zebrafish.* v.5 n. 4 p. 297-307, 2008.

RALEVIC, V., e BURNSTOCK, G. Receptors for purines and Pyrimidines. *Pharmacol Rev.* v. 50 n. 3 p. 413-492, 1998.

RAMASSAMY, C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. *Eur J Pharmacol.* v.545 p.51–64, 2006.

RAMPE, D., WANG, L., RINGHEIM, G.E. P2X7 receptor modulation of beta-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. *J Neuroimmunol.* v. 147 n.1-2 p.56-61, 2004.

REDDY, P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. *Antioxid Redox Signal.* v.9 n.10 p.1647–1658, 2007.

RIBEIRO, J.A., SEBASTIAO, A.M., MENDONCA, A. Participation of adenosine receptors in neuroprotection. *Drug News Perspect.* v.16 n.2 p. 80-86, 2003.

- RICATTI, M.J., *et al.* Immunocytochemical localization of NTPDases1 and 2 in the neural retina of mouse and zebrafish. *Synapse*. v. 63 n. 4 p. 291-307, 2009.
- RICO, E.P., *et al.* ATP and ADP hydrolysis in brain membranes of zebrafish (*Danio rerio*). *Life Sci*. v. 73 p. 2071-2082, 2003.
- RICO, E.P., *et al.* Methanol alters ecto-nucleotidases and acetylcholinesterase in zebrafish brain. *Neurotoxicol Teratol*. v.28 n.4 p. 489-96, 2006.
- RICO, E.P., *et al.* Expression and functional analysis of Na(+)-dependent glutamate transporters from zebrafish brain. *Brain Res Bull*. v. 81 n. 4-5 p. 517-23, 2010.
- RIHEL, J., *et al.* Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation, *Science* v.327 p.348-351, 2010.
- RINK, E., e GUO, S. The too few mutant selectively affects subgroups of monoaminergic neurons in the zebrafish forebrain. *Neuroscience*. v.127 p.147-154, 2004.
- RITCHIE, K., *et al.* The neuroprotective effects of caffeine: a prospective population study (the Three City Study). *Neurology*. v. 69 p.536-545, 2007.
- ROBERSON, E.D., e MUCKE, L. 100 Years and Counting: Prospects for Defeating Alzheimer's Disease. *Science* v. 314 p.781-784, 2006.
- ROBSON, S.C., SÉVIGNY, J., ZIMMERMANN, H. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. *Purinergic Signal*. v. 2 p. 409-430, 2006.
- ROSEMBERG, D.B., *et al.* NTPDase family in zebrafish: Nucleotide hydrolysis, molecular identification and gene expression profiles in brain, liver and heart. *Comp Biochem Physiol B Biochem Mol Biol*. v. 155 n. 3 p. 230-40, 2010.
- ROSS, J.A., e KASUM, C.M. Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annu Rev Nutr*. v. 22 p.19-34, 2002.

ROSSI, L., *et al.* Benefits from dietary polyphenols for brain aging and Alzheimer's disease. *Neurochem Res.* v.33 p. 2390-2400, 2008.

RUBINSTEIN, A.L. Zebrafish: from disease modelling to drug discovery. *Cur Opin Drug Discov Devel.* v. 6, p. 218-223, 2003.

RUBINSTEIN, A.L. Zebrafish assays for drug toxicity screening. *Exp Opin Drug Metab Toxicol.* v. 2, p. 231-240, 2006.

SAGER, J.J., BAI, Q., BURTON, E.A. Transgenic zebrafish models of neurodegenerative diseases. *Brain Struct Funct.* V. 214 n. 2-3 p. 285-302, 2010.

SAMBAMURTI, K., GREIG, N., LAHIRI, D.K. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. *Neuromolecular Med.* v.1 p. 1-10, 2002.

SCHETINGER, M.R., *et al.* NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health. *Biofactors.* v. 31 n.2 p.77-98, 2007.

SCHILLING, T. The morphology of larval and adult zebrafish. In: *Zebrafish.* (eds. C. Nüsslein-Volhard, & R. Dahm) p.59-94. Oxford University Press, Oxford. (2002).

SCHWARZSCHILD, M.A., *et al.* Targeting adenosine A2A receptors in Parkinson's disease. *Trends Neurosci.* v.29 p.647-654, 2006.

SCHWEITZER, J., e DRIEVER, W. Development of the dopamine systems in zebrafish. *Adv Exp Med Biol.* v. 651 p. 1-14, 2009.

SEBASTIÃO, A.M., e RIBEIRO, J.A. Adenosine receptors and the central nervous system. *Handb Exp Pharmacol.* v. 193 p. 471-534, 2009.

SELKOE, D.J. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev.* v.81 p.741-66, 2001.

SENGER, M.R., *et al.* Ecto-5'-nucleotidase activity in brain membranes of zebrafish (*Danio rerio*). *Comp Biochem Physiol.* v.139 n.2 p.203-207, 2004.

SHERVA, R., *et al.*, Variation in Nicotinic Acetylcholine Receptor Genes is Associated with Multiple Substance Dependence Phenotypes. *Neuropsychopharmacology* v. 35 p. 1921-1931, 2010.

SHIGETA, M., e HOMMA, A. Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles. *CNS Drug Rev.* v. 7 p. 353-368, 2001.

SHIN, J.T., e FISHMAN, M.C. From zebrafish to human: modular medical models. *Annual Rev Genomics Hum Genet.* v.3 p. 311-40, 2002.

SIEMERS, E., *et al.* Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. *Biomark Med.* v. 4 n. 1 p. 81-9, 2010.

SINGH, M., *et al.* Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. *J Agric Food Chem.* v. 56 p. 4855-4873, 2008.

SKAPER, S.D., DEBETTO, P., GIUSTI, P. The P2X7 purinergic receptor: from physiology to neurological disorders. *FASEB J.* v. 24 n. 2 p. 337-45, 2010.

SPENCE, R., *et al.* The diet, growth and recruitment of wild zebrafish (*Danio rerio*) in Bangladesh. *J Fish Biol.* v. 71, p. 304-309, 2007.

SPENCE, R., *et al.* The behaviour and ecology of the zebrafish, *Danio rerio*. *Biol Rev Camb Philos Soc.* v. 83 n.1 p. 13-34, 2008.

SPINELLI, S., *et al.* Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys. *Neuropharmacology.* v. 51 p. 238-250, 2006.

STONE, T.W., CERUTI, S., ABBRACCHIO, M.P. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. *Handb Exp Pharmacol.* v. 193 p. 535-87, 2009.

STRATTON, L.O., e PETRINOVICH, L., Post-trial injections of an anti-cholinesterase drug and maze learning in two strains of rats. *Psychopharmacologia* v. 5 p. 47-54, 1963.

SURPRENANT, A., e NORTH, R.A. Signaling at purinergic P2X receptors. *Annu Rev Physiol.* v. 71 p. 333-59, 2009.

TAKAHASHI, R.N., *et al.* Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. *Front Biosci* v. 13 p. 2614-2632, 2008.

TALWAR, P.K., e JHINGRAN, A.G. Inland fishes of India and adjacent countries. Oxford & I. B. H. Publishing, Calcutta, 1991.

TAYLOR, M.R., *et al.* Zebrafish model for pyruvate dehydrogenase deficiency: rescue of neurological dysfunction and embryonic lethality using a ketogenic diet. *Proc Natl Acad Sci USA.* v.101 n.13 p. 4584-4589, 2004.

TRINCAVELLI, M.L., DANIELE, S., MARTINI, C. Adenosine receptors: what we know and what we are learning. *Curr Top Med Chem.* v. 10 n. 9 p. 860-77, 2010

VOGT, A., *et al.* Development of automated imaging and analysis for zebrafish chemical screens. *J Vis Exp* v. 40. pii: 1900, 2010.

WANG, H., LU, Y., CHEN, H.Z. Differentiating effects of anisodamine on cognitive amelioration and peripheral muscarinic side effects induced by pilocarpine in mice, *Neurosci. Lett.* v. 344 p. 173-176, 2003.

WARDA, C.P., *et al.* Ginkgo biloba extract: cognitive enhancer or antistress buffer. *Pharmacol Biochem Behav.* v. 72 p. 913-22, 2002.

WEINBERGER, N.M. Food for Thought: Honeybee Foraging, Memory, and Acetylcholine. *Sci. STKE* (336) pe23, 2006.

WEINREB, O., *et al.* Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. *J Nutr Biochem.* v.15 p.506-516, 2004.

WESSLER, I., KIRKPATRICK, C.J., RACKÉ, K. The cholinergic 'pitfall': acetylcholine, a universal cell molecule in biological systems, including humans. *Clin Exp Pharmacol Physiol.* v. 26 n. 3 p. 198-205, 1999.

XIANG, X.H., *et al.* Ethological analysis of scopolamine treatment or pretreatment in morphine dependent rats. *Physiol Behav.* v.88 p.183-189, 2006.

YANG, C.Y., *et al.* Bioavailability and Metabolic Pharmacokinetics of Rutin and Quercetin in Rats. *J Food Drug Anal.* v. 13 n. 3 p. 244-250, 2005.

YANG, L., *et al.* Zebrafish embryos as models for embryotoxic and teratological effects of chemicals. *Reprod Toxicol.* v. 28 n.2 p.245-53, 2009.

YOUDIM, K.A., *et al.* Dietary flavonoids as potential neuroprotectants. *Biol Chem.* v. 383 n.3-4 p.503-519, 2002.

YOUDIM, K.A., *et al.* Flavonoid permeability across an in situ model of the blood-brain barrier. *Free Radic Biol Med.* v.36 p.592-604, 2004.

YOUNG, M.T. P2X receptors: dawn of the post-structure era. *Trends Biochem Sci.* v.35 n.2 p. 83-90, 2010.

ZETTERBERG, H., *et al.* Biochemical markers in Alzheimer's disease clinical trials. *Biomark Med.* v. 4 n.1 p. 91-8, 2010.

ZHANG, L., e LEUNG, Y.F. Microdissection of zebrafish embryonic eye tissues. *J Vis Exp.* v. 40. pii: 2028, 2010.

ZHANG, W.W., *et al.* Differential neuropsychopharmacological influences of naturally occurring tropane alkaloids anisodamine versus scopolamine. *Neurosci Lett.* v. 443 p. 241-245, 2008.

ZHELEVA-DIMITROVA, D., *et al.* Simultaneous determination of benzophenones and gentisein in *Hypericum annulatum* Moris by high-performance liquid chromatography. *Phytochem Anal.* v.18 p.1-6, 2007.

ZIMMERMANN, H. Extracellular metabolism of ATP and other nucleotides. *Naunyn Schmiedebergs Arch Pharmacol.* v. 362, n. 4-5, p. 299-309, 2000.

ZIMMERMANN, H. Ectonucleotidases: Some recent developments and a note on nomenclature. *Drug Dev Res.* v. 52, n. 1-2, p. 44-56, 2001.

ZIMMERMANN, H. ATP and acetylcholine, equal brethren. *Neurochem Int.* v. 252 n. 4-5 p. 634-48, 2008.

ZON, L.I. e PETERSON, R.T. In vivo drug discovery in the zebrafish, *Nat. Rev. Drug Discov.* v. 4 p. 35-44, 2005.

ANEXOS

ANEXO I - ARTIGO CIENTÍFICO

PROJETO PARALELO EXECUTADO PELA MESTRANDA

RICHETTI, S.K., ROSEMBERG, D.B., VENTURA-LIMA, J., MONSERRAT, J.M., BOGO, M.R., BONAN, C.D. Acetylcholinesterase activity and antioxidant capacity of zebrafish brain is altered by heavy metal exposure.

Artigo submetido em 06 de agosto de 2010 ao periódico Neurotoxicology.

De: ees.neutox.0.adb2a.5122b3fb@eesmail.elsevier.com em nome de NeuroToxicology

Enviada: sex 6/8/2010 11:21

Para: Carla Denise Bonan

Assunto: Submission Confirmation

Dear Dr. Carla Bonan,

Your submission entitled "Acetylcholinesterase activity and antioxidant capacity of zebrafish brain is altered by heavy metal exposure" has been received by journal Neurotoxicology

You will be able to check on the progress of your paper by logging on to Elsevier Editorial System as an author. The URL is <http://ees.elsevier.com/neutox/>.

Your manuscript will be given a reference number once an Editor has been assigned.

Thank you for submitting your work to this journal.

Kind regards,

Professor Joan Cranmer
Editor-in-Chief, NeuroToxicology

For further assistance, please visit our customer support site at <http://epsupport.elsevier.com>. Here you can search for solutions on a range of topics, find answers to frequently asked questions and learn more about EES via interactive tutorials. You will also find our 24/7 support contact details should you need any further assistance from one of our customer support representatives.

Elsevier Editorial System(tm) for Neurotoxicology
Manuscript Draft

Manuscript Number: NEUTOX-D-10-00142

Title: Acetylcholinesterase activity and antioxidant capacity of zebrafish brain is altered by heavy metal exposure

Article Type: Full Length Article

Keywords: Heavy metal; Pollution; Acetylcholinesterase; Zebrafish; Oxidative stress.

Corresponding Author: Dr. Carla Bonan,

Corresponding Author's Institution: Pontificia Universidade Católica do Rio Grande do Sul

First Author: Stefânia K Richetti

Order of Authors: Stefânia K Richetti; Denis B Rosemberg; Juliane Ventura-Lima; Jose M Monserrat; Maurício R Bogo; Carla Bonan

Abstract: Pollution is a world problem with immeasurable consequences. Heavy metal compounds are frequently found as components of anthropogenic pollution. Here we evaluated the effects of the treatment with cadmium acetate, lead acetate, mercury chloride, and zinc chloride in acetylcholinesterase activity and gene expression pattern, as well as the effects of these treatments in antioxidant competence in the brain of an aquatic and well-established organism for toxicological analysis, zebrafish (*Danio rerio*, Cyprinidae). Mercury chloride and lead acetate promoted a significant decrease in acetylcholinesterase activity whereas they did not alter the gene expression pattern. In addition, the antioxidant competence was decreased after exposure to mercury chloride. The data presented here, together with bioinformatic analysis, allowed us to hypothesize a signal transmission impairment, through posttranslational modifications, alterations in cholinergic transmission, and also in the antioxidant competence of zebrafish brain tissue as some of the several effects elicited by these pollutants.

Cover Letter

August 6, 2010

Joan Marie Cranmer,
Editor-in-chief
Neurotoxicology,
Department of Pediatrics - Mail #512-19C, University of Arkansas for Medical Sciences, &
Arkansas Children's Hospital, 11 Children's Way, Little Rock, AR 72202, USA

Dear Dr. Cranmer

We are sending for submission to Neurotoxicology the manuscript entitled "**Acetylcholinesterase activity and antioxidant capacity of zebrafish brain is altered by heavy metal exposure**". Authors: Richetti, S.K., Rosemberg, D.B., Ventura-Lima, J., Monserrat, J.M., Bogo, M.R., Bonan, C.D.

The paper contains original data and it is not been submitted for publication elsewhere. All authors approve the submission of the manuscript.

The following researchers are considered potential reviewers of this manuscript:

Dr. Zhang, J.

Division of Biofunctional Science, Graduate School of Science and Technology, Kobe University, Nada, Kobe, Japan. zhjunmba@hotmail.com

Dr. Schetinger, M.R.

Departamento de Química, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Av. Roraima, 97105-900, Santa Maria, RS, Brazil.
mariaschetinger@gmail.com

Dr. Amado, L.L.

Universidade Federal do Pará
lilian.amado@gmail.com

1 **Acetylcholinesterase activity and antioxidant capacity of zebrafish brain is altered**
2 **by heavy metal exposure.**

3 Richetti, S.K.^{1,2}, Rosenberg, D.B.³, Ventura-Lima, J.⁴, Monserrat, J.M.⁴, Bogo, M.R.^{2,5},
4 Bonan, C.D.^{1,2*}.

5

6 ¹ Laboratório de Neuroquímica e Psicofarmacologia, Faculdade de Biociências, Pontifícia
7 Universidade Católica do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto
8 Alegre, RS, Brazil.

9 ² Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM)
10 90035-003, Porto Alegre, RS, Brazil.

11 ³ Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade
12 Federal do Rio Grande do Sul. Rua Ramiro Barcelos 2600-Anexo, 90035-003 Porto
13 Alegre, RS, Brazil.

14 ⁴ Instituto de Ciências Biológicas (ICB), Universidade Federal do Rio Grande - FURG,
15 Rio Grande, RS, Brazil

16 ⁵ Laboratório de Biologia Genômica e Molecular, Faculdade de Biociências, Pontifícia
17 Universidade Católica do Rio Grande do Sul. Avenida Ipiranga, 6681, 90619-900. Porto
18 Alegre, RS, Brazil.

19

20 Corresponding author:

21 Bonan, C.D. Laboratório de Neuroquímica e Psicofarmacologia Departamento de
22 Biologia Celular e Molecular, Faculdade de Biociências, Pontifícia Universidade Católica

23 do Rio Grande do Sul; Avenida Ipiranga, 6681, 90619-900. Porto Alegre, RS, Brazil.

24 Tel.: +55 51 3353 4158; fax: +55 51 3320 3568. cbonan@pucrs.br

25

26 **Abstract**

27 Pollution is a world problem with immeasurable consequences. Heavy metal compounds
28 are frequently found as components of anthropogenic pollution. Here we evaluated the
29 effects of the treatment with cadmium acetate, lead acetate, mercury chloride, and zinc
30 chloride in acetylcholinesterase activity and gene expression pattern, as well as the effects
31 of these treatments in antioxidant competence in the brain of an aquatic and well-
32 established organism for toxicological analysis, zebrafish (*Danio rerio*, Cyprinidae).
33 Mercury chloride and lead acetate promoted a significant decrease in acetylcholinesterase
34 activity whereas they did not alter the gene expression pattern. In addition, the
35 antioxidant competence was decreased after exposure to mercury chloride. The data
36 presented here, together with bioinformatic analysis, allowed us to hypothesize a signal
37 transmission impairment, through posttranslational modifications, alterations in
38 cholinergic transmission, and also in the antioxidant competence of zebrafish brain tissue
39 as some of the several effects elicited by these pollutants.

40

41 **Keywords:** Heavy metal, Pollution, Acetylcholinesterase, Zebrafish, Oxidative stress.

42

43

44

45

46 **1. Introduction**

47

48 The pollutant emissions are increasing worldwide and bringing huge health and
49 environmental problems, particularly in aquatic milieu. The pollution is frequently
50 composed of a mixture of heavy metals, including the three most expressive: cadmium
51 (Cd^{2+}), lead (Pb^{2+}) and mercury (Hg^{2+}); and the second most important trace metal in the
52 body, zinc (Zn^{2+}) (Coleman, 1992; Monnet-Tschudi et al., 2006; Vallee and Falchuk,
53 1981).

54 Cadmium is incorrectly disposed in the environment as a result of anthropogenic
55 activities, as mining exploration, as a constituent of color pigments and re-chargeable
56 nickel-cadmium batteries (Jarup, 2003). The cadmium effects on health are countless, and
57 vary from kidney damage, bone effects and also many types of cancer, being classified by
58 the IARC (International Agency for Research on Cancer) as carcinogenic to humans
59 (Group 1) (IARC, 1993).

60 Another metal which the general population is exposed is the lead, being the
61 mines, industries of glass, food bowls, and wine considered important sources of its
62 emission. In relation to its health effects, they are well established, including its action in
63 various neurotransmitter systems (Cory-Slechta, 1995). There is evidence of the
64 carcinogenic potential of lead compounds, which ranks it as a compound probably
65 carcinogenic to humans (Group 2A) (IARC, 2006).

66 Mercury is used since the pre-history as a pigment, passing through a cure for
67 syphilis in the 1800's and arriving in the present as diuretics, dental amalgam fillings,
68 thermometers and several uses that despise its toxicity. A high intake of mercury by

69 humans comes together with an elevated consumption of fish. When in contact with
70 animals, mercury can cause lung damage, neurological and psychological disturbances
71 and also, but in a lesser extent, development of cancer, being classified by the IARC as
72 possibly carcinogenic to humans (Group 2B) (IARC, 1993)

73 Although the transition metal zinc plays a neuromodulatory role in the CNS, it
74 may be a neurotoxic agent following Zn^{2+} influx, carried out in large part through
75 voltage-gated Ca^{2+} channels (Sheline et al., 2002). The increase of cytosolic Zn^{2+}
76 concentrations triggers several downstream mechanisms which culminate in neuronal cell
77 death (Cai et al., 2006). In contrast to the very low levels of free intracellular Zn^{2+} , toxic
78 exposures to this metal strongly rises $[Zn^{2+}]_i$ to 400-600 nM (Sensi et al., 1999). At this
79 concentration, Zn^{2+} can decrease the activity of key glycolytic enzymes, such as GAPDH
80 (Krotkiewska and Banas, 1992) and phosphofructokinase in purified forms (Ikeda et al.,
81 1980). Studies also reported that Zn^{2+} induces mitochondrial dysfunction by inhibiting
82 the activities of enzymes involved in electron transport, leading to an increase in neuronal
83 reactive oxygen species and, consequently, oxidative stress (Kim et al., 1999; Manev et
84 al., 1997; Noh et al., 1999). Furthermore, a recent data showed that Zn^{2+} -mediated
85 neurotoxicity is dependent of intracellular NAD^+ levels and the sirtuin activity, indicating
86 that alterations in energy metabolic pathways could be regulated at transcriptional level
87 (Cai et al., 2006).

88 The cholinergic system, with acetylcholine (ACh) as the neurotransmitter, is
89 involved in cognitive processes, through the activation of metabotropic muscarinic and
90 ionotropic nicotinic cholinergic receptors. The reaction responsible for the maintenance
91 of levels of ACh is catalyzed by two cholinesterases (ChE): Acetylcholinesterase (AChE)

92 (E.C. 3.1.1.7) and Butyrylcholinesterase (BuChE) (E.C. 3.1.1.8). Zebrafish (*Danio rerio*)
93 is an emergent vertebrate model for studying several biological events, such as
94 neurochemical alterations promoted by heavy metal toxicity (Senger et al., 2006). This
95 teleost possesses only the gene for AChE, which is responsible for the whole ACh
96 degradation, being the BuChE absent. The AChE gene was already identified, cloned and
97 functionally detected in the zebrafish brain (Bertrand et al., 2001). Acetylcholinesterase is
98 an important biomarker for several environmental contaminants in zebrafish (Rico et al.,
99 2006; Senger et al., 2006). In addition, it is also known the important role of this enzyme
100 in diseases with an increasing incidence in the elderly population, such as Alzheimer
101 disease (Han et al., 2007, Kim et al., 2008).

102 There is evidence of the interaction between heavy metals as mercury and lead
103 and the etiology of neurodegenerative diseases, since many of these metals can cross the
104 blood brain barrier and accumulate in the brain, promoting the generation of oxidative
105 stress and alterations in the metabolism of some proteins associated with the development
106 of neurodegenerative diseases, such as Alzheimer disease, Parkinson disease, and
107 Amyotrophic Lateral Sclerosis (reviewed in Monnet-Tschudi et al., 2006).

108 Therefore, considering the increase of the pollution, incorrect disposal of heavy
109 metals as industrial effluents, the immersion of organisms in this impaired environment
110 and the possible consequences of this exposure, the aim of the present study was to
111 investigate the effects of four heavy metal compounds in AChE activity and its gene
112 expression pattern. Furthermore, we have analyzed the effects of some of these heavy
113 metal treatments in parameters related to antioxidant defenses and lipid peroxidation in
114 the brain of an aquatic and well-stabilished organism for toxicological analysis, zebrafish.

115 **2. Materials and methods**

116

117 *2.1 Chemicals*

118

119 Zinc chloride ($ZnCl_2$; CAS number 7648-85-7) was purchased from Nuclear (Brazil) and
120 cadmium acetate [$Cd(CH_3COO)_2$; CAS number 543-90-8], mercury chloride ($HgCl_2$,
121 CAS Number 7487-94-7) and lead acetate [$Pb(CH_3COO)_2$ CAS Number 301-04-2] were
122 purchased from QM (Brazil). Trizma Base, EDTA, EGTA, sodium citrate, Coomassie
123 Blue G, bovine serum albumin, acetylthiocholine, 5,5'-dithiobis-2-nitrobenzoic acid
124 (DNTB), HEPES, BHT (99%), 2,2'-Azobis(2-methylpropionamide) dihydrochloride
125 (ABAP) and 1,1,3,3-tetramethoxypropane were purchased from Sigma-Aldrich Corp. (St.
126 Louis, MO, USA). KCl and SDS (90%) were purchased from Labsynth (Brazil).
127 Tetramethoxypropane (TMP) and 2',7'-dichlorodihydrofluorescein diacetate were
128 purchased from Acros Organics (Morris Plains, NJ, USA) and Molecular Probes Inc.
129 (Eugene, OR, USA) respectively. $MgCl_2$ and Acetic acid 99,7% was purchased from
130 Isofar and Vetec (Brazil) respectively. TRIZOL, GelRed and Taq DNA polymerase were
131 purchased from Invitrogen Corp. (Carlsbad, CA, USA). All other reagents used were of
132 analytical grade.

133

134 *2.2 Animals*

135 Adult and healthy Zebrafish of both sexes were obtained from specialized supplier
136 (Redfish Agroloja, RS, Brazil) and kept in standard conditions (tap water treated with
137 Tetra's AquaSafe® to neutralize chlorine, chloramines, and heavy metals present in tap

138 water that can be harmful to fish) continuously aerated water, $25 \pm 2^\circ\text{C}$, under a 14-10 h
139 light/dark cycle photoperiod) in 50L housing tank for at least 2 weeks to acclimate before
140 the experiments. The animals were maintained healthy and free of any signs of disease
141 and fed three times a day with TetraMin Tropical Flake Fish. The Ethics Committee of
142 Pontifical Catholic University of the Rio Grande do Sul (PUCRS) approved the protocol
143 under the number 0703854- CEUA.

144

145 *2.3 Determination of Acetylcholinesterase activity*

146

147 Zebrafish were cryoanesthetized and immediately euthanized by decapitation, and whole
148 brains were homogenized on ice in 60 vol (v/w) of 0.05 M Tris-HCL, pH 8.0, using a
149 Teflon-glass homogenizer. For the AChE activity analysis, a pool of 3 brains was
150 considered as an sample. To ensure the consistence of our results, the tests were
151 performed at least in quadruplicates, using a total of 12 animals per group. AChE activity
152 was determined according the method of Ellmann et al, (1961) with minor modifications.
153 Briefly, the activity on the homogenate was measured by determining the rate of
154 hydrolysis of acetilthiocholine iodide (ACSch, 0.88 mM) in a final volume of 300 μL ,
155 with 33 μL of 100 mM phosphate buffer, pH 7.5, and 2 mM DTNB. In this solution, 5 μg
156 of protein of each sample were added and pre-incubated at 25°C for 10 min. The reaction
157 was started with the addition of the substrate acetilthiocholine, and as soon as the
158 substrate was added the hydrolysis and the formation of the dianion of DTNB were
159 analyzed in 412 nM for 2.5 min (in intervals of 30 s) using a microplate reader. AChE

160 activity was expressed as micromole of thiocholine (SCh) released per hour per milligram
161 of protein.

162

163 *2.4 In vivo treatments*

164

165 The animals were separated in groups of 12 animals and housed in 3L tanks with the
166 respective treatment. The animals were transferred to the test aquarium filled with reverse
167 osmosis water to avoid the presence of any metal in the tap water and also to avoid the
168 use of the metal chelant Tetra's AquaSafe®. The animals were kept in continuously
169 aerated water, $25 \pm 2^\circ\text{C}$, under a 14-10 h light/dark cycle photoperiod, fed three times a
170 day with TetraMin Tropical Flake fish. The treatments were as follows: mercury chloride
171 or lead acetate at a final concentration of $20 \mu\text{g/L}$, which has been chosen in previous
172 studies from our laboratory (Senger et al., 2006) based on reportings about the aquatic
173 environment (Berzas Nevado et al., 2003, Jha et al., 2003 and). The concentrations of
174 zinc chloride (5 mg/L) or cadmium acetate (0.1 mg/L) were chosen according the
175 National Council for the Environment (Brazil) (Resolution 357/2005), that allow the
176 disposal of these heavy metal concentrations as industrial effluents in the environment.
177 Control group was kept in the same conditions as the other groups, but without the
178 addition of any metals in the reverse osmosis water. The animals were maintained in the
179 test aquarium for 24, 96 h and 30 days for acute, subchronic and chronic exposures,
180 respectively. The water of the tanks was changed every two days to guarantee the
181 concentration desired of the heavy metal treatment.

182

183 2.5 *In vitro* assays

184

185 Mercury chloride and Lead acetate (1–250 μM) were added to the reaction medium
186 before preincubation with the enzyme and maintained throughout the enzyme assays
187 described in the section 2.3. Zinc Chloride and Lead acetate were not analyzed *in vitro*
188 because they were already analyzed by Senger et al., 2006. Each metal was added to the
189 reaction medium at 75nm, 150nm, 500nm, 1000nm , 25 μM and 250 μM ; these
190 concentrations were chosen in order to analyze the effect of a wide spectrum of
191 concentrations, ranging from the concentration of heavy metal found in the test tank
192 water, which was already shown in the environment (Berzas Nevado et al., 2003 and Jha
193 et al., 2003) to higher concentrations chosen based on previous studies showing the effect
194 of these metals on other enzymes involved in nucleoside/nucleotide metabolism (Aikawa
195 et al., 1980, Senger et al., 2006a), Control group was performed with no addition of metal
196 in the enzyme assay.

197

198 2.6 *Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR)*

199

200 Total RNA was isolated from a pool of 5 zebrafish brains constituting each group using
201 TRIzol reagent according manufacturer instructions. The RNA was quantified
202 spectrophotometrically and all samples were adjusted to 160 ng/ μl . cDNA species were
203 synthesized with SuperScriptTM First-Strand (Synthesis System for RT-PCR, Invitrogen),
204 in accordance with the suppliers. PCR reactions were performed as previously described
205 in Rico et al., (2006). The *AChE* and β -*actin* gene amplifications were conducted in a

206 final volume of 20 μ L, with 0.1 μ M of each primer, 0.2 μ M of dNTP, 2 mM of $MgCl_2$
207 and 0.5 U of Taq DNA polymerase. The PCR reaction were performed following the
208 conditions below: 2 min at 94°C , 1 min at 60°C or 58.5°C for *AChE* and *β -actin* gene
209 respectively, 1 min at 72 °C for 35 cycles. A post-extension period of 10 min at 72°C was
210 performed. A negative control for the PCR product was conducted. The PCR products
211 were analyzed in a 1% agarose gel in an UV transilluminator using GelRed 10X. The
212 band intensities were analyzed in a semi-quantitative way using Image J software. The
213 primers used for the gene amplification were
214 CCAAAAGAATAGAGATGCCATGGACG (forward) and TGTGATGTTAAGCAGA
215 CGAGGCAGG (reverse) for *AChE* (Rico et al., 2006) and
216 GTCCCTGTACGCCTCTGGTCG (forward) and GCCGGACTCATCGTACTCCTG
217 (reverse) for *β -actin* (Chen et al., 2004). To ensure the consistence of our results, the tests
218 were performed at least in quadruplicates, using a total of 20 animals per group.

219

220 2.7 Antioxidant capacity against peroxy radicals

221

222 Total antioxidant competence against peroxy radicals was evaluated through reactive
223 oxygen species (ROS) determination in tissues samples treated or not with a peroxy
224 radical generator (Amado et al., 2009). Briefly, on a white 96-well microplate, 10 μ L of
225 brain homogenates were disposed into the wells, six wells per sample. The reaction buffer
226 (127.5 μ l) containing 30 mM HEPES (pH 7.2), 200 mM KCl and 1 mM $MgCl_2$ were
227 added to the wells containing the samples. In three of the six wells of each sample, 7.5 μ L
228 of 2,2'-azobis 2 methylpropionamide dihydrochloride (ABAP; 4 mM) were added. In

229 the other three wells the same volume of ultrapure water was pipetted. After this, the
230 microplate was put into a fluorescence microplate reader (Victor 2, Perkin Elmer),
231 programmed to keep temperature at 35 °C. At this temperature, peroxy radicals are
232 produced by thermal decomposition of ABAP (Winston et al., 1998). Immediately before
233 microplate reading, it was added in all wells 10 µL of the fluorescent probe 2',7'
234 dichlorofluorescein diacetate (H₂DCF-DA) in a final concentration of 40 µM, according
235 to the methodology employed by Ferreira-Cravo et al. (2007). H₂DCF-DA is deacetylated
236 and the product H₂DCF is oxidized by ROS to the fluorescent compound DCF, which is
237 detected at wavelengths of 488 and 525 nm, for excitation and emission, respectively.
238 Fluorescence readings (fluorescence units or FU) were performed every 5 min during 30
239 min. Total fluorescence production was calculated by integrating the fluorescence units
240 (FU) along the time of the measurement, after adjusting FU data to a second order
241 polynomial function. The results were expressed as area difference of FU x min in the
242 same sample with and without ABAP addition and standardized to the ROS area without
243 ABAP (background area). The relative difference between ROS area with and without
244 ABAP was considered a measure of antioxidant capacity, with high area difference
245 meaning low antioxidant capacity, since high fluorescence levels were obtaining after
246 adding ABAP, meaning low competence to neutralize peroxy radicals (Amado et al.,
247 2009).

248

249

250 *2.8 Measurement of lipid peroxidation*

251

252 Lipid peroxidation was measured through determination of thiobarbituric acid reactive
253 substances (TBARS), following the methodology of Oakes and Van der Kraak (2003).
254 Brain homogenates (10 μ l) were added to a reaction mixture made with 150 μ l of 20%
255 acetic acid, 150 μ l of thiobarbituric acid (0.8%), 50 μ l of Milli Q water and 20 μ l of
256 sodium dodecyl sulfate (SDS, 8.1 %). Samples were heated at 95°C during 30 min and
257 after cooling by 10 min, 100 μ l of Milli Q water and 500 μ l of n-butanol was added.
258 After centrifugation (3,000 x g during 10 min at 15 °C), the organic phase (150 μ l) was
259 placed in a microplate reader and the fluorescence registered after excitation at 515 nm
260 and emission of 553 nm. The concentration of TBARS (nmols/mg of wet tissue) was
261 calculated employing tetramethoxypropane (TMP) as standard.

262

263 *2.9 Protein determination*

264

265 Protein was measured with two different methods in accordance with the sensitivity
266 required for the analysis. For the AChE activity analysis, protein was measured by the
267 Coomassie Blue method considering bovine serum albumin as standard (Bradford, 1976).
268 For the antioxidant procedures, total protein content was measured by the Biuret method
269 using a commercial Total Protein Kit (Doles Inc. Brazil) in accordance with the supplier
270 instructions.

271

272 *2.10 Statistical Analysis*

273

274 Data for the enzymatic and antioxidant analyses were expressed as means \pm S.E.M. and
275 analyzed by one-way analysis of variance (ANOVA), following the post-hoc test of
276 Tukey, considering $P < 0.05$ as significant. Before ANOVA analysis, its assumptions
277 (normality and variances homogeneity) were checked.

278

279

280 **3. Results**

281

282 *Acetylcholinesterase enzymatic activity and gene expression*

283

284 As shown by Figure 1, the effect of zinc chloride, cadmium acetate, mercury chloride and
285 lead acetate were investigated on AChE activity in zebrafish brain. Zinc chloride did not
286 affect the enzyme activity ($P > 0.05$), even when in the graph is observed a slight augment
287 of the activity after 24 h exposure (Fig. 1A). As with zinc chloride, cadmium acetate did
288 not alter the enzyme activity in the concentration tested (Fig. 1B; $P > 0.05$). The two
289 compounds that altered AChE activity were lead acetate and mercury chloride. In relation
290 of the effects of the treatment with mercury chloride, we can observe a reduction (-25%,
291 $P < 0.05$) of the AChE activity in the 24h-treated animals, following an elevation (+16%,
292 $P < 0.05$) of the AChE activity in the 96h-treated animals in relation to control. This
293 alteration is stabilized after 30 days of treatment (Fig. 1C). Lead acetate induced a
294 reduction (-18%, $P < 0.05$) of the AChE activity in the 24h-treated animals, following a
295 progressive restoration of the normal activity after 96 h and 30 d of treatment (Fig. 1D).
296 We also evaluate the gene expression of this enzyme to investigate in what molecular
297 level these compounds were acting. analyzed the effects of the 24 h treatment with lead
298 acetate and mercury chloride and after 96 h of mercury chloride treatment. As shown by
299 Figure 2, there were no significant changes ($P > 0.05$) in the *Ache* mRNA transcript levels
300 after lead acetate and mercury chloride exposure.

301

302 ***In vitro effects of heavy metal treatments on acetylcholinesterase activity***

303

304 According to the Figure 3, neither mercury chloride nor lead acetate were able to interfere
305 directly in the enzyme at the concentrations reached with the in vivo treatment. Only
306 mercury chloride at higher concentrations tested in vitro (25 and 250 μM) was capable to
307 inhibit AChE activity (77% and 55%, respectively) (Fig. 3A). Although we have
308 observed a significant effect on AChE activity, these concentrations are much higher than
309 the mercury levels detected in the aquatic environment.

310

311 ***Antioxidant analysis***

312

313 Samples of animals treated for 24 hours with mercury chloride showed a decrease in total
314 antioxidant competence (<0.05) against peroxy radicals (Fig. 4A) as a result of an
315 augmented relative area (162%) when compared to the control group ($p<0.05$). The
316 treatment with lead acetate for 24 hours was not able to interfere in the total antioxidant
317 competence, as shown by a relative area statistically similar to the control group
318 ($P>0.05$). No differences in the TBARS content (Fig. 4B) were observed under the
319 experimental conditions.

320

321

322

323

324

325 **4. Discussion**

326

327 In present study, we have evaluated the effect of different treatments with four
328 heavy metal compounds (zinc chloride, cadmium acetate, lead acetate, and mercury
329 chloride) on the AChE activity and gene expression in zebrafish brain. In the
330 concentrations tested, only the animals treated for 24h with lead acetate and mercury
331 chloride and after 96h with mercury chloride have shown alterations in the AChE
332 activity. In addition, we have shown the effects of the treatments above in the antioxidant
333 competence and lipid peroxidation in zebrafish brain. The 24 h-treatment with mercury
334 chloride had the ability to reduce the antioxidant competence against peroxy radicals.

335 Environmental pollutants, such as insecticides, herbicides and heavy metal
336 compounds, have been associated with the development of PD and AD (Allam, 2005;
337 Gorell, 1999; Mutter, 2004; Sherer, 2003). The slow accumulation of heavy metals in the
338 brain, due to their widespread and permanent presence in the environment (Bahn, 2005;
339 Björkman, 1997; Bloom, 1994; Ely, 2001; Halbach 1998; Lopez, 2005; Swarup, 2005)
340 can be a potential predictor for the development of a neurodegenerative disease. Yet, a
341 short-term exposure but during early or critical and vulnerable developmental periods
342 (Carpenter, 2001; Finkelstein, 1998) also contributes to increase the susceptibility for
343 developing a neurodegenerative disease later in life (Bolin et al., 2006; Finkelstein, 1998;
344 Landrigan, 2005; Monnet-Tschudi, 2006; Mutter, 2004; Pabello, 2005).

345 Acute and chronic toxicoses caused by cadmium, mercury, and lead are known
346 for all forms of life (Hu, 2005, Kosnett, 2007). A general consensus holds that the

347 harmful effects of heavy metals as cadmium, mercury, and lead mainly result from their
348 interactions with protein and/or DNA (Sharma et al., 2008). Sharma et al., (2008) have
349 shown that heavy metal ions are potent inhibitors of protein folding, suggesting that the
350 interference of metal ions with non native forms of proteins might result in quantitative
351 deficiencies of the affected proteins and in the formation of proteotoxic aggregates, which
352 can contribute to explain the pleiotropic symptomatology of heavy metal poisoning (Hu,
353 2005; Kosnett, 2007; Waisberg, 2003). There is also evidence that heavy metals can
354 affect diverse post-translational modifications of proteins, which are a decisive step for
355 some proteins to achieve its correct folding and enzyme activity. Other action attributed
356 to heavy metals is the alteration of ion-dependent events at the synapses, such as the
357 impairment of calcium channels and NMDA receptors-mediated events, and also the
358 disruption of zinc-fingers motif containing proteins. Zinc finger proteins are the largest
359 class of transcription factors, which, in the presence of this ion, shows the correct folding
360 and stability allowing the binding to nucleic acids to regulate transcription (Zawia et al.,
361 2000; Zeng and Kagi, 1995). This motif is present in a number of critical brain specific
362 proteins and the substitution of zinc by environmental heavy metal ions, mainly as a
363 consequence of lead exposure can induce structural and functional changes in these
364 proteins, contributing to the cellular degeneration, disturbed gene expression, signal
365 transduction, and DNA repair (Zawia et al., 2000). Considering this hypothesis, we have
366 evaluated the possible influence of the heavy metals tested in AChE gene expression.
367 AChE transcript levels were not affected by the treatment with heavy metals, suggesting
368 other metabolic target for the treatments.

369 As multi-targeted disturbing agents, heavy metals can induce or exacerbate
370 pathogenic cascades by acting in signal transduction elements, such as enzymes, ion
371 channels or receptors. Considering that these networks of signal transducers determine
372 the conversion of environmental cues into cellular actions (Rosse et al., 2010), an
373 alteration in this balanced pathway may trigger a variety of altered signals, including the
374 activation of messengers that can modulate the actions of other cell components. The
375 main players in these networks are protein kinases, such as PKC and PKA.

376 There is data that demonstrate that Pb^{+2} can activate PKC in immature rat brain
377 microvessels and in brain tissues, by mimicking calcium (Markovac and Goldstein 1988a,
378 1988b). The prevalent theory is that lead may affect calcium metabolism, and, in several
379 systems, it can mimic calcium actions at cellular level or disrupt calcium homeostasis
380 (Lu, Guizzetti and Costa, 2002). Pb can substitute calcium action in activating PKC
381 (reviewed in Costa, 1998). It also have been reported the inhibitory effects of lead in
382 purified PKC enzymes from rat brains and hepatoma cultured cells (Murakami, Feng and
383 Chen, 1993, Tonner and Heiman, 1997). Despite these data, there is also evidence that
384 lead plays a dual role, activating or inhibiting PKC according to the lead dose tested (Sun
385 et al., 1999; Tomsig and Suszkiw, 1995). This discrepancy of lead effects can be a result
386 of a partial agonist role of lead at low concentrations, activating the enzyme with its
387 interaction with high affinity sites that would normally interact with calcium at the
388 regulatory domain of the enzyme. At higher concentrations, lead may also interact with a
389 low affinity site, and this interaction results in inhibition of calcium-stimulated PKC
390 activity (Tomsig and Suszkiw, 1995). PKA is other kinase that is a target to heavy metals.

391 According with the literature data, heavy metal can inhibit adenylate cyclase (Rodrigues
392 et al., 1999), altering cAMP levels, which in turn can restrict PKA activity.

393 Considering that post-translational modification are targets for heavy metals, and
394 also may be responsible for regulating AChE activity (reviewed in Nalivaeva and Turner,
395 2001), we have analyzed AChE zebrafish protein sequence (using NetPhosK) to search
396 for possible phosphorylation sites. Interestingly, we found possible sites of
397 phosphorylation involving different enzymes, including PKA (7 sites, maximum score of
398 0.75 at positions Ser612 and Ser613), PKC (9 sites, highest score of 0.76 at position
399 Thr271) and p38MAPK (2 sites, score of 0.61 in Thr128 and Ser237). Existing data
400 shows that PKA phosphorylation of AChE increased up to 10 times the rate of
401 acetylthiocholine hydrolysis by the recombinant human enzyme (Grifman et al., 1997).
402 Therefore, we propose that the pattern of activity restoration shown here after 96h and
403 30d of treatments could be due to an influence of possible post-translational
404 modifications. Previous studies demonstrated that *in vivo* phosphorylation of AChE by
405 PKA may play a protective feedback role against long lasting impairments of cholinergic
406 neurotransmission (Grisaru et al., 1999; Soreq and Zakut, 1993). Further studies are
407 required to elucidate the susceptibility of signal transduction pathways of zebrafish brain
408 to heavy metal toxicity.

409 Oxygen, a vital fuel for all eukaryotic organisms is also a reason of concern. This
410 occurs by its ability to continuously generate reactive oxygen species (ROS) that can be
411 extremely harmful to cell constituents when in high cellular levels. However, organisms
412 have a protective machinery composed of enzymatic and non-enzymatic defenses
413 (Halliwell and Gutteridge, 2007), that are responsible to counteract the actions of ROS

414 and prevent oxidative stress. These actions range from lipid peroxidation, protein
415 oxidation, enzyme inactivation and DNA breakage up to carcinogenesis, ageing and
416 neurodegenerative diseases, which occur when ROS formation exceeds antioxidant
417 defense capability or disrupt redox signaling, affecting cell functionality (Jones, 2006 and
418 reviewed in Monnet-Tschudi, 2006). There is evidence that environmental contaminants
419 can alter antioxidant status of the cell, being the antioxidant and oxidative stress
420 parameters used as biomarkers of pollution (Halliwell and Gutteridge, 2007; Regoli et al.,
421 2002). Because of their multitargeted actions, heavy metals can increase ROS levels by
422 the perturbation of diverse pathways, including enzymatic processes, mitochondrial
423 functions, and endogenous antioxidant defense mechanisms. ROS-induced protein
424 oxidation promotes the aggregation of protein as synuclein and A β peptides, which are
425 characteristics of PD and AD, respectively (Liu and Yang , 2005; Moreira et al., 2005;
426 Tabner et al., 2005).

427 The stress oxidative analysis were perfomed only in groups where a kinetic
428 alteration has occurred. Here we have analyzed the effects of 24h treatment with mercury
429 chloride and lead acetate in the total ROS production to look for general alterations rather
430 than be restricted to one unique component of this pathway (Amado et al., 2009).
431 Mercury chloride has reduced the antioxidant competence, as shown by a higher relative
432 area than the control group in the analysis of competence against peroxy radicals.

433 The data presented herein contributes to increase the knowledge about heavy
434 metal brain contamination. In accordance with the literature we have shown that the
435 heavy metal targets occur at different levels, such as alteration in cholinergic transmission

436 and also in the antioxidant competence of the tissue, which are a small portion of the
437 wide spectrum of actions promoted by these pollutants.

438

439 **Acknowledgments**

440 This work was supported by Conselho Nacional de Desenvolvimento Científico e
441 Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
442 (CAPES), Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS)
443 and by the FINEP research grant “Rede Instituto Brasileiro de Neurociência (IBN-Net)” #
444 01.06.0842-00. C.D. Bonan, M.R. Bogo and J.M. Monserrat are productivity research
445 fellowship form Brazilian agency CNPq.

446

447 **Conflict of Interests**

448 The authors declare no conflict of interests.

449

450 **References**

451

452 Aikawa, T., Aikawa, Y., and Brady, T.G. 1980. The pH-dependence of the inhibitory
453 effects of several divalent cations on the bovine intestine adenosine deaminase activity,
454 *Int J Biochem* 12 (3): 493–495

455

456 Allam, M.F., et al., 2005. Parkinson's disease risk factors: genetic, environmental, or
457 both? *Neurol Res.* 27(2): 206-8.

458

459 Amado, L.L., et al., 2009. A method to measure total antioxidant capacity against peroxy
460 radicals in aquatic organisms: application to evaluate microcystins toxicity. *Sci Total*
461 *Environ.*, 407: 2115-2123.

462

463 Bahn, A., and Sakar N.N., 2005. Mercury in the environment: effect on health and
464 reproduction. *Rev Environ Health* 2005; 20: 39 – 56.

465

466 Bertrand, C., et al., 2001. Zebrafish Acetylcholinesterase Is Encoded by a Single Gene
467 Localized on Linkage Group 7. *Journal of Biological Chemistry*, 276: 464-474.

468

469 Berzas Nevado, J.J., Bermejo, L.F.G., Martin-Doimeadios, R.C.R., 2003. Distribution of
470 mercury in the aquatic environment atalmeden, Spain. *Environ. Pollut.* 122, 261–271.

471

- 472 Björkman, L., et al., 1997. Mercury in saliva and feces after removal of amalgam fillings.
473 *Toxicol appl Pharmacol.* 144: 156-162
474
- 475 Bloom, N.S., and Porcella, D.B., 1994. Less mercury? *Nature* 367:694
476
- 477 Bolin, C.M., et al., 2006. Exposure to lead and the developmental origin of oxidative
478 DNA damage in the aging brain. *FASEB J.*, 20: 788-790.
479
- 480 Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram
481 quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 72:
482 248-254.
483
- 484 Cai, A.L., et al., 2006. Zinc neurotoxicity is dependent on intracellular NAD levels and
485 the sirtuin pathway. *Eur. J. Neurosci.* 24: 2169–2176.
486
- 487 Carpenter, D.O., 2001. Effects of metals on the nervous system of humans and animals.
488 *Int J Occup Med Environ Health.* 14: 209-218.
489
- 490 Coleman, J.E., 1992. Zinc Proteins: Enzymes, Storage Proteins, Transcription Factors,
491 and Replication Proteins. *Annual Review of Biochemistry.* 61: 897-946.
492

- 493 Cory-Slechta, D. 1995. Relationships between lead-induced learning impairments and
494 changes in dopaminergic, cholinergic, and glutamatergic neurotransmitter system
495 functions. *Ann Rev Pharmacol Toxicol.* 35:391-415.
496
- 497 Costa, L.G., 1998. Signal transduction in environmental neurotoxicity. *Annu Rev*
498 *Pharmacol Toxicol.* 38: 21-43
499
- 500 Ellman, G.L., et al., 1961. A new and rapid colorimetric determination of
501 acetylcholinesterase activity. *Biochem Pharmacol.* 7: 88-95.
502
- 503 Ely, J.T.A., 2001. Mercury induced Alzheimer's disease: accelerating evidence? *Bull*
504 *Environ Contamin.* 67: 800-806
505
- 506 Ferreira-Cravo, M., et al., 2007. Antioxidant responses and reactive oxygen species
507 generation in different body regions of the estuarine polychaeta *Laeonereis acuta*
508 (Nereididae). *Chemosphere*, 66: 1367-1374.
509
- 510 Finkelstein, Y., et al., 1998. Low-level lead-induced neurotoxicity in children: an update
511 on central nervous system effects. *Brain Res Rev.* 27: 168-176.
512
- 513 Gorell J.M., et al., 1999. Occupational metal exposures and the risk of Parkinson's
514 disease. *Neuroepidemiology* 18:303-308.
515

- 516 Grifman, M., et al., 1997. In vitro phosphorylation of acetylcholinesterase at non-
517 consensus protein kinase A sites enhances the rate of acetylcholine hydrolysis. *Brain Res.*
518 *Mol. Brain Res.* 51 (1–2):179–187.
- 519
- 520 Grisar, D., et al., 1999 Structural roles of acetylcholinesterase variants in biology and
521 pathology. *Eur J Biochem.* 264(3):672-86.
- 522
- 523 Gutteridge, J.M. and Halliwell, B., 2000. Free radicals and antioxidants in the year 2000.
524 A historical look to the future. *Ann N Y Acad Sci.* 899:136-47.
- 525
- 526 Halbach, S., et al., 1998. Systemic transfer of mercury from amalgam fillings before and
527 after cessation of emission. *Environ Res.* 77: 115-123.
- 528
- 529 Halliwell, B., and Gutteridge, J.M.C. 2007. Free radicals in biology and medicine. New
530 York: Oxford University Press. 963 p.
- 531
- 532 Han, C.K., et al., 2007. SK-PC-B70M from *Pulsatilla koreana* improves scopolamine-
533 induced impairments of memory consolidation and spatial working memory. *Brain Res.*
534 1184:254 – 259.
- 535
- 536 Hu, H., Heavy metal poisoning, 2005. In: Kasper., D.L. et al., (Eds.), *Harrison's*
537 *Principles of Internal Medicine*, 16th ed., McGraw-Hill, New York, p. 2577-2580.
- 538

539 Ikeda, T., et al., 1980. Inhibitory effects of Zn²⁺ on muscle glycolysis and their reversal
540 by histidine. *J. Nutr. Sci. Vitaminol.*, 26, 357–366.

541

542 International Agency for Research on Cancer (IARC) 1993. Beryllium, cadmium,
543 mercury, and exposes in the glass manufacturing Industry. IARC Monographs on the
544 evaluation of carcinogenic risks to humans, vol 58. Lyon, p.119 – 237.

545

546 International Agency for Research on Cancer (IARC) 2006. Inorganic and organic lead
547 compounds. IARC Monographs on the evaluation of carcinogenic risks to humans, 87:1-
548 471.

549

550 Jha, S.K., et al., 2003. Geochronology of Pb and Hg pollution in a coastal marine
551 environmental using global fallout ¹³⁷Cs. *J Environ Radioact* 69: 145–157.

552

553 Jarup, L. 2003. Hazards of heavy metal contamination. *British Medical Bulletin* 68:167-
554 182.

555

556 Kim, M.J., et al., 2008. Zeatin Supplement Improves Scopolamine-Induced Memory
557 Impairment in Mice. *Biosci Biotechnol Biochem* 72(2):577–581.

558

559 Kim, Y.H., et al., 1999. Zinc-induced cortical neuronal death with features of apoptosis
560 and necrosis: mediation by free radicals. *Neuroscience*. 89: 175–182.

561

- 562 Kosnett, M.J., 2007. Heavy metal intoxication and chelators. In: Katzung, B.G. (Ed.),
563 Basic and Clinical Pharmacology, 10th ed., McGraw-Hill, New York, p.945-957.
564
- 565 Krotkiewska, B. and Banas, T., 1992. Interaction of Zn²⁺ and Cu²⁺ ions with
566 glyceraldehyde-3-phosphate dehydrogenase from bovine heart and rabbit muscle. *Int. J.*
567 *Biochem.*, 24: 1501–1505.
568
- 569 Landrigan, P.J., et al., 2005. Early environmental origins of neurodegenerative disease in
570 later life. *Environ Health Perspect.* 113: 1230-1233.
571
- 572 Liu, Y. and Yang, H., 2005. Environmental toxins and alpha-synuclein in Parkinson's
573 disease. *Mol Neurobiol.* 31(1-3): 273-82.
574
- 575 Lopes, J.M. et al., 2005. Levels of selected metals in ambient air PM₁₀ in an urban site of
576 Zaragoza (Spain). *Environ Res.* 99: 58-67.
577
- 578 Lu, H. et al., 2002. Inorganic lead activates the mitogen-activated protein kinase kinase-
579 mitogen-activated protein kinase-p90(RSK) signaling pathway in human astrocytoma
580 cells via a protein kinase C-dependent mechanism. *J Pharmacol Exp Ther.* 300(3):818-23.
581
- 582 Manev, H et al., 1997. Characterization of zinc-induced neuronal death in primary
583 cultures of rat cerebellar granule cells. *Exp. Neurol.*, 146: 171–178.
584

585 Markovac J. and Goldstein G.W., 1988a Picomolar concentrations of lead stimulate brain
586 protein kinase C. *Nature*. 334(6177):71-73.

587

588 Markovac J. and Goldstein G.W., 1988b Lead activates protein kinase C in immature rat
589 brain microvessels. *Toxicol Appl Pharmacol*. 96(1):14-23.

590

591 Monnet-Tschudi F. et al., 2006. Involvement of environmental mercury and lead in the
592 etiology of neurodegenerative diseases. *Rev Environ Health*. 21(2):105-17.

593

594 Moreira, P.I. et al., 2004. Oxidative stress mechanisms and potential therapeutics in
595 Alzheimer disease. *J Neural Transm*. 112(7):921-32.

596

597 Murakami, K. et al., 1993. Inhibition of brain protein kinase C subtypes by lead. *J*
598 *Pharmacol Exp Ther*. 264(2):757-61.

599

600 Mutter, J. et al., 2004. Alzheimer disease: mercury as pathogenetic factor and
601 apolipoprotein E as a moderator. *Neuro Endocrinol Lett*. 25(5): 331-9.

602

603 Noh, K.M. et al., 1999. Mediation by membrane protein kinase C of zinc-induced
604 oxidative neuronal injury in mouse cortical cultures. *J. Neurochem.*, 72:1609–1616.

605

- 606 Oakes, K.D. and Van der Kraak, G.J., 2003. Utility of TBARS assay in detecting
607 oxidative stress in white sucker (*Catostomus commersoni*) populations exposed to pulp
608 mill effluent. *Aquatic Toxicology*, 63: 447-463.
- 609
- 610 Pabello, N.G. and Bolivar, V.J., 2005. Young brains on lead: adult neurological
611 consequences? *Toxicol Sci.* 86: 365-374.
- 612
- 613 Ram, A. et al., 2003 Mercury in sediments of Ulhas estuary, *Mar Pollut Bull* 46 (7): 846–
614 857.
- 615
- 616 Regoli, F. et al., 2002. Oxidative stress in ecotoxicology: from the analysis of individual
617 antioxidants to a more integrated approach. *Mar Environ Res.* 54(3-5):419-23.
- 618
- 619 Rico, E.P. et al., 2006. Methanol alters ecto-nucleotidases and acetylcholinesterase in
620 zebrafish brain. *Neurotoxicol Teratol.* 28(4):489-96.
- 621
- 622 Rodrigues, A.L.S. et al., 1999. Effects of lead on adenylate cyclase activity in rat cerebral
623 cortex. *Neurochemical Research.* 24(8):1037-1042.
- 624
- 625 Rosse, C. et al., 2010. PKC and the control of localized signal dynamics. *Nat Rev Mol*
626 *Cell Biol.* 11(2):103-12.
- 627

- 628 Senger, M.R. et al., 2006. Exposure to Hg²⁺ and Pb²⁺ changes NTPDase and ecto-5'-
629 nucleotidase activities in central nervous system of zebrafish (*Danio rerio*). *Toxicology*.
630 226:229-237.
- 631
- 632 Sensi, S.L. et al., 1999. Preferential Zn²⁺ influx through Ca²⁺-permeable AMPA/
633 kainate channels triggers prolonged mitochondrial superoxide production. *Proc. Natl.*
634 *Acad. Sci. USA*, 96: 2414–2419.
- 635
- 636 Sharma, S.K. et al., 2008. Heavy metals are potent inhibitors of protein folding. *Biochem*
637 *Biophys Res Commun*. 372: 341-345.
- 638
- 639 Sheline, C.T. et al., 2002 Depolarization-induced (65) zinc influx into cultured cortical
640 neurons. *Neurobiol. Dis.*, 10, 41–53.
- 641
- 642 Sherer T.B. et al., 2003. Mechanism of toxicity in rotenone models of Parkinson's
643 disease. *J Neurosci* 23: 10756-10764.
- 644
- 645 Smart, T.G. et al., 2004. Zn²⁺ Ions: Modulators of Excitatory and Inhibitory Synaptic
646 Activity. *Neuroscientist*.10(5): 432-442.
- 647
- 648 Soreq, H. and Zakut, H., 1993. Human cholinesterases and anti-cholinesterases.
649 Academic Press, San diego, USA. 47-61.
- 650

- 651 Sun, X. et al., 1999. Analysis of differential effects of Pb²⁺ on protein kinase C
652 isozymes. *Toxicol Appl Pharmacol.* 156(1):40-5.
653
- 654 Swarup, D. et al., 2005. Blood lead levels in lactating cows reared around polluted
655 localities. *Sci Total Environ.* 347: 106-110.
656
- 657 Tabner, B.J. et al., 2005. Protein aggregation, metals and oxidative stress in
658 neurodegenerative diseases. *Biochem Soc Trans.* 33(Pt 5):1082-1086.
659
- 660 Takeda, A. 2001. Zinc homeostasis and functions of zinc in the brain. *Biometals*, 14 (3-4):
661 343 – 351.
662
- 663 Tomsig, J.L. and Suszkiw, J.B., 1995. Multisite interactions between Pb²⁺ and protein
664 kinase C and its role in norepinephrine release from bovine adrenal chromaffin cells. *J*
665 *Neurochem.* 64(6):2667-73.
666
- 667 Tonner L.E., and Heiman A.S., 1997. Lead may affect glucocorticoid signal transduction
668 in cultured hepatoma cells through inhibition of protein kinase C. *Toxicology.*
669 119(2):155-66.
670
- 671 Vallee B.L. and Falchuk K.H., 1981. Zinc and gene expression. *Philos. Trans. R. Soc.*
672 *Lond. B Biol. Sci.* 294:185–197.
673

- 674 Waisberg, M. et al., 2003. Molecular and cellular mechanisms of cadmium
675 carcinogenesis. *Toxicology*. 192: 95-117.
676
- 677 Winston, G.W et al., 1998. A rapid gas chromatographic assay for determining oxyradical
678 scavenging capacity of antioxidants and biological fluids. *Free Rad. Biol. Med.*, 24: 480–
679 493.
680
- 681 Zawia, N.H. et al., 2000. Disruption of the Zinc Finger Domain: A common Target that
682 Underlies Many of the effects of Lead. *Neurotoxicology*. 21(6):1069-80.
683
- 684 Zeng, J. and Kagi, J.H.R., Zinc Fingers and Metallothionein in gene Expression. 1995
685 In: *Toxicology of Metals*, Goyer, R.A., Cherian, M.G., (Eds.), Berlin, Heidelberg,
686 Springer-Verlag, p. 333-335.

Figure legends

Figure 1: In vivo effect of different treatments (24 h, 96 h, and 30 days) with ZnCl₂ (A), Cd(CH₃COO)₂ (B), HgCl₂ (C), and Pb(CH₃COO)₂ (D) in AChE activity in zebrafish brain. Data represent means \pm S.E.M of at least three independent experiments. * Significantly differences from control group (ANOVA followed by Tukey's test as post-hoc, P <0.05).

Figure 2: Relative gene expression pattern of *AChE* after Pb(CH₃COO)₂ (24 h) and HgCl₂ (24 and 96 h) treatments in zebrafish brain. Data represent means \pm S.E.M of the *AChE* versus \square -*actin* mRNA ratio of at least four independent experiments. The results were analyzed by densitometry using Image J 1.37 for Windows.

Figure 3: In vitro effect of varying concentrations of HgCl₂ (A) and Pb(CH₃COO)₂ (B) in AChE activity in zebrafish brain. Data represent means \pm S.E.M of four independent experiments. * Significantly differences from control group (ANOVA followed by Tukey's test as post-hoc, P <0.05).

Figure 4: Total antioxidant capacity against peroxy radicals (A) and lipid peroxides content expressed as thiobarbituric acid reactive substances (TBARS) (B) in zebrafish brain after 24 h treatments with Pb(CH₃COO)₂ and HgCl₂. Data represent means \pm S.E.M of at least three independent experiments. * Significantly differences from control group (ANOVA followed by Tukey's test as post-hoc, P <0.05).




Fig. 1




Fig 2




Fig 3




Fig 4